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Abstract
During the past decade the field of developing highly concentrated protein solutions, especially
antibodies, have grown significantly within the pharmaceutical industry. In spite of the growing
interest, the distinctive properties of concentrated solutions remains only sporadically explored
experimentally. In fact, most biophysical work has strived to investigate solutions, which are as
dilute as the experimental method permits, so that forces between protein molecules and restricted
volume effects are practically absent, and the intrinsic stability of the protein can be unravelled.
Therefore, a major obstacle for a deeper understanding of concentrated protein solutions currently
appears to be a shortage of experimental data. Thus, we have investigated the thermodynamic
stability of chicken egg lysozyme by Differential Scanning Calorimetry (DSC) with respect to pro-
tein concentration, pH and added salt. Despite excluded volume effects the data indicate that
lysozyme is destabilised at high protein concentration. It is suggested that the lowered thermo-
dynamic stability at high protein concentration reflects electrostatic repulsion between the native
protein molecules or electrostatic attraction between the unfolded protein molecules. This un-
favourable effect is speculated to be less severe in the more flexible denatured state and hence to
displace the thermal equilibrium towards unfolding.
Besides the commercial approach to develop highly concentrated protein solutions, proteins do in
fact often exist in solutions far from ideal and at high concentrations or in crowded environments
and protein-protein interactions will in these cases contribute to the stability of the protein. There
are several challenges involved in working with highly concentrated protein formulations, most
of these regarding the decreased stability of the protein such as the concentration dependent
degradation route of aggregation. In order to prevent e.g. aggregation there are several ways of
improving the stability of the protein. Excipients as sugars, salts or amino acids can be added
the formulation to increase the stability of the protein formulation. Another way of improving the
stability, decreasing the risk of aggregation and increasing the solubility is covalently to attach a
polymer e.g. a poly-ethylene-glycol (PEG) group to the protein. There are a range of advantages in
using PEGylation in therapeutic application in the pharmaceutical industry. It has been shown that
PEGylating a protein prolongs its half-life in the circulatory system, increase the drug efficiency
dramatically, mask and reduce immune-recognition and clearance from the body, protect from
enzymatic or chemical degradation, enhance hydrodynamic size and reduce glomerular filtration.
We have investigated the effects of PEGylation and GlycoPEGylation on Bovine Serum Albumin
(BSA) and recombinant human Factor VIIa (rFVIIa), respectively using classical biophysical char-
acterisation tools. Biophysical characterisation of pharmaceutical proteins is widely used through-
out the whole drug development process as an invaluable tool to determine possible changes in the
structural, thermal and kinetic stability of the protein in question. The effects of PEGylation on
the structural, thermal and functional stability of BSA were investigated using BSA and six linear,
monoPEGylated BSA compounds, and the effects of GlycoPEGylation on the structural, kinetic
and thermal stability of rFVIIa were investigated using rFVIIa and linear 10 kDa and branched
40 kDa GlycoPEGylated recombinant human FVIIa derivatives. In addition the effects of Glyco-
PEGylation on the molar hydrodynamic volume of recombinant human FVIIa were investigated.
In general the secondary and tertiary structure of BSA and rFVIIa measured by Circular Dichro-
ism (CD) was maintained upon PEGylation and GlycoPEGylation, respectively. In contrast, the
thermal stability of both model proteins was affected by the covalently attached PEG polymer.
For BSA the apparent unfolding temperature, Tm, measured by DSC decreased with PEGylation,
whereas Tm for rFVIIa increased with GlycoPEGylation. The temperature of aggregation, Tagg,
measured by Dynamic Light Scattering (DLS) increased with PEGylation or GlycoPEGylation for
both proteins in questions. Possible functional changes of BSA after PEGylation were estimated
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by Isothermal Titration Calorimetry (ITC), where the binding of Sodium Dodecyl Sulphate (SDS)
to BSA and PEGylated BSA was analysed. At 25 ℃ two distinct classes of binding sites (high
affinity and low affinity) for BSA and one class of binding site (low affinity) for PEGylated BSA
were identified. The binding isotherm was modelled assuming independence and thermodynamic
equivalence of the sites within each class. Thus BSA appears to have an altered functionality
(binding profile) upon PEGylation. This observation is supported by Surface Plasmon Resonance
(SPR) measurements, which indicate changes in the binding between BSA and anti-BSA com-
pared to PEGylated BSA and anti-BSA. These biophysical characteristics are all independent of
the molecular weight of the attached polymer chain.
From a pharmaceutical formulation point of view altering the salt concentration in the protein
buffer is of interest in relation to its effect on the protein stability, and thus we have investigated
the effect of calcium chloride on the structural, kinetic and thermal stability of rFVIIa and its two
GlycoPEGylated compounds using three different CaCl2 concentrations and the same biophysical
characterisation tools as mentioned above. From the obtained results it is concluded that Glyco-
PEGylation postpones the calcium induced thermal destabilisation of rFVIIa, and a much higher
calcium concentration also postpones the thermally induced aggregation of rFVIIa. The thermally
induced aggregation of the GlycoPEGylated rFVIIa compounds is unaffected by an increasing
calcium chloride concentration.
In addition, the effects of GlycoPEGylation on the molar hydrodynamic volume of rFVIIa were
investigated using capillary viscometry and mass spectrometry to measure the intrinsic viscosity
and the molecular mass. The results show that the molar hydrodynamic volume of the conjugated
protein is not just an addition of the molar hydrodynamic volume of the PEG and the protein.
The molar hydrodynamic volume of the GlycoPEGylated protein is larger than the volume of its
composites. These results suggest that both the linear and the branched PEG are not wrapped
around the surface of rFVIIa but chains are significantly stretched out when attached to the protein.
Resumé
Udviklingen af højkoncentrerede protein formuleringer, især antistoffer, i den farmaceutiske in-
dustri har været støt stigende i løbet af det sidste årti. Men på trods af den stigende interesse
er der kun få eksperimentelle studier til karakterisering af disse opløsningers egenskaber. Dette
skyldes primært, at de fleste eksperimentelle teknikker er designet til at undersøge fortyndede
opløsninger, hvor påvirkningerne mellem proteinmolekylerne og påvirkningerne fra ’resticted vol-
ume’ nærmest er forsvundet, og stabiliteten af det enkelte proteinmolekyle kan belyses. Den største
forhindring i en dybere forståelse af koncentrerede proteinopløsninger synes derfor at være man-
glen på eksperimentelle data. Derfor har vi undersøgt den termodynamiske stabilitet af lysozym
med differentiel skanningskalorimetri i forhold til ændringer i proteinkoncentrationen, pH og tilsat
salt. De opnåede resultater indikerer at lysozym destabiliseres ved høj proteinkoncentration på
trods af påvirkningerne fra ’excluded volume’. En forklaring herpå kunne være, at den lavere
termodynamiske stabilitet ved høj proteinkoncentration skyldes elektrostatisk frastødning mellem
de native proteinmolekyler eller elektrostatisk tiltrækning mellem de udfoldede proteinmolekyler.
Denne ufordelagtige effekt tænkes at være mindre kraftig i det mere fleksible, udfoldede stadie, og
derfor forskydes den termodynamiske ligevægt hen mod udfoldning.
Udover den kommercielle tilgangsvinkel til udviklingen af højkoncentrerede proteinopløsninger, så
findes proteiner ofte naturligt i langt fra ideelle opløsninger, i høj koncentration eller i trængte
omgivelser, og i disse tilfælde vil protein-protein interaktionerne bidrage væsentligt til proteinets
stabilitet. I arbejdet med højkoncentrerede proteinopløsninger er der involveret adskillige udfor-
dringer, primært relateret til den reducerede stabilitet som for eksempel den koncentrationsafhængige
aggregering. Proteiner kan dog behandles kemisk og derved kan blandt andet aggregering for-
bygges. For eksempel kan tilsætningsstoffer som sukkere, salte eller aminosyrer tilsættes for at
øge stabiliteten af proteinformuleringen. En anden mulig måde at øge stabiliteten, nedsætte ag-
gregeringsrisikoen og forbedre opløseligheden er ved kovalent at binde en bio-polymer som f.eks.
poly-etylen-glykol (PEG) gruppe til proteinet. Der er en lang række fordele ved at benytte PEGy-
lering som terapeutisk applikation i den farmaceutiske industri. Det er påvist at protein PEGy-
lering forlænger proteinets halveringstid i kredsløbet, øger lægemidlets effekt, reducerer immun-
genkendelse og udskillelsen fra kroppen, beskytter mod enzymatisk eller kemisk nedbrydning,
forøger den hydrodynamiske størrelse og reducerer filtreringen gennem nyren.
Vi har undersøgt PEGylerings- og GlycoPEGyleringseffekten på både Bovin Serum Albumin (BSA)
og rekombinant human Faktor VIIa (rFVIIa) ved bruge af klassiske biofysiske karakteriseringsværk-
tøjer. Biofysisk karakterisering af farmaceutiske proteiner er udbredt i hele forsknings- og ud-
viklingsfasen som et uvurderligt værktøj til at undersøge mulige ændringer i den strukturelle,
termiske og kinetiske stabilitet af det pågældende protein. Effekten af PEGylering på BSA og
6 mono-PEGylerede BSA species blev undersøgt med henblik på ændringer i den strukturelle,
termiske og funktionelle stabilitet, og effekten af GlycoPEGylering på rFVIIa, 10 kDa lineær og
40 kDa forgrenet glycoPEGyleret rFVIIa blev undersøgt med henblik på ændringer i den struk-
turelle, kinetiske og termiske stabilitet. Derudover blev ændringer i det hydrodynamiske volu-
men af rFVIIa som følge af GlycoPEGylering undersøgt. Den sekundære og tertiære struktur af
BSA og rFVIIa blev undersøgt med Cirkulær Dichroism (CD), og begge proteiner havde bevaret
deres struktur efter hhv. PEGylering og GlycoPEGylering. Den termiske stabilitet, derimod,
var påvirket af PEGylering. Udfoldningstemperaturen, Tm, for BSA faldt med PEGylering, hvo-
rimod Tm for rFVIIa steg med GlycoPEGylering. Aggregeringstemperaturen, Tagg, blev målt
med Dynamisk Lysspredning (DLS), og denne steg med PEGylering eller GlycoPEGylering for
begge undersøgte proteiner. Mulige funktionelle ændringer af BSA pga. PEGylering blev under-
søgt med Isotermisk Titreringskalorimetri (ITC), hvor bindingen mellem Natrium Dodecyl-Sulfat
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(SDS) og BSA/PEGyleret BSA blev målt. Ved 25 ℃ blev to forskellige slags bindingssteder (høj
og lavaffinitet) identificeret på BSA, hvorimod en slags bindingssted (lavaffinitet) blev fundet for
PEGyleret BSA. Bindingsisotermen blev modelleret under forudsætning af at bindingsstederne,
både høj- og lavaffinitet, var uafhængige og termodynamisk set ens. BSA synes derfor at have en
ændret funktionalitet (bindingsprofil) som følge af PEGylering. Denne observation understøttes
af Surface Plasmon Resonance (SPR) bindingsstudier, der indikerer ændringer i bindingen mellem
BSA og anti-BSA sammenlignet med bindingen mellem PEGyleret BSA og anti-BSA. Samtlige
biofysiske karakteristika er uafhængige af molekylvægten af den bundne PEG polymer.
Ændringer af saltkoncentrationen i en proteinbuffer er ud fra et farmaceutisk formuleringssyn-
spunkt ofte interessant eftersom det påvirker proteinets stabilitet, og vi har derfor undersøgt ef-
fekten af at ændre kalciumkloridindholdet i bufferen på den strukturelle, kinetiske og termiske
stabilitet af rFVIIa og to GlycoPEGylerede varianter heraf. Vi benyttede tre forskellige CaCl2
koncentration og de samme karakteriseringsværktøjer, som blev nævnt ovenfor. På baggrund af de
opnåede resultater vi konkluderede, at GlycoPEGylering udskyder den calcium inducerede termiske
destabilisering af rFVIIa, og at en tilpas høj kalciumkloridkoncentration også udsatte den termisk
inducerede aggregering af rFVIIa. Den termisk inducerede aggregering af de GlycoPEGylerede
rFVIIa varianter var upåvirket af ændringen i kalciumkloridkoncentrationen.
Kapillærviskometri og massespektrometri blev benyttet til at måle hhv. grænseviskositet og
molekylmasse af rFVIIa og to GlycoPEGylerede rFVIIa varianter for dermed at kunne estimere
eventuelle ændringer i det hydrodynamiske volumen af rFVIIa som følge af GlycoPEGylering. Re-
sultaterne viste at det molære volumen af det konjugerede protein ikke blot er en addition af det
molære hydrodynamiske volumen af PEG og protein. Det hydrodynamiske volumen af GlycoP-
EGyleret rFVIIa er større end den samlede volumen af kompleksets komponenter sammenlagt.
Resultaterne tyder på, at både den lineære og den forgrenede PEG polymer ikke omslutter over-
fladen på det konjugerede protein, men derimod tyder resultaterne på at PEG kæderne strækker
sig ud og væk fra proteinet.
Overordnet set afspejler de opnåede resultater med PEGylerede og GlycoPEGylerede proteiner i
dette studie resultaterne publiceret i litteraturen. Gennem PEGylering eller GlycoPEGylering af
en protein opnår man en reduceret termisk induceret aggregeringstendens, bevarer den sekundære
og tertiære struktur, påvirker bindingsegenskaberne og et større hydrodynamisk volumen.
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Preface
This dissertation entitled "Biophysical characterisation of PEGylated proteins and highly
concentrated protein solutions" is submitted to meet the requirements for obtaining the
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carried out under the supervision of Professor, PhD Peter Westh and Associate Professor,
PhD Søren Hvidt, both at Roskilde University and Research Scientist, PhD Anders Dybdal
Nielsen at Novo Nordisk A/S.
The experimental work was performed in the Research Unit for Functional Biomaterials,
Department of Science, Roskilde University, Denmark and Department of CMC Analytical
Support, CMC, Novo Nordisk A/S, Denmark and at the Department of Chemical and
Process Engineering at the University of Canterbury, New Zealand. The PhD project
was carried out from August 2007 to October 2010 in collaboration between Roskilde
University and Novo Nordisk A/S.
Aim of the thesis
The aim of the thesis is bipartite, and the thesis treats both highly concentrated protein
solutions and PEGylated proteins in solution.
Highly concentrated protein solutions
While most of the studies on highly concentrated protein solutions have aimed to shed light
on antibody solutions due to the immediate interest from the pharmaceutical industry,
we have investigated a well-known and well characterised protein at high concentrations
in aqueous solutions. This study primarily contributes to the discussion on which of
these two opposite forces dominate at high protein concentration; the effect of excluded
volume phenomena or electrostatic interactions. Lysozyme is a highly soluble, globular
protein with an isoelectric point of 10.5-11. The latter dictates a high positive charge
at low and intermediate pH values and we found that this was sufficient to essentially
prevent aggregation, which is otherwise dominating thermal denaturation at high protein
concentration. As a result we were able to study reversible unfolding and hence single
out the thermodynamic functions at various salt concentrations even at very high protein
load.
PEGylated proteins
PEGylating proteins affect a number of the biophysical properties of the bioconjugated
protein. We focus on the changes in the binding properties, the thermal, kinetic and struc-
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tural stability as well as hydrodynamic volume upon PEGylation. Two different model
systems were chosen; Bovine Serum Albumin and recombinant human Factor VIIa which
were PEGylated and GlycoPEGylated respectively. The possible altered binding proper-
ties of a PEGylated protein as compared to the unmodified protein are investigated by
Surface Plasmon Resonance and ITC, two complementary techniques for measuring bind-
ing properties of proteins. These measurements contribute specifically to further elucidate
the changes in the pharmacokinetic profile of PEGylated proteins as described in section
1.2.1. The thermal stability is investigated by Differential Scanning Calorimetry (DSC),
which is mainly used to describe possible changes in the apparent unfolding temperature.
The thermogram is also used for predicting whether the protein aggregates upon unfold-
ing or stays in solution. Dynamic Light Scattering (DLS) has been used to describe the
aggregation behaviour of PEGylated proteins and their unmodified counterparts, as the
postponed aggregation is one of the most characteristic features of a PEGylated protein
compared to the unmodified protein. Another key feature obtained by PEGylation is the
increased hydrodynamic volume, which is estimated by measuring the intrinsic viscosity
and the molecular mass. The change in the intrinsic viscosity is measured by an Ubbe-
lohde viscometer. Finally the secondary and tertiary structure of BSA and rFVIIa as
well as their PEGylated or GlycoPEGylated counterparts have been measured by Circu-
lar Dichroism (CD) in order to investigate possible changes in the protein structure upon
PEGylation. These techniques represent a wide range of classical biophysical character-
isation tools, and the obtained results all reflect pharmaceutically relevant properties of
the potential protein drug.
Outline of the thesis
The thesis consists of 8 chapters and is divided into three parts. Part I consists of chapter
1 and this chapter is intended as an introduction to the fundamental subjects covered in
the thesis and includes a short description of the scientific results obtained and reported in
part II and part III. The chapters in part II and part II are either constructed as research
papers or as short introductions to the less common biophysical techniques used, followed
by experimental results of that technique. Due to this composition of the thesis, there are
some overlapping introduction and materials and methods sections on BSA in chapters 3
and 4 and on rFVIIa in chapters 5, 6 and 7.
Part II, Highly Concentrated Protein Solution, consists of one chapter.
Chapter 2 describes the effect of surface charge on the thermal stability of highly concen-
trated lysozyme solutions.
Part III, PEGylated proteins, consists of five chapters.
Chapter 3 treats the effects of PEG size on the structure, function and stability of PEG-
ylated BSA. This manuscript entitled Effects of PEG size on the structure, function and
stability of PEGylated BSA was submitted to European Journal of Pharmaceutics and
Biopharmaceutics in December 2010.
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Chapter 4 gives a short introduction to Surface Plasmon Resonance, SPR, followed by
experimental results on PEGylated BSA.
Chapter 5 describes the biophysical characterisation of GlycoPEGylated recombinant hu-
man Factor VIIa. This manuscript entitled Biophysical Characterisation of GlycoPEG-
ylated recombinant human Factor VIIa, was submitted to International Journal of Phar-
maceutics in September 2010 and accepted for publication in December 2010.
Chapter 6 also describes the biophysical characterisation of GlycoPEGylated recombinant
human Factor VIIa but focuses on the effect of CaCl2 on the stability of GlycoPEGylated
rFVIIa. This manuscript entitled The effect of GlycoPEGylation on the physical stability
of human rFVIIa with increasing calcium chloride concentration was submitted to Eu-
ropean Journal of Pharmaceutics and Biopharmaceutics in September 2010 and accepted
for publication in December 2010.
Chapter 7, which treats the hydrodynamic volume changes of rFVIIa due to GlycoPEG-
ylation. This manuscript entitled The hydrodynamic volume changes of Factor VIIa due
to GlycoPEGylation was submitted to Journal of Pharmaceutical and Biomedical Analysis
in October 2010.
Chapter 8, the concluding remarks.
Three appendices are included in the thesis. Appendix A contain additional data on Highly
Concentrated Lysozyme Solutions measured by High Resolution Ultrasonic Spectroscopy
(HRUS). The content of appendices B and C refers to work in relation to Surface Plasmon
Resonance and has been placed as appendices as the work is not fully developed but serves
as a basis for further exploration and development in the future. The content of appendix
B has been presented as a poster on the 2009 Colorado Protein Stability Conference.
xThroughout the report several abbreviations and symbols are used.
AUC Analytical Ultracentrifugation
BSA Bovine Serum Albumin
Cp Heat capacity
CD Circular Dichroism
CV Column Volume
∆H Enthalpy change
DLS Dynamic Light Scattering
DSC Differential Scanning Calorimetry
ELISA Enzyme-Linked ImmunoSorbent Assay
EMA European Medicines Agency
FDA Federal Drug Agency
FTIR Fourier Transform Infra Red Spectroscopy
η Viscosity
HSA Human Serum Albumin
IEC Ionic Exchange Chromatography
IFN Interferon
IM Intramuscular
IP Intraperitoneal
ITC Isothermal Titration Calorimetry
IV Intravenous
K Binding constant
ka Association rate constant
kd Dissociation rate constant
KD Equilibrium constant
MALDI-TOF Matrix Assisted Laser Desorption Ionisation - Time of Flight
mAb Monoclonal Antibody
MW Molecular Weight
n Refractive index
N Number of binding sites
NMR Nuclear Magnetic Resonance
PBS Phosphate Buffered Saline
PEG Poly(ethylene) glycol
xi
rFVIIa Recombinant Human Factor VIIa
Rg Radius of gyration
RH Viscosity radius
Rmax Maximum SPR response
RU Response Units from SPR measurements
S Entropy
SC Subcutaneous
SDS Sodium Dodecyl Sulfate
SDS-PAGE Sodium Dodecyl Sulfate Poly-Acrylamide Gel Electrophoresis
SEC Size Exclusion Chromatography
SPR Surface Plasmon Resonance
SANS Small Angle Neutron Scattering
SAXS Small Angle X-ray Scattering
Tagg Temperature of aggregation
Tm Temperature of unfolding
Tonset Onset temperature
TF Tissue Factor
VH Hydrodynamic Volume
Two fundamental terms are recurring throughout the thesis: PEGylation and GlycoPEG-
ylation. PEGylation refers to the covalent attachment of poly-ethylene-glycol (PEG) to
a protein and does not take the PEGylation method into account. GlycoPEGylation
refers to a specific PEGylation method, where glycosyltransferases is used to attach PEG
to glycan residues, the enzyme based GlycoPEGylation technology. All the investigated
proteins, which have been PEGylated by the GlycoPEGylation technology, have been de-
noted GlycoPEGylated. However both the PEGylated and GlycoPEGylated proteins are
proteins whereto a PEG polymer has been attached.
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Part I
Introduction
2
1 Introduction
Since the late 1980s the number of protein pharmaceuticals has increased dramatically
due to recombinant DNA technology. By then only three recombinant protein products
were on the US market, while twenty antibody products and almost 150 protein-based
products are now available [1]. Proteins provide a number of unique possibilities with
regard to treatment for human diseases and conditions including diabetes, cancer and
haemophilia. But even though the development of more pharmaceutical proteins appear
to help in curing many diseases, the benefits of the protein drug will not be fully utilised
unless the protein is stable throughout the whole process. As the number of therapeutic
protein products in the pharmaceutical industry continues to increase, protein stability,
chemically as well as physically, will continue to be a relevant issue [1, 2].
1.1 Highly concentrated proteins solutions
Proteins often exist in concentrated solutions or in crowded environments, where the
biophysical properties of aqueous protein solutions are characterised by a pronounced
non-ideality. During the past decades there has been a growing interest within both the
pharmaceutical industry and the scientific society in general to explore the origin of this
non-ideality. The focus on highly concentrated protein solutions has increased dramati-
cally during the last decades as the use of antibodies as pharmaceutical drug has gained
ground [3, 4]. This growing interest is primarily due to the fact that high protein con-
centration liquid formulation typically is required to better address the therapeutical goal
and patient convenience of subcutaneous (SC), self-administration of the biopharmaceu-
ticals. The SC route of delivery is appealing for protein based pharmaceutical products
that require frequent and chronic administration. SC administration is easier compared
to the intravenous route (IV) of delivery, which often requires administration in a hospital
or similar facility. In combination with a relevant device, SC administration allows home
administration for the patient. SC administration often requires high protein concentra-
tion due to volume limitations (<1.5 mL) and high dose requirements (50 mg/mL or even
higher) [5] and the development of a dosage form in the concentration range 50-200 mg/mL
with adequate stability and deliverability presents a technical challenge [6]. As seen in
table 1.1 most of the marketed monoclonal antibodies are administered by intravenous
injection due to the high doses.
The development of highly concentrated protein products includes several potential chal-
lenges with respect to manufacturing, formulation, analysis and delivery. Relevant issues in
relation to pharmaceutical formulations are macromolecular crowding, the concentration-
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Brand Name Antibody Type Dose Indication
Route of Administration
Orthoclone-OKT3 IgG2, 1 mg/mL Transplant
Murine (liquid, IV) rejection
Remicade IgG1, 3-10 mg/kg Crohn’s disease,
Chimeric (lyophilizate, IV) rheumatoid arthritis
Herceptin IgG1, 160 mg Breast cancer
humanized, (lyophilizate, IV)
CDR-grafted
Mylotarg IgG4, 9 mg/m2 Myeloid leukemia
humanized, (lyophilizate, IV)
CDR-grafted
Humira IgG1, 50 mg/mL Rheumatoid
Human (Liquid, SC) arthritis
Simulect IgG1, 450 mg Transplant
Murine (lyophilizate, IV) rejection
Synagis IgG1, 15 mg/kg Respiratory
humanized, (lyophilizate, IM) syncytial virus
CDR-grafted
Table 1.1: A short list of some of the approved and marketed Antibody (mAb) drugs [3, 4].
dependent aggregation and tendency to form viscous solutions due to the high potential
of intermolecular interactions. It is crucial to obtain further knowledge about the various
factors influencing the stability of highly concentrated protein formulations for the further
development of these pharmaceutical products.
In spite of this growing interest in the special properties of concentrated protein solutions
remains only sparsely explored [7]. A lot of the obtained biophysical information is based
on dilute solutions resulting in the absence of forces between protein molecules as well
as restricted volume effects [7]. Most of the classic biophysical characterisation methods
are simply not designed to measure highly concentrated protein solutions. Sensitive in-
struments requiring very small quantities have been dominating the market of biophysical
characterisation instruments. Especially instruments requiring small quantities have been
of great importance due to the shortage of sample material which in the early discov-
ery phases often is only available in very few milligrams. However, due to the growing
interest especially from the pharmaceutical industry in investigating highly concentrated
protein solutions more and more experimental techniques are now available for these pur-
poses. Currently the major limitation for further understanding of concentrated protein
solutions appears to be a shortage of experimental data.
In relation to biophysical characterisation of highly concentrated protein solutions a few
papers are worth mentioning. One of the most comprehensive studies on the biophysical
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stability of proteins at high concentration has been done by Guo et al. [8]. Guo et al. stud-
ied the colloidal and conformational stability of proteins in highly concentrated solutions
by Fourier Transform Infra Red Spectroscopy (FTIR), Dynamic Light Scattering (DLS)
and Circular Dichroism (CD). Based on the results obtained Guo et al. conclude that the
conformational and colloidal stability of a protein is determined by a variety of factors.
Guo et al. also state that while the prediction of excluded volume theory should conforma-
tionally stabilise proteins at high concentrations, other factors such as pH, kinetics, protein
dynamics, and intermolecular charge-charge effects may affect the overall stability of pro-
teins at high concentrations under certain conditions. Harn et al. [9] have investigated
highly concentrated monoclonal antibody formulations by various biophysical methods
including UV spectroscopy, fluorescence spectroscopy, FTIR, CD and DSC. Harn et al.
concludes that UV spectroscopy and fluorescence spectroscopy demonstrate a decrease in
the apparent thermal melting temperature of ∼ 5-20 ℃ of the proteins with increasing
protein concentration. In contrast, DSC thermograms and CD thermal experiments sug-
gest a minor degree of stabilization (∼ 2 ℃) of the antibodies although protein association
could be responsible for these observations. Matheus et al. [10] have studied highly con-
centrated protein formulations using FTIR and nano-DSC. Matheus et al. conclude that
FTIR is preferred over nano-DSC for analysis of high-concentration protein formulations
because the protein can be measured without prior dilution, that is at real solution con-
ditions without the fear of artificial changes in the protein’s physical state. In another
study by Matheus et al. from the same year [11], they report the use of Fourier-transform
infrared (FTIR) spectroscopy in determining the protein melting temperature of highly
concentrated liquid IgG1 antibody in various formulations. Matheus et al. conclude, that
Tm(FTIR) values did not necessarily correspond to the storage stability at 40 ℃ analyzed
by means of SEC-HPLC and SDS-PAGE. Therefore Tm(FTIR) should only be employed
as supportive information to the results from both real-time and accelerated stability
studies. Liu et al. [12] have studied the effect of reversible protein self-association on
the viscosity of concentrated monoclonal antibody solutions using capillary viscometer or
cone-plate rheometer. Liu et al. concludes that the reversible multivalent self-association
of this protein appears to be mediated mainly by electrostatic interactions of charged
residues and results in unusually high viscosity of this monoclonal antibody in solution at
low ionic strength conditions. Patel et al. [13] have investigated an analytical method to
calculate the complex modulus and viscosity of high concentration protein solutions from
measurements using quartz crystal microbalance with dissipation monitoring (QCM-D).
Patel et al. concluded that the characterisation of the rheological properties of high con-
centration antibody solutions provided insight into protein-protein interactions, and the
presented methodology demonstrates a straightforward way to determine the viscoelastic
properties using ultrasonic rheology without the drawbacks of numerical fitting.
1.1.1 Crowding theory and excluded volume phenomena
Studies on the structure and function of proteins have traditionally been performed on
solutions which are dilute. However, many physiological media do have considerable
macromolecular content, and all together the macromolecular species occupy a substan-
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tial fraction (10% or larger) of the fluid volume [14]. In general at low concentration, the
stability of a protein is mostly dependent on intramolecular interactions and hydration
effects, whereas at high concentration, protein-protein interactions are more dominant
[8]. At high concentration intramolecular interactions as apolar and electrostatic effects,
hydrogen bonds and van der Waals forces might also be altered. Furthermore covalent
alternations such as deamidation, oxidation, rupture of peptide bonds and broken disulfide
bridges are also very concentration dependent [8].
More than 35 years ago Laurent showed that adding a water-soluble polymer to a protein
solution resulted in a significant reduction of the solubility of the protein, suggesting that
the thermodynamic activity of the protein was changed due to the exclusion of protein
from that fraction of solution volume occupied by polymer [15]. During the 1980s it
became the general conception that
. . .in solutions containing a total protein concentration comparable to that
found in physiological media, the exclusion of a given protein molecule from the
combined volume occupied by other protein molecules can have energetic con-
sequences which are comparable in magnitude to those of commonly invoked
inter- and intramolecular electrostatic and hydrophobic interactions [14].
The theoretical fundament of this conception was provided by Minton and coworkers in a
number of papers throughout the past three decades [14, 16–23]. The heart of this sta-
tistical mechanical approach is to describe the effect of concentration on the Gibbs free
energy of the protein molecule. Differentiation of the free energy function with respect
to temperature, pressure and composition subsequently enables a comprehensive thermo-
dynamic description of the system. In its simplest form, this theory only accounts for
the steric accessibility (i.e. volume exclusion) but more sophisticated versions of the the-
ory also provide some descriptions of electrostatic interactions. While crowding theory
has been successful in accounting for some experimental data such as osmotic pressure
and diffusion rates [18, 24] it is far from sufficient to rationalize - let alone predict - the
physical properties of concentrated protein solutions in general. For example, little infor-
mation can be derived on hydrodynamic properties such as viscosity, which are of obvious
importance. Also, conjugates such as glycosylated or PEGylated proteins, which are not
readily described as a hard-sphere, are not easily applicable to the theory. When applying
excluded volume theory or crowding theory to a model system, it is important to distin-
guish between media, which are termed crowded and media which are termed concentrated,
because in vitro no single macromolecular species will occur at high concentration but,
taken together, the macromolecules occupy a significant fraction (typically 20-30 %) of the
total volume [22]. In other words a crowded media is one, where no single macromolecular
species is present at high concentration, but all species taken together occupies a signifi-
cant fraction of the volume of the medium, and a concentrated medium is one where one
specific macromolecule occupy a significant fraction of the medium [23].
In the simple version of the excluded volume theory, it predicts that at high concentration
of inert macromolecules, e.g. a protein, should be stabilised in the native state relative
1.1 Highly concentrated proteins solutions 7
to any less compact unfolded or partially folded state of the protein, and in these cases
the inert macromolecules are referred to as background molecules or crowding agents.
The assumption here being that the background molecules interact with the reactants
exclusively through steric exclusion, which is arising from the impenetrable nature of each
macromolecule [22]. Steric repulsion models have successfully predicted and accounted for
changes in a variety of reactions and processes where addition of inert volume-excluding
macromolecules have been added. These reactions include protein folding and the forma-
tion of protein-protein complexes [25]. However steric exclusion is not entirely non-specific
and it is evident that crowding will have an influence on protein aggregation within more
complex heterogeneous media too. This is not depending on but in addition to the influ-
ence of other interactions and for this reason these must also be taken into account when
seeking to understand reaction rates and equilibria in such media [22, 25].
The excluded volume theory predicts that crowded fluids will promote self-association
and hetero-association of proteins [19]. Hence, the conformational stability of the protein
is thought to increase while the colloidal stability is thought to decrease. The theory,
however, is not directly applicable to proteins without alternations and reservations as
proteins are not inert macromolecules. The well-defined secondary and tertiary structure
of a protein may change upon stress, and the protein may be more prone to interact more
with other proteins. The degree of interaction depends on concentration, temperature and
buffer composition.
The continuous progress within the pharmaceutical industry for the development of highly
concentrated antibody solutions call for further experimental investigations of the non-
ideal properties of concentrated proteins solutions as described earlier in this section.
One of these experimental investigations could be to study the effect of concentration,
pH and salt on the thermal stability of highly concentrated protein solution mimicking
an antibody. In this context we investigated the thermodynamic stability of chicken egg
lysozyme by Differential Scanning Calorimetry (DSC) with respect to protein concentra-
tion, pH and added salt (see Chapter 2). Lysozyme is chosen due to its high solubility
and unusually high isoelectric point. The latter ensures a high positive surface charge at
low pH, and it turned out that this surface charge was high enough to prevent aggrega-
tion, which is otherwise dominating thermal denaturation at high protein concentration.
This experimental setup enabled us to study reversible unfolding and hence single out the
thermodynamic functions even at very high protein load, an aspect we believe, based on
the current literature, needs to be studied in further detail. Due to the extensive amount
of literature on various subjects in relation to dilute lysozyme solutions [8, 10, 26–46] new
results obtained by studying lysozyme at high concentration can be correlated to those
at low concentration, and differences relating to concentration issues will appear more
clearly.
As seen in figure 1.1 at all the investigated pH values the apparent unfolding tempera-
ture, Tm, decreases with increasing protein concentration at low salt concentration. Thus
despite excluded volume effects the data indicate that lysozyme is thermally destabilised
at high protein concentration. At high salt concentration the picture is different, as Tm
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decreases with increasing protein concentration at low pH, whereas Tm increases with
increasing protein concentration at high pH.
Figure 1.1: The apparent unfolding temperature is plotted as a function of lysozyme
concentration. The three figures show the pH depending differences in Tm at different
salt concentration. I is the salt concentration in mM. To illustrate the variations in Tm
further, the ranges on the y-axis are different in each figure.
The results of this study can generally be categorised in one of two ways either (i) the
apparent unfolding temperature decreases with increasing protein concentration or (ii)
the apparent unfolding temperature increases with increasing protein concentration, both
of which depends on pH and salt concentration. It is suggested that the lowered ther-
modynamic stability at high protein concentration reflects either electrostatic repulsion
between the native protein molecules or electrostatic attraction between the unfolded pro-
tein molecules. This unfavourable effect is speculated to be less severe in the more flexible
denatured state and hence to displace the thermal equilibrium towards unfolding.
There are several challenges involved in working with highly concentrated protein formu-
lations, most of these regarding the decreased stability of the protein such as the con-
centration dependent degradation and aggregation. In order to prevent e.g. aggregation
there are several ways of stabilising the protein. Excipients as sugars, salts, surfactants
or amino acids can be added the formulation to increase the stability. A another way of
improving the stability, decreasing the risk of aggregation and increasing the solubility is
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to covalently attach a polymer e.g. a poly-ethylene-glycol (PEG) to the protein, a method
of modification which has been used in the pharmaceutical industry for the past decades.
1.2 PEGylated proteins in solution
The process of covalently attaching a PEG polymer to a protein, called PEGylation,
was first described in the 1970s by Davis and Albuchowsky and subsequently reported in
two key papers, one on catalase modification [47] and one on albumin modification [48].
Frank Davis and his colleagues generated the findings regarding the effect of PEGylation.
They showed that besides protecting the protein from degrading during drug delivery,
PEGylation improves the pharmacokinetic and pharmacodynamic properties of the protein
drug by increasing water solubility, reducing renal clearance and limiting toxicity [49].
Modification of pharmaceutical proteins with hydrophilic polymers such as poly-ethylene-
glycol (PEGylation) is an established method for prolonging the circulatory half-life of
proteins, reducing self-aggregation, increasing water solubility and decreasing antibody
recognition, and it has been used successfully in several marketed proteins [50, 51]. In
table 1.2 a few of the PEGylated drugs on the current marked are listed.
Brand Name Product PEG size (kDa) Indication Year (approved)
PEGasysr PEG-IFN-α-2a 40 Hepatitis 2001
(interferon)
PEG-Intronr PEG-IFN-α-2b 12 Hepatitis 2000
(interferon)
Neulastrar PEG-filgrastim 20 Neutropenia 2002
(granulocyte colony-)
(stimulating factor)
Oncasparr PEG-aspargase 5 Cancer 1994
(asparaginase)
Somavertr PEG-visomant 4-5 × 5 Acromegaly 2003
(growth hormone)
Table 1.2: A short list of some of the PEGylated protein drugs on the current marked
[52–54].
PEG, -(CH2-CH2-O)n-, is a highly soluble, amphiphilic polyether diol. PEG is not charged
in solution. X-ray structural analysis shows that PEG chains can adopt two very different
structural conformations: a zigzag, random coil structure for shorter chains, or a winding,
helical structure for longer chains [55]. These two extreme conformations are reversible in
water and dependent on solution conditions [56]. The oxygen atoms allow for hydration
of the highly mobile polymer chains resulting in the formation of three water bridges per
monomer unit [52, 57, 58]. For this reason the PEG chains are heavily hydrated and
consequently they have a large excluded volume which among other things inhibits the
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approach of another molecule. The hydration of the PEG chain determines the overall
hydrodynamic properties of PEG bioconjugates [59].
Most of the benefits of PEGylated proteins reflect the properties of the PEG polymer
itself [60]. Generally the polymer is prepared by anionic polymerisation, which provides
a number of molecular sizes. PEG contains two OH end groups, both of which can be
activated for chemical PEGylation purposes [61]. The polymerisation process can be
controlled such that the molecular weight distribution is narrow, so the PEGs on the
market today are much less polydisperse than those employed initially [59, 62]. Still, the
polydispersitivity should be taken into account when PEGylating peptides or other low
molecular weight drugs as the molecular weight of the PEG can be a significant part of
the molecular weight of the whole complex.
PEG is EMA1- and FDA-approved for use as a vehicle or base in foods, cosmetics and
pharmaceuticals including in injectable, topical, rectal and nasal formulations [49]. PEG
shows little toxicity and is cleared from the body, intact, through the kidneys (PEGs <30
kDa) or through the liver or faeces (PEGs >30 kDa) [52, 59]. In general PEGylation
reduces kidney clearance simply because PEGylation makes the hydrodynamic volume
of a pharmaceutical molecule larger, and the kidney filters molecules according to size,
the larger the molecule the slower the clearance. As mentioned earlier, the binding of
water makes the PEGylated compounds function as though they are much larger than
a corresponding soluble protein of the same mass [49]. This is confirmed by e.g. gel
electrophoresis.
1.2.1 Pharmacokinetics
There are many benefits from PEGylating a pharmaceutical drug. One is the altered
pharmacokinetics, which already was observed by Abuchowski et al. [47] in 1977. When
PEGylating a protein the new molecule will exhibit different pharmacokinetic and phar-
macodynamic properties from the parent drug, although it acts on the same target. A
reduced binding affinity is often the result of the steric hindrance by the large conjugated
PEG polymer. This reduction is often compensated by a prolonged circulation time which
together with the reduced immunogenicity creates an overall improved pharmacokinetic
profile, which often result in not only an improved efficacy, but also a reduced dosing
frequency and an increased patience compliance [52]. The efficacy of a PEGylated pro-
tein drug is illustrated in figure 1.2, and discussed in a thorough review by Fishburn [52],
where comparative pharmacokinetic and pharmacodynamic parameters from PEGylated
proteins and their parent unmodified protein drugs in several in vivo animal models are
represented. In the review by Fishburn 15 PEGylated enzymes, cytokines, hormones and
antibodies have been tested in mice, rats and monkeys. These data show an 100 fold
increase in the half-life and a 60 % retained activity on average [52]. Harris et al. [63] have
reported similar data in a 2001 review.
1 Abbreviation for European Medicines Agency, which had the acronym EMEA until December 2009.
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In vivo efficacy of drug
Systemic exposure
PharmacokineticPharmacodynamic
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Figure 1.2: PEGylation alters the in vivo efficacy of drugs by altering the balance between
their pharmacodynamic (PD) and pharmacokinetic (PK) properties. The decrease in
potency can be due to a reduced binding affinity which can be compensated for by the
increase in the overall exposure caused by a prolonged circulation time. The resulting
change in the PK-PD profile provides an overall improved therapeutic efficacy, adapted
from [52].
The prolonged circulation time which is one of the main characteristics of a PEGylated
protein is primarily a result of two effects; the low clearance through the kidney and the
protection from proteolytic degradation, the latter being one of the largest challenges in
manufacturing viable protein drugs. The low clearance is a result of the heavily hydrated
PEG polymer which increases the effective molecular size of the PEG conjugate. The
protection from proteolytic degradation is a result of the constantly mobile PEG moiety
which impairs access for proteolytic enzymes. It is the perception that this mechanism also
underlies the reduced immunogenicity of PEG-proteins, as the PEG polymer minimises
the exposure of antigens and thus reduces or even prevents the formation of neutralising
antibodies [52]. Some examples of different classes of PEGylated protein drugs are found
in table 1.3, and in the literature. Bailon et al. [51] report that PEGylated α-interferon,
Pegasysr, retains only 7% of the antiviral activity of the native protein. It still shows a
greatly improved performance in vivo compared with the unmodified enzyme because of
the improved pharmacokinetics. Stennicke et al. [64] have shown that GlycoPEGylated
recombinant Factor VIIa (rFVIIa) has a significantly lower clearance and an increased
half-life compared to a variety of rFVIIa from animal species . Hinds and Kim [65] in-
vestigated the effect of chemically coupling a single low molecular weight PEG on the
physical and pharmacological properties of insulin, and reported that PEGylation of in-
sulin almost completely eliminated the immunogenicity, allergenicity and antigenicity of
the conjugated protein. In addition, Yang et al. [66] have studied the effect of PEG-
ylation on the pharmacokinetic profile of anti-TNF-alpha scFv. The studies showed that
PEGylated scFv has a 100-fold prolonged circulation life in mice compared to comparable
clinical antibodies. Clark et al. [67] have studied the effect of PEGylation on derivatives
of human growth hormone (hGH), and their studies showed, that the clearance of hGH
in rats was inversely proportional to effective molecular weight (which changed with the
number of PEGs attached), and that the potency (in vivo and in vitro) was increased
by about 10-fold compared with unmodified hGH. They concluded that PEGylation im-
proved the hormone’s clearance properties, which even at the expense of reducing receptor
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binding affinity, would lead to dramatic increases in hormone efficacy.
Class Molecule PEG size PEGs Mechanism
(kDa) per Molecule of Action
Enzymes Adenosine deaminase 5 Multiple Proteolytic protection
reduced immugenicity
Asparaginase 5 Multiple Reduced immugenicity
Cytokines Interferon - α2a 40 1 Increase size to
slow renal clearance
Interferon - α2b 12 1 Increase size to
slow renal clearance
Hormones GH antagonist 5 4-5 Protection from protease
Growth hormone 20 1 Protection from protease
Antibodies Fab’ fragments 5, 25, 40 Multiple Increase size to
slow renal clearance
Anti-TNFα Fab’ nd a 1 Increase size to
slow renal clearance
Nucleic acids Anti VEGFb aptamer 40 1 Slow diffusion away
from site of action
of in vitreous tumor
Anti PDGFc aptamer 40 1 Increase size to
slow renal clearance
a nd, not disclosed
b VEGF, vascular-endothelial growth factor
c PDGF, platelet-derived growth factor
Table 1.3: Different classes of drugs benefit from different altered properties of the PEG-
ylated protein, adapted from [52].
1.2.2 PEG polymer size and shape
The PEG polymer size does also play a role in the immunological properties of the PEG-
ylated protein. First and foremost several studies have shown that by increasing the
number of conjugated polymers or the PEG polymer size the immunogenicity and anti-
genicity decrease [58], and it was found that branched were more effective than the linear
ones in improving the immunological properties of proteins. Veronese et al. [68] found that
the binding of branched 10 kDa PEG to asparaginase reduced the antigenic character of
the protein about 10-fold as compared to the counterpart obtained by modification with
5 kDa PEG, and Caliceti et al. [69] found that branched 10 kDa PEG reduced the uricase
immunogenicity and antigenicity more efficiently than the linear 5 kDa polymer, see figure
1.3. Harris et al. [63] argue that attachment at multiple sites will increase the likelihood
of steric interference at the active site of the native protein, which will result in a possible
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inhibition or reduction of the activity. Monfardini et al. [70] have shown that branched
PEG polymers have increased the pH and thermal stability as well as increased the resis-
tance to proteolytic digestion compared with linear PEG conjugates. These results suggest
that high molecular weight and branched structures are more efficient in preventing the
approach of anti-protein antibodies and do improve the immunogenicity more efficiently.
Branched PEGLinear PEG
An approacing molecule can not reach the surface
An approacing molecule can reach the surface
Figure 1.3: The branched PEG decreases the probability of an approaching molecule
reaching the surface of the protein compared to the linear PEG. Adapted from [63] and
[71].
A side effect of having an efficient prevention of an approaching molecule is also expressed
in the lower biological activity. Veronese et al. [72] showed that when PEGylating the
enzyme uricase, the residual PEGylated enzyme activity was 32 % of the starting one us-
ing a branched PEG, whereas it was only 2.5 % if a linear PEG of the same mass was used.
1.2.3 PEG-protein linkage
It is crucial to ensure that the linkage between the PEG moiety and the protein drug is
stable in order to ensure that the pharmaceutical advantages are maintained. Normally
PEGylation of a protein is achieved either chemically or enzymatically.
Chemical PEGylation
The chemical PEGylation process is attained by the formation of linkages between a
surface available amino acid and an active carbonate, active ester, aldehyde or tresy-
late derivative of PEG [73]. The modification of the terminal hydroxyl group of PEG
is synthesised chemically, and the PEG is activated through the substitution of the hy-
droxyl group by an electrophilic functional group [74]. Subsequently, the activated PEG
can be covalently bound to a specific amino acid, most often lysine or the N-terminus
of the protein. The PEG derivatives which are used for amine coupling include N-
hydroxysuccinimidyl-activated esters (producing an amide linkage), PEG-epoxide (amine
linkage), PEG-carbonyl imidazole (urethane linkage), PEG-tresylate (amine linkage) and
PEG-aldehyde (amine linkage). The thiol groups in cysteine can also be used for PEG-
ylation, in this case a PEG-maleimide is among the most utilised [63], see figure 1.4 for
the reaction mechanism. In a typical PEGylation reaction process where the lysines or
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N-terminal amines are PEGylated, the PEG will be attached to one or several potential
sites on the protein. Each of these PEGylated compounds represents one isoform, and the
compounds will differ in either degree of PEGylation (mono-, di- or triPEGylated) or site
of PEGylation. Most studies on chemical PEGylation refer to liquid phase conjugation,
but Suo et al. [75] has developed a method for solid phase chemical conjugation, and with
haemoglobin as a model protein Suo et al. obtained a yield of 75%, in comparison to the
yield of 30 % obtained in the liquid phase.
mPEG N
O
O
+ R mPEG N
O
O
SH
S R
Figure 1.4: The Michael reaction. The PEG-maleimide is reactive under acidic conditions,
and is often used when PEGylating thiol groups [76].
We have used chemical PEGylated with PEG-maleimide to PEGylate BSA, see section
3.2 and section 4.2.
Enzymatic PEGylation
Enzymatic PEGylation take advantage of the fact that enzymes can recognise and specif-
ically modify a single or a few amino acid residues in the native protein [77]. As an exam-
ple of site specific enzymatic PEGylation Sato [78] have used transglutaminase (TGase).
Here alkylamine derivatives of PEG could be site-specifically incorporated into intact or
modified proteins without decreasing the bioactivities. However the incorporation site
of the TGase-catalyzed modification is limited to the substrate Gln residues for TGases.
Additionally DeFrees et al. [79] have designed a strategy for site-directed enzymatic PEG-
ylation using glycosyltransferases to attach PEG to O-glycans. Here the enzymatic N-
Acetylgalactosamine (GalNAc), an amino sugar derivative of galactose) glycosylation at
specific serine and threonine residues in proteins expressed without glycosylation in Es-
cherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the
introduced GalNAc residues. DeFrees et al. have demonstrated this method of site directed
enzymatic attachment of large PEG moieties to three recombinant therapeutic proteins
including interferon-αb2, and they suggest that this method enables the manufacture of
long-acting protein drugs with greater structural homogeneity compared with chemically
PEGylated proteins [80].
The enzyme based GlycoPEGylation technology, which uses glycosyltransferases to attach
PEG to N-glycans has been used to produce the GlycoPEGylated recombinant human
Factor VIIa, which has been characterised in chapters 5, 6 and 7.
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1.2.4 Location of the conjugation site
The location of the conjugation site is another important parameter which can influence
the immunogenic and antigenic properties of a PEGylated protein.
Vanwetswinkel et al. [81] have investigated recombinant staphylokinase (Sak-STAR), where
variants were obtained by substituting lysines and serines with cysteines, which were sub-
sequently modified with one or two 5, 10 or 20 kDa PEG polymers. Vanwetswinkel et al.
found that there were significant differences in the pharmacokinetic parameters among
the 5 kDa PEGylated compounds, depending on the site of conjugation. They found pro-
nounced differences between PEGylated compounds having two 5 kDa PEG polymers or
one 10 kDa PEG polymers at different conjugation sites. The authors suggest that these
observations are a result of the PEG polymer being attached to amino acids which may be
exposed to antibody binding or proteolytic enzymes. In addition, Francis et al. [80] have
reported that conjugation chemistry can have a dramatic influence on the immunogenicity
of the conjugated protein. Thus, in order to obtain the best immunological properties of
the PEGylated compound it is important to choose the polymer conjugation site carefully.
Caliceti and Veronese [58] report that in relation to cost effectiveness, therapeutic efficacy
and regulatory acceptability the mono- or diPEGylated proteins using high molecular
weight PEGs are preferred compared to mixtures of multi-PEGylated protein compounds
using low molecular weight PEGs. This is primarily due to the fact that mono- or diP-
EGylated proteins with high PEG molecular weight in themselves demonstrate enhanced
bio-pharmaceutical properties as well as high biomolecular activity compared to the multi-
PEGylated proteins with low molecular weight PEGs.
Route of administration
There are several parameters to consider when choosing the proper route of administration.
These parameters include among others the molecular weight of the PEG polymer and the
degree of PEGylation as this will be reflected in the volume of distribution and the half-life
of the PEGylated protein drug [82]. Both intramuscular (I.M.) and subcutaneous (S.C.)
adminstration could slow down both adsorption and diffusion and thus the PEGylated
drug from reaching the bloodstream for further circulation. In such cases the PEGylated
protein might act as a depot, however the degradation may also be increased. Thus the
intravenous (I.V.) route of administration might be preferred.
Veronese et al. [83] have studied the pharmacokinetic effect of administering PEG-superoxide
dismutase (PEG-SOD) by intravenous, intraperitoneal, subcutaneous and intramuscular
injection, see figure 1.5. This study showed that compared to the intravenous route (100
%) the bioavailability of SOD was 71, 54 and 29 % after intraperitoneal, intramuscular
and subcutaneous adminstration, respectively. Compared to the native SOD, the bioavail-
ability were in general 100 fold higher, regardless of which route of administration was
used. As as seen on figure 1.5, the time for maximal concentration peak is higher when
using I.M. and S.C. injection compared to the two other adminstration routes [58].
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Figure 1.5: Pharmacokinetic profiles of PEG-superoxide dismutase (SOD) in rats after in-
travenous, intraperitoneal, intramuscular and subcutaneous administration, adapted from
[58].
1.2.5 Purification of PEGylated proteins
Chromatographic methods are used to both purify and characterise PEGylated proteins
as these methods have both preparative and analytical purposes. Besides from purifying
the PEGylated protein by removing PEGylation byproducts and unconverted reactant,
information regarding the characteristics of the molecule is also obtained.
Ionic Exchange Chromatography (IEC)
The most common chromatographic method for purifying PEGylated proteins is IEC,
and this method has been successfully used to separate several different monoPEGylated
proteins from their native counterparts including interleukin 2, papain, caricain, glycyl
endopeptidase and human granulocyte colony-stimulating factor, [84, 85]. Fee [85] states
three ways in which PEG can affect the charge properties of the protein. First of all, the
PEG polymer may weaken the electrostatic interactions by shielding the surface charges.
Second of all, the conjugation of PEG to charged residues can affect the isoelectric point
(pI) of the protein conjugate. Finally, the PEG polymer bind by hydrogen bonding to some
of the surface available amino acids and thus raise or reduce their pKa and in this way
affect the charge versus pH behaviour. An observation reported by both Fee [85] and Pabst
et al. [86] regarding IEC is that the heavily PEGylated proteins (longer chain length or di-,
tri-PEGylated species) elute at a lower ionic strength than their less heavily PEGylated
counterparts. Pabst et al. [86] also report a very large decrease in the dynamic binding
capacity of PEGylated BSA species compared to the native BSA. These observations are
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explained by modulation of the electrostatic interactions associated with the binding of
the neutral PEG chain to the charged surface amino acids and an increased mass transfer
resistance due to the large size of the PEGylated molecule [85, 86].
Size Exclusion Chromatography (SEC)
SEC can be used to purify a PEGylated sample as well as determine the PEGylation
extent, keeping in mind that the elution volumes for SEC relates to the protein size not
the molecular weight [85]. The PEGylation extent of a PEGylated protein can be de-
termined qualitatively [87]. SEC is useful as a desalting method, and due to the large
hydrodynamic radius of PEGylated proteins small by-product molecules will also be re-
moved during the SEC experiment, and can also be used to separate the native protein
from its PEGylated compounds. Generally, the best peak separation is obtained if the
proteins differ in molecular weight by no less than two times [85].
Both chromatographic methods have been used to purify PEGylated BSA, see section 3.2
and section 4.2.
1.2.6 Biophysical properties
Thorough characterisation and knowledge about the distribution of the PEGylated com-
pounds are important throughout the whole development process of a PEGylated phar-
maceutical drug, which includes formulation changes, process changes and up-scaling [63].
Biophysical characterisation can provide crucial and essential information about the struc-
tural, thermal, kinetic and functional stability, all of which can be used in the further
development steps.
Structural and thermal stability
Despite the reported altered properties of the PEGylated protein compared to the unmod-
ified protein in relation to prolonged circulation time and reduced activity, most studies
report an unchanged secondary and tertiary structure of the protein upon PEGylation.
Hinds and Kim [65] have studied PEGylation of insulin by Circular Dichroism (CD), and
conclude that PEGylation did not substantially alter insulin’s secondary/ tertiary struc-
ture. Meng et al. [88] have also used CD to investigate the effect of PEGylation using
human serum albumin (HSA) as the model protein. Meng et al. report, that the CD
spectra of the conjugates showed that PEGylation of HSA has only little influence on the
secondary structure of HSA, whereas Freitas and brahao Neto [89] have studied 5 kDa
mono-PEGylated lysozyme with CD and FTIR, and concluded, that the protein structure
of lysozyme did not change with PEGylation. Digilio et al. [90] have conducted Nu-
clear Magnetic Resonance (NMR) spectroscopy on monoPEGylated derivatives of human
growth hormone-releasing factor, fragment 1-29. Digilio et al. report that lysine PEG-
ylation does not alter the tendency of the peptide to adopt a stable R-helix conformation,
nor does it induce appreciable conformational mobility in the proximity of the PEGylation
sites. Dhalluin et al. [91] have studied the thermal and kinetic stability of monoPEGylated
human recombinant Interferon-α2a, and they report an unchanged secondary and tertiary
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structure upon PEGylation too. Furthermore Dhalluin et al. conclude, that PEGylated
interferon-α2a compound has a significantly decreased tendency for heat induced irre-
versible aggregation, coupled with a slightly elevated denaturation melting temperature.
In addition, Ramon et al. [92] studied the conjugation of interferon-α2b (IFN-α2b) to a
branched 40 kDa polyethylene glycol with several methods including ELISA and thermal
stability (storage at 60 ℃). Ramon et al. concluded, that the immunorecognition against
IFN was reduced by the attached PEG moiety, and that PEGylation markedly enhanced
the thermal stability of IFN-α2b. Stigsnaes et al. [93] investigated the effect of 5 kDa
mono-PEGylation on the conformation and physical stability of glucagon during purifi-
cation and freeze-drying using FTIR, CD and Thioflavin T asays. Stigsnaes et al. report
that the formation of intermolecular β-sheet was less apparent for 5 kDa PEG-glucagon,
and that no fibrillation was detected. Stigsnaes et al. conclude, that 5 kDa PEG-glucagon
showed a significantly improved physical stability during purification and freeze-drying
compared to glucagon. In addition, Hinds and Kim [65] studied the fibril formation of
insulin and PEGylated insulin compounds by accelerated shake tests, and conclude that
PEGylation significantly increase the fibrillation-resistance, mainly due to steric blocking
and increased physical stability.
Even though there appears to be a number of biophysical characterisation studies done
on the effect of protein PEGylation, no fundamental study exists which encompasses the
effect of PEGylation and different PEG chain lengths on the thermal and kinetic as well
as the structural stability. Measuring the thermally induced unfolding and subsequent
aggregation by DSC and DLS, and combining this with the thermally induced changes
in tertiary structure of an unmodified protein and its PEGylated counterpart has yet to
be done. A combination of these methods will enable us to relate changes in the tertiary
structure with the formation of aggregates while the overall heat uptake or release is mon-
itored. This would give us a good platform for interpreting the behaviour of PEGylated
proteins upon heating.
We have used three complementary classical biophysical characterisation methods which
all illustrate each different aspects of the protein unfolding or aggregation processes. The
biophysical characterisation has been done on two different protein model systems; Bovine
Serum Albumin (BSA) and the more pharmaceutically relevant recombinant human Factor
VIIa (rFVIIa). BSA was monoPEGylated with 6 linear PEG ranging from 5 to 60 kDa
(chapter 3), and rFVIIa was GlycoPEGylated with a 10 kDa linear PEG or a 40 kDa
branched PEG (chapters 5 and 6).
Structural Characterisation
The secondary structure and tertiary structure of both BSA and rFVIIa and their PEG-
ylated and GlycoPEGylated compounds have been measured by Circular Dichroism (CD).
The structural information obtained with far-UV-CD and near UV-CD scans shows that
both the secondary structure and the tertiary structure of rFVIIa are maintained upon
GlycoPEGylation and the structures do not change with PEG chain length nor with the
PEG conformation (linear or branched), see figure 1.6.
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Figure 1.6: Far-UV CD scan and near-UV CD scan of rFVIIa, 10 kDa PEG-rFVIIa and 40
kDa PEG-rFVIIa. The far-UV CD scans show only little variation between the spectrum
of 10 kDa PEG-rFVIIa and the two spectrums of rFVIIa and 40 kDa PEG-rFVIIa, and
the near-UV CD scans show that GlycoPEGylation has no notable effect on the tertiary
structure (near-UV CD) of rFVIIa.
The secondary structure and tertiary structure of BSA is also maintained upon PEGylation
(fig. 3.2 and fig. 3.3).
Thermal stability
While the secondary and tertiary structure appear to be maintained upon PEGylation
and GlycoPEGylation, the thermal stability of both model proteins was affected by the
covalently attached PEG polymer. For BSA the apparent unfolding temperature, Tm,
measured by DSC decreased with PEGylation (fig. 1.7), whereas Tm for rFVIIa increased
with GlycoPEGylation (fig. 1.8). The temperature of aggregation, Tagg (see fig. 1.8 for
definition), measured by Dynamic Light Scattering (DLS) increased with PEGylation or
GlycoPEGylation for both proteins in questions (fig. 1.7 and fig. 1.8).
The apparent unfolding temperature, Tm decreases for BSA and increases for rFVIIa
upon PEGylation and GlycoPEGylation, a result which indicates that the alterations in
the thermal stability upon covalently attaching a PEG moiety is very protein specific.
All the PEGylated BSA compounds seems to be unfolding at a lower temperature than
unmodified BSA, whereas unmodified rFVIIa unfolds at a lower temperature than its
GlycoPEGylated compounds. For both model proteins it is evident that a longer PEG
chain length does not contribute more to the stability of the protein than a short PEG
chain. Rather, it appears that the thermal stability is independent of the molecular weight
of the attached PEG polymer. For both model proteins the temperature of aggregation,
Tagg, increased markedly with PEGylation and GlycoPEGylation, and the unfolded state
of the proteins appear to be stabilised.
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Figure 1.7: DSC scan and DLS measurements of BSA and the 6 PEGylated BSA species
with various covalently attached linear PEGs. The DSC scans reveal that PEGylation
slightly decreases the apparent unfolding temperature, Tm. The DLS measurements are
plotted with the DSC scans, and as expected, the aggregation temperature, Tagg, increases
with PEGylation.
Formulation
The effect of altering the salt concentration in the buffer was also investigated in the case
with GlycoPEGylated rFVIIa (chapter 6). As with lysozyme (chapter 2) the thermal
stability of rFVIIa and its GlycoPEGylated compounds also depend on the concentration
of CaCl2 in the buffer (fig. 1.8 and table 1.4). Three different CaCl2 concentrations were
used: 10 mM, 35 mM and 100 mM.
From the thermograms in fig 1.8 it is evident, that the thermal stability of rFVIIa depends
on both CaCl2 content and GlycoPEGylation. The apparent unfolding temperature of
rFVIIa decreases at 35 mM and 100 mM CaCl2 compared to 10 mM CaCl2, whereas 10
kDa PEG-rFVIIa and 40 kDa PEG-rFVIIa are not thermally destabilised until the CaCl2
concentration reaches 100 mM. There is a significant difference between the appearances
of the thermograms after Tm has been reached. From the DSC thermograms and the LS
intensities for the GlycoPEGylated rFVIIa compounds, it appears that GlycoPEGylation
delay the thermally induced aggregation of rFVIIa at 10 mM CaCl2 and 35 mM CaCl2.
At 100 mM CaCl2 the unmodified rFVIIa and the GlycoPEGylated rFVIIa compounds
display similar aggregation behaviour.
In relation to the biophysical characterisation of rFVIIa and GlycoPEGylated rFVIIa, it
is noticeable how all three compounds display different aggregation behaviours at 100 mM
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Figure 1.8: DSC thermograms and LS intensity measurements of rFVIIa, 10 kDa PEG-
rFVIIa and 40 kDa PEG-rFVIIa are plotted as a function of temperature in buffers with
3 different CaCl2 concentrations. The dotted line correspond to the LS intensity, the
solid line correspond to the DSC thermogram. The insert illustrate where the onset
temperature, Tonset, the temperature of aggregation, Tagg, and the apparent unfolding
temperature, Tm, are found. The rFVIIa aggregates formed close to Tagg were too large
for the LS detector to measure, and continuous intensity measurements as a function of
temperature were impossible after 53 ℃ for rFVIIa.
CaCl2 as compared to the lower calcium concentrations. At 100 mM CaCl2 the aggregation
is not only postponed for all the investigate proteins, native and GlycoPEGylated, the
difference between Tonset and Tagg is 10-11 degrees as opposed to 1-5 degrees at lower
CaCl2 concentrations. The main conclusion form these results is that GlycoPEGylation
postpones the calcium induced thermal destabilisation of rFVIIa, and a much higher
calcium concentration also postpones the thermally induced aggregation of rFVIIa. The
thermally induced aggregation of the GlycoPEGylated rFVIIa compounds is unaffected
by an increasing calcium chloride concentration.
Lumry-Eyring model
For all the investigated PEG-protein systems the unfolding and aggregation pathway can
be described by a model put forward by Lumry and Eyring in 1954 [94]. According to the
Lumry Eyring model, irreversible protein denaturation involves at least two steps. The
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Tonset (℃) Tm (℃) ∆H (kJ/mol) Tagg (℃) (Tonset-Tagg)
(DSC) (DSC) (DSC) (LS)
10 mM CaCl2
rFVIIa 50.9±0.2 57.7±0.2 NA 50.8±0.4 0.1
10 kDa PEG-rFVIIa 53.3±0.1 59.0±0.2 140 57.1±0.2 -3.8
40 kDa PEG-rFVIIa 52.9±0.1 59.0±0.2 134 57.9±0.9 -5
35 mM CaCl2
rFVIIa 49.0±0.1 55.2 ±0.2 NA 49.8±0.7 -0.8
10 kDa PEG-rFVIIa 51.0± 0.1 58.0 ±0.2 140 56.8±0.3 -5.8
40 kDa PEG-rFVIIa 52.3±0.1 58.6±0.2 153 57.7±0.2 -5.4
100 mM CaCl2
rFVIIa 48.3±0.1 55.1±0.2 NA 59.3±0.4 -11
10 kDa PEG-rFVIIa 47.6±0.2 55.3±0.2 147 59.2±0.4 -11.6
40 kDa PEG-rFVIIa 47.1±0.1 55.0±0.2 156 56.7±0.2 -9.6
Table 1.4: The onset temperature Tonset, the Tm and corresponding enthalpy measured
by DSC, the aggregation temperature, Tagg, measured by LS and the difference between
Tonset and Tagg. The extraction of the enthalpy of unfolding of rFVIIa is not possible due
to the irreversibility of the denaturation process.
first step is the reversible unfolding of the native protein (N), characterised by the rate
constants, k1 and k2. This step is followed by an irreversible change of the unfolded protein
(D), into an inactivated, irreversible aggregate (A), characterised by the rate constant k3.
The unfolded state, D, is characterised by having some tertiary structure.
2k
k1 k3 k1
k2
N D A K=
Figure 1.9: The Lumry Eyring model, N is the native protein, D is the unfolded protein
and A is the aggregated protein.
Thus we suggest that the covalent attachment of a PEG polymer to a protein (BSA or
rFVIIa) slightly increases the equilibrium constant K (lowers Tm) but has a stronger,
reducing effect on k3, so that the aggregation of the denatured (D) is slowed down. The
general suppression of protein aggregation by PEG observed here is in accord with earlier
reports [65, 95] and the suggestion that this is mainly due to changes in k3 (and not K) has
also been put forward before [65]. Steric hindrance of favourable peptide-peptide contacts
appears to be a likely course for the effect of PEG on k3, but the lack of a correlation of
PEG size and Tagg suggests that other as of yet unidentified factors may be involved in
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the PEG induced increase of the colloidal stability. In particular in relation to the study
on the effect of calcium, it is suggested that rFVIIa (unmodified and GlycoPEGylated)
in general is stabilised by electrostatic interactions which are weakened by the addition of
CaCl2, and that CaCl2 might interact preferentially with the protein in the unfolded state,
’D’. Both effects stabilise the aqueous ’D’ state, as the equilibrium constant K increases
and the rate constant k3 decreases with increasing calcium concentration, leading to a
lower apparent Tm and a higher Tagg.
Binding properties
Even though the structure of the PEGylated proteins appears to be maintained upon
PEGylation, the binding properties of the protein can be altered. Kubetzko et al. [96]
have constructed a site-specifically PEGylated variants of anti-p185(HER-2) antibody
fragments in the format of a monovalent single-chain variable fragment and a divalent
mini-antibody and characterized the antigen binding properties using Surface Plasmon
Resonance (SPR). Kubetzko et al. found that the attachment of a 20-kDa PEG moiety
led to a reduction in apparent affinity of approximately 5-fold, despite a maintained im-
munoreactivity of the antibody fragments upon PEGylation. In relation to the obtained
results, Kubetzko et al. suggest that PEGylation can alter the binding-competent fraction
of both ligands and receptors significantly and that this may help to explain some of the
beneficial effects of PEGylation in vivo. Larson et al. [97] investigated 5 kDa or 20 kDa
multi-PEGylated monoclonal anti-GAD antibodies with CD, 1H-NMR and ELISA. The
1H NMR analysis of the modified antibody showed reasonably similar results from 5 to 60
PEG per antibody, and the CD spectra of the polyclonal rabbit IgG showed only small
differences at variously modified antibody. The ELISA method revealed that the bind-
ing affinity of anti-GAD was lower for all PEG modifications with respect to unmodified
anti-GAD, and binding to GAD or anti-mouse-IgG decreased as the degree of modification
increased. Wang et al. [98] have investigated the effect of PEGylation on human galectin-2
and report that PEGylation enhanced the protein’s stability towards aggregation but did
not alter the binding properties.
There are several ways of investigating possible changes in the binding properties of pro-
teins and how these properties can be altered upon PEGylation. One way is to study ligand
binding; another is to study the binding between a protein and it’s antibody. These two
methods elucidate different aspects of the binding process and can be used complemen-
tary. To illustrate possible alterations in the ligand binding properties of proteins due
to PEGylation, we have investigated the ligand binding properties of BSA and 6 linear,
monoPEGylated BSA compounds with Isothermal Titration Calorimetry (ITC) (chapter
3). We chose BSA as a model protein because previous studies of the binding of serum
albumins have examined the thermodynamics and stoichiometry of fatty acids or mim-
ics of these (like SDS) to BSA with ITC [99–101]. As the experimental foundation on
the unmodified protein already was present, the effects of PEGylation were elucidated by
comparing the experimental results obtained with the various PEGylated BSA molecules
with the literature values.
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At 25 ℃ two distinct classes of binding sites (high affinity and low affinity) for BSA and
one class of binding site (low affinity) for PEGylated BSA were identified (fig. 1.10). The
binding isotherm was modelled assuming independence and thermodynamic equivalence
of the sites within each class. Thus BSA appears to have an altered functionality (binding
profile) upon PEGylation. These biophysical characteristics are all independent of the
molecular weight of the attached polymer chain.
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Figure 1.10: Enthalpograms showing the binding of SDS to native BSA and the 6 PEG-
ylated BSA compounds. The ordinate shows the observed enthalpy change ∆Hobs in kJ
per mole SDS injected, and the abscissa is the concentration of SDS expressed by the
surfactant: protein molar ratio. Visually and thermodynamically, there is a significant
difference between the binding profiles of the native BSA compared to the PEGylated
BSA species. The enthalpogram for native BSA show two inflection points and three
plateaus are found, whereas the PEGylated BSA species all have only one inflection point
and two plateaus. This indicates that SDS binds differently to native BSA compared to
PEGylated BSA.
It is noticeable how little variation there is within the parameters characterising the low
affinity sites of the 6 PEGylated BSA compounds. The function of PEGylated BSA
seems to be the same whether a small PEG polymer chain or a long PEG polymer chain
is attached. Crystallographic and thermodynamic investigations of the these sites on
structurally similar serum albumin have revealed that the binding sites for negatively
charged ligands with large acyl chains can be roughly divided into two classes: high
affinity and low affinity, and that within each class the binding parameters are similar
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[99, 102, 103]. It has been suggested that the hydrophobic regions of PEG would interact
with the hydrophobic clusters on the protein surface, resulting in a structure of the PEG-
protein complex, where PEG is coiled on the protein surface [104]. This may explain
the change in the binding properties of BSA upon PEGylation. The PEG polymer may
compete with SDS for interaction sites on the protein surface and thus weaken SDS-BSA
affinities; although control ITC experiments in which an 8 kDa PEG polymer was titrated
to unmodified BSA failed to show direct binding.
Besides investigating the effect of PEGylation on the binding properties of BSA with
ITC, we have also investigated these properties with Surface Plasmon Resonance (SPR)
(Chapter 4). The binding kinetics of BSA and PEGylated BSA to anti-BSA is investigated
with two identical but reversed assay orientations. The SPR response to the binding of
BSA or PEGylated BSA to anti-BSA is depending significantly on PEGylation, and it
applies to both assay orientations that the binding between anti-BSA and unmodified
BSA results in the largest SPR response compared to the binding between anti-BSA and
the PEGylated BSA compounds. The SPR response due to complex formation between
anti-BSA and PEGylated BSA seems to be independent of the molecular weight of the
grafted PEG moiety, which is in accordance with the binding results we obtained with
ITC. In addition, we observed that the rate of association was unaffected of PEGylation,
molecular weight of the attached PEG polymer as well as assay orientation, and overall
KD appeared to be slightly depending on PEGylation, but independent of the molecular
weight of the attached PEG polymer and of the orientation of the assay.
Hydrodynamic volume
When developing a pharmaceutical protein solution intended for injection, the viscosity of
the solution plays a key role. In the end it is the viscosity which determines how easy it
will be and how long time it will take to press the solution through the syringe. The final
viscosity of an aqueous protein solution can be estimated from knowledge of the intrin-
sic viscosity or the molar hydrodynamic volume of the protein in question together with
the concentration of protein in solution. Investigations regarding possible changes in the
molar hydrodynamic volume of a pharmaceutical protein upon PEGylation are of high
relevance in the drug development process, and we have examined the change in molar hy-
drodynamic volume of recombinant human Factor VIIa (rFVIIa) upon GlycoPEGylation
by measuring the intrinsic viscosity and the molar mass of rFVIIa, PEG and two different
GlycoPEGylated rFVIIa compounds, a 10 kDa linear GlycoPEGylated rFVIIa and a 40
kDa branched GlycoPEGylated rFVIIa (see Chapter 7). The results show that the mo-
lar hydrodynamic volume of the conjugated protein is not just an addition of the molar
hydrodynamic volume of the PEG and the protein. The molar hydrodynamic volume of
the GlycoPEGylated protein is larger than the volume of its composites. These results
suggest that both the linear and the branched PEG are not wrapped around the surface of
rFVIIa but chains are significantly stretched out when attached to the protein, see figure
1.11.
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Figure 1.11: The molar hydrodynamic volume of rFVIIa, pure PEG and GlycoPEGylated
rFVIIa. The molar hydrodynamic volumes of the conjugated protein indicate that the
PEG polymer is not wrapped around the protein; on the contrary it appears to be stretched
out from the protein surface.
Further reading
The intentions of this part of the thesis was to give the reader an introduction to and
background knowledge on and a short description of the data obtained on the two subjects
treated in part II and III. Part II and III are a more detailed description of experiments,
result and discussions of the two subjects and the chapters are all constructed as research
papers, four of them have been submitted, two have been accepted for publication (chapter
5 and 6) and two are currently under peer review (chapter 3 and 7).
Part II
Highly Concentrated Protein
Solutions
28
2 Thermal stability of Lysozyme at high
concentrations: Effect of surface charge
Abstract
The non-ideal properties of concentrated proteins solutions are attracting increasing inter-
est. However the experimental analysis of the relatively strong intermolecular interactions
and the excluded volume effects which may modulate the stability of the protein remain
sparse. Here the thermodynamic stability of chicken egg lysozyme was investigated by
DSC with respect to protein concentration, pH and added salt. Despite excluded volume
effects the data indicate that lysozyme is destabilised at high protein concentration and low
salt concentration. This indicates that electrostatic interactions favour protein unfolding
in the investigated systems. The results generally emphasized the role of intermolecular
electrostatic interactions for the stability of lysozyme at high concentration. Thus, in
de-salted solutions the unfolding temperature, Tm, decreased at all investigated pH values
as the protein concentration was raised from 40 to 200 mg/ml. At pH 2.0 and 2.5, where
lysozyme is highly charged, this tendency seems to be reverted so that Tm increased with
protein concentration by the addition of 250 mM NaCl. At pH 5.0, on the other hand,
where the estimated net charge was lower than at pH 2.0 and 2.5, Tm decreased slightly
at all investigated salt concentrations. It is suggested that the lowered thermodynamic
stability at high protein concentration reflects electrostatic repulsion between the native
protein molecules or electrostatic attraction between the unfolded protein molecules. This
unfavourable effect is speculated to be less severe in the more flexible denatured state and
hence to displace the thermal equilibrium towards unfolding.
Keywords: highly concentrated protein solutions, protein stability, surface charge, elec-
trostatic interactions, DSC.
2.1 Introduction
Concentrated protein solutions are characterised by a pronounced non-ideality, which be-
comes particularly strong above 10-20 % by weight [105]. This is of interest e.g. for the
understanding of enzyme catalysis in vivo, where very high protein concentrations (10-35
%) may significantly modify kinetic parameters measured in dilute systems [106].
Theoretical aspects of the work on highly concentrated protein solutions include the macro-
molecular crowding theory or excluded volume theory developed by Minton and co-workers
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[20, 21]. In the simple case of inert molecules, this theory predicts that the equilibrium of
a highly concentrated protein solution will shift towards the native state of the protein;
away from the less compact, unfolded state and thus that the thermal stability of the na-
tive conformation will increase at high concentration. These excluded volume effects are
related to the mutual impenetrability of inert macromolecules and hence mutual steric re-
pulsion, yielding an increased conformational stabilisation at higher protein concentration
[8]. However, contributions to the chemical potential from the intramolecular electrostatic
effects as well as a number of intermolecular interactions including van der Waals forces
and hydrogen bonding may change considerably with increasing protein concentration.
This, in turn, may affect the chemical potential of the native and denatured states of the
protein differently and hence shift the thermodynamic stability in a more complex fashion.
Within the pharmaceutical industry there is a growing interest in investigating proteins
in highly concentrated solutions primarily due to the increasing interest in highly con-
centrated antibody solutions. The administration of highly concentrated protein drugs,
especially antibodies [3, 4, 9, 107], is often associated with the subcutaneous route of deliv-
ery. This route of administration most often requires a higher concentration of the protein
drug due to the limited volume given. In spite of the growing interest, the distinctive prop-
erties of concentrated solutions remains only sporadically explored experimentally [9, 22].
In fact, most biophysical work has strived to investigate solutions, which are as dilute as
the experimental method permits, so that forces between protein molecules and restricted
volume effects are practically absent, and the intrinsic stability of the protein can be un-
ravelled. Therefore, a major obstacle for a deeper understanding of concentrated protein
solutions currently appears to be a shortage of experimental data. There are a number
of works concerning the conformation, interactions and colloidal stability of proteins in
crowded systems [105, 108–111], but data on thermodynamic, hydrodynamic and catalytic
properties are sparse. In some cases, the concentrated solutions need to be diluted prior
to analysis due to experimental limitations [112], but this strategy clearly holds a risk of
making mistakes in relation to evaluation of the protein stability. Dilution can signifi-
cantly change for example the kinetics of irreversible processes as protein aggregation and
storage stability.
We have used chicken egg lysozyme as a model protein to investigate the influence of pH,
and added salt on the thermal stability of lysozyme at high concentration. Lysozyme
is an adequate model protein for this work as it is a highly soluble, globular protein
with an isoelectric point of 10.5-11. The latter dictates a high positive net charge at
low and intermediate pH values and it turned out that this was sufficient to essentially
prevent aggregation, which is otherwise dominating thermal denaturation at high protein
concentration. As a result we were able to study reversible unfolding and hence single
out the thermodynamic functions even at very high protein load. The structure, folding
mechanisms and stability of dilute lysozyme solutions have been studied intensively over
the past decades [8, 10, 26–44]. This includes thermal stability and unfolding pathways
as a function of pH [8, 30–32], buffer concentration [8, 45], and denaturants such as
guanidinium chloride and urea [8, 31, 40, 42, 46]. This wealth of information provides
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a unique opportunity of interpreting high concentration lysozyme data, a subject which
still remain to be investigated.
2.2 Materials and Methods
Materials
Chicken Egg Lysozyme (L7651) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Lysozyme stock was prepared by dissolving the protein in MilliQ water (Millipore 0.22 µm).
The solution was subsequently filtered (0.45 µm). The solution was diluted with Milli Q
water and then concentrated through an Amicon tube (Millipore, Carrigtwohill, Ireland),
repeating the procedure 6 times to remove excess ions. At high protein concentration
lysozyme has a significant buffering capacity, and the current preparations consistently
had a pH of 4.1 at 200 mg/mL. The pH was subsequently adjusted with 1 M NaOH
or 1 M HCl (VWR, Briare, France). The salt concentration of the solution was deter-
mined by the amount of NaOH or HCl added to the most concentrated sample i.e. the
sample requiring most acid/base to achieve the desired pH. After adjustment of pH, the
concentrated samples were diluted with a NaCl-buffer with the same salt concentration
as the concentrated protein solution and pH was adjusted again. In this way, series of
the low-salt samples, with identical concentration of salt and protein concentrations from
40-200 mg/ml could be prepared at three different pH values. The concentration of added
NaCl was 60 mM for pH 2.0, 50 mM for pH 2.5 and 18 mM for pH 5.0. In addition
to this "low-salt" series, we prepared analogous solutions by adding either 90 mM NaCl
("medium-salt") or 250 mM NaCl ("high-salt") to the solvents. Again, these medium and
high salt solutions were prepared at pH 2.0, 2.5 and 5.0 and with a lysozyme concentration
ranging from 40-200 mg/mL., The concentration of lysozyme was determined using diluted
solutions, the published extinction coefficient 37.860, [113] and A280 measurements. The
solutions were kept at -20 ℃ until used. All experiments are made in duplicates.
Differential Scanning Calorimetry (DSC)
DSC experiments were performed with a Perkin Elmer Pyris 1 DSC with auto sampler
(Waltham, MA). An empty steel sample pan with lid was used as reference and the scans
were preformed with a scan rate of 10 ℃/min. All samples were heated from 5 ℃ to 110
℃, cooled from 110 ℃ to 5 ℃ and re-heated from 5 ℃ to 110 ℃. DSC data was analysed
using Origin software from MicroCal Inc. (Northampton, MA). A baseline was subtracted
prior to analysis. The apparent denaturation temperatures (Tm) values were determined
as the temperature corresponding to the maximum heat capacity (Cp). The enthalpy is
calculated from the area under the peak bound by the baseline. The difference in heat
capacity is found as described in [30], and the uncertainties are determined based on 3
different tangents on each side of the peak.
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Protein pKa (PROPKA)
The online programme PROPKA [114, 115] was used to estimate the value of the surface
charge of the lysozyme molecule as a function of pH. PDB file number 2vb1 was used
[116]. PROPKA uses all the available amino acids of the native and unfolded protein,
respectively, in calculating the total surface charge of the given conformational state. The
amino acids individual contributions to the total surface charge depend on their individual
location within the protein. In the native state the amino acids are categorised as buried,
at the surface or bonded, the latter only apply to cysteine. In the unfolded state pKa values
are similar to the actual pKa values for the given amino acids (personal communication;
Associate Professor Jan H. Jensen).
2.3 Results and Discussion
DSC thermograms
The DSC scans were conducted so that all the samples were heated, cooled and re-heated.
We found that although the samples had been heated 20-40 ℃ above Tm in the first
heating scan, the enthalpy change was only reduced by 5-10% in the subsequent heating
scan. Thus, it seems reasonable to assume, that the denaturation process around Tm
occurs close to equilibrium with a small contribution from coupled, kinetically controlled
processes such as aggregation, see figure 2.1.
Figure 2.2 shows two families of raw DSC data for low-salt/pH 2.5 (fig. 2.2a) and high-
salt/pH 5.0 (fig. 2.2b), respectively. In both of these examples the apparent unfolding
temperature of lysozyme decreases with increasing concentration of the protein. The
tendency is particularly pronounced at low pH and low salt concentration (fig. 2.2a).
To further illustrate the observed decrease in the apparent unfolding temperature with
increasing lysozyme concentration, Tm is plotted as a function of the protein concentration
for all the investigated systems (fig. 2.3). It appears that for the low-salt samples (fig.
2.3, low salt) Tm consistently decreases with protein concentration. However, this trend
is changed by the addition of salt (fig. 2.3, medium salt and high salt).
The observed variations in Tm due to changes in pH are also found in a very comprehensive
work by Pfeil and Privalov [30–32]. They found Tm values of 48 ℃ at pH 1.5 and 78
℃ at pH 4.5 by using a 1 mg/mL lysozyme, 100 mM NaCl buffer [30]. Both values are
comparable to the values obtained in this work.
Enthalpy
The unfolding enthalpy is calculated for all the DSC thermograms by integrating the
area under the peak. The enthalpy at infinite dilution is found by plotting the unfolding
enthalpy as a function of concentration at different pH values. Using linear regression
and subsequently extrapolating to zero result in values in the range of 240-750 kJ/mol,
see figure 2.4. The enthalpies at low lysozyme concentration (40 mg/mL) are outliers,
but repeated experiments have given the same result. The values of the enthalpies are
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Figure 2.1: Thermograms of the first and second up scans of a 120 mg/mL lysozyme
sample, pH 5.0, 18 mM NaCl. The small difference in peak size (∼ 6%) corroborates the
view that the denaturation may be described as a simple unfolding equilibrium.
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(a) DSC thermograms obtained at pH 2.5 and low
salt concentration.
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(b) DSC thermograms obtained at pH 5.0 and high
salt concentration.
Figure 2.2: DSC thermograms of various concentrations of lysozyme at pH 2.5/low salt
and 5.0/high salt.
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Figure 2.3: The unfolding temperature, Tm, of lysozyme at different salt concentrations.
The legend, I, represent the salt concentration in the solution.
comparable to values obtained by Pfeil and Privalov [30–32].
Heat capacity
The heat capacity change associated with the unfolding of the protein is found as described
in section 2.2. The values for the heat capacity are positive and independent of pH and
attain values of 8 ± 2 kJ mol−1K−1, when disregarding the enthalpies obtained at 40
mg/mL. This value is in the range of the values found in the literature [30–32].
The interactions in the pH range from 2.0 to 5.0 are particularly interesting, as the protein
is far from its pI and consequently highly charged. The results obtained in this work
illustrate the interrelationships of protein concentration and the well known pH [30–32]
and salt effects on the thermodynamic stability.
At low salt concentration Tm decreases with increasing protein concentration at all pH
values, (fig. 2.6) and it seem reasonable to assume, that at low salt concentration the
contributions to the overall protein stability is dominated by other effects than the ex-
cluded volume effect. The excluded volume theory stipulates that the increase in volume
associated with increasing concentration of macromolecules will increase the chemical po-
tential of the unfolded species relative to the native state. This in turn will shift the
equilibrium towards the native state and hence result in an increase in Tm with increasing
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Figure 2.4: The plot shows corresponding values of ∆H as a function of concentration.
The filled squares correspond to measurements at pH 2.0, the open squares correspond to
measurements at pH 2.5 and the filled triangles correspond to measurements at pH 5.0, all
at different salt concentrations. The enthalpies at low lysozyme concentration are outliers,
but repeated experiments have given the same result.
protein concentration. However from the unfolding temperatures obtained at low salt con-
centration, it is observed that the native state of lysozyme is destabilised with increasing
concentration. At both medium and high salt concentration Tm decreases with increasing
concentration at high pH, whereas Tm increases with increasing concentration at low pH
(fig. 2.3).
These results indicate that the thermal stability of lysozyme in a highly concentrated envi-
ronment is particularly influenced by electrostatic interactions, as the changes in Tm with
concentration are highly influenced by the salt concentration in the solution. These elec-
trostatic interactions can to a certain extent be quantified by values of the pH-depending
surface charge. The surface charge of lysozyme has been calculated using PROPKA. The
native lysozyme molecule has a surface charge of ~18 at pH 2, see figure 2.5. This value
has been experimentally validated [30–32].
The pH-dependent surface charge values are obtained on the basis of calculation of dif-
ference in pKas of all the proteins amino acids, including the N and C terminals, as a
function of pH. From the theoretical calculations illustrated in figure 2.5 it is clear, that at
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Figure 2.5: The surface charge of lysozyme as a function of pH, calculated by PROPKA
[114, 115] using the lysozyme pdb-file: 2vb1 [116]. The filled circles correspond to the
unfolded protein; the open circles correspond to the folded protein.
low pH the unfolded state of lysozyme has a higher surface charge than the native state.
This difference in surface charge can be explained by the fact that more amino acids are
exposed, and then able to contribute to the overall charge, when the protein is unfolded
as compared to the native, folded protein.
In figure 2.6 it is seen how the apparent unfolding temperature, Tm, changes as the salt
concentration increases within each pH series. From this figure it is clear that the thermal
stability of lysozyme at pH 2.0 and pH 2.5 are influenced the most by the increase in salt
concentration. For these low pH measurements Tm decreases significantly as the salt con-
centration increases, the effect being most pronounced at low protein concentration. This
may indicate that the electrostatic interactions are strongest at low protein concentration
and at low pH. The change in salt concentration from medium to high salt does not seem
to affect the unfolding temperature much.
For the thermal stability measurements of lysozyme at pH 5.0, the effect of increasing the
salt concentration is not as marked as it was the case with the low pH measurements.
There are only small variations in Tm with increasing salt concentration, and not until
the salt concentration is increased to 250 mM an effect is found, and then only at the 160
mg/mL and 200 mg/mL.
Overall the thermal stability results indicate that the intermolecular interactions of lysozyme
are dominated by electrostatic interactions. This effect is pronounced at low pH and at
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Figure 2.6: The apparent unfolding temperature is plotted as a function of protein con-
centration. The three figures show the pH depending differences in Tm at different salt
concentration. To illustrate the variations in Tm further, the ranges on the y-axis are
different in each figure.
low salt concentrations, indicating that the interactions between the unfolded species of
lysozyme are more favourable than interactions between the native protein molecules un-
der these conditions, despite the fact that the unfolded state has a higher charge than the
native state. This suggests that the electrostatic interaction forces in this case are stronger
than the otherwise dominating ’excluded volume’ forces. The low salt measurements all
display the same tendency, decreasing Tm with increasing lysozyme concentration, and
this is illustrated in figure 2.7.
At high salt concentration the changes in Tm with protein concentration is depending
on the pH of the solution. As seen in figure 2.6 Tm decreases with increasing protein
concentration at low pH, whereas Tm increases with increasing protein concentration at
high pH. This is illustrated in figure 2.8.
The results of this study can generally be categorised in one of two ways either (i) the
apparent unfolding temperature decreases with increasing protein concentration or (ii)
the apparent unfolding temperature increases with increasing protein concentration. The
former was unanticipated, but the tendencies observed are supported by High Resolution
Ultrasonic Spectroscopy (HRUS) measurements (appendix A). The latter is in accordance
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Figure 2.7: For highly concentrated lysozyme solutions at low salt concentration the value
of the change in the apparent in Tm with concentration is independent of the pH of the
solution. Tm decreases with increasing protein concentration at all pH values. The figure
shows a schematic drawing of the native state and the unfolded state of lysozyme, and
illustrates that the equilibrium is shifted towards the unfolded state of the protein.
Figure 2.8: For highly concentrated lysozyme solutions at high salt concentration, the
value of the apparent Tm is depending on the pH of the solution. Tm decreases with
increasing protein concentration at high pH, and Tm increases with increasing protein
concentration at low pH. The figure shows a schematic drawing of the native state and the
unfolded state of lysozyme. It illustrates that the equilibrium shifts towards the native or
the unfolded state depending on the pH of the solution.
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with the excluded volume theory stating that the equilibrium between the native and the
unfolded state of the protein is shifted towards the native state upon crowding [20, 21].
Harn et al. [9] have investigated the thermal stability of a highly concentrated monoclonal
antibody (mAb) solution, and they report a decrease in the apparent unfolding tempera-
ture with increasing concentration. They argue, that the decrease in structural stability
observed in these studies is probably the result of aggregation or self association of the
recombinant mAbs upon heating in crowded solutions and not due to a decrease in the
intrinsic structural stability of the mAbs. Due to the high degree of reversibility in the
thermal unfolding process (fig.2.1), the decrease in thermal stability of lysozyme does not
seem to be a result of aggregation, rather unfolding and subsequent reversible association
seems to be the case here.
Guo et al. [8] who have worked with the stability of helix-rich proteins at high concentration
including lysozyme argue that the complexity of protein surface and surface related effects
could dominate excluded volume phenomena and could make a significant contribution to
the stability of the protein. Our results consolidate this argument. Both results emphasise
that other phenomena besides conformational stability must be taken under consideration
when interpreting data from highly concentrated protein solutions. As the effects on Tm
differ with pH and salt concentration, especially the influence of electrostatic interactions
must be taken under consideration when the experimental data are interpreted.
The results obtained in this study point to the fact that the native state of a highly charged
protein is more likely to be thermally destabilised at high protein concentration, than a
protein with a lower surface charge. In this case the thermal stability of the native state
of the proteins can be enhanced by adding a sufficient amount of salt to the solution.
In addition, the results from the high salt measurements indicate that the addition of
salt alters the intermolecular as well as the intramolecular electrostatic interaction. Both
illustrated by the increase in Tm with increasing protein concentration. Chi et al. [2] argue
that the intramolecular charge-charge interactions affect the conformational stability of
the protein, whereas intermolecular electrostatic interactions affect equilibrium and the
formation of aggregates. Whether the addition of salt ends up stabilising or destabilising
the native state of the protein is thus a balance between various mechanisms, and is
influenced by the interactions between the salt and the protein itself as well as the effect
of salt on the protein-protein interactions.
2.4 Conclusion
From the results obtained it is concluded, that the apparent unfolding temperature, Tm, of
highly concentrated lysozyme dissolved in an aqueous solution with low salt concentration
decreases as the protein is exposed to even more crowded environment. According to
our studies this is independent of the pH of the solution. At high salt concentration the
thermal stability of lysozyme depends on the pH of the aqueous solution. At low pH the
thermal stability is shifted towards the native state of the protein, in accordance with the
crowding theory. At high pH the thermal stability is shifted towards the unfolded state,
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suggesting that electrostatic forces dominate excluded volume phenomena.
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Abstract
The effects of PEGylation on the structural, thermal and functional stability of Bovine
Serum Albumin (BSA) were investigated using BSA and 6 linear, monoPEGylated BSA
compounds. The secondary and tertiary structure of BSA measured by Circular Dichro-
ism (CD) was independent of PEGylation. In contrast, the thermal stability of BSA was
affected by PEGylation. The apparent unfolding temperature Tm measured by Differ-
ential Scanning Calorimetry (DSC) decreased with PEGylation, whereas the tempera-
ture of aggregation, Tagg, measured by Dynamic Light Scattering (DLS) increased with
PEGylation. The unfolding temperature and the temperature of aggregation were both
independent of the molecular weight of the PEG chain. Possible functional changes of
BSA after PEGylation were measured by Isothermal Titration Calorimetry (ITC), where
the binding of Sodium Dodecyl Sulphate (SDS) to BSA and PEGylated BSA was anal-
ysed. At 25 ℃ two distinct classes of binding sites (high affinity and low affinity) for
BSA and one class of binding site (low affinity) for PEGylated BSA were identified. The
binding isotherm was modelled assuming independence and thermodynamic equivalence
of the sites within each class. From the present biophysical characterisation it is concluded
that after PEGylation BSA appears to be unaffected structurally (secondary and tertiary
structure), slightly destabilised thermally (unfolding temperature), stabilised kinetically
(temperature of aggregation) and has an altered functionality (binding profile). These
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biophysical characteristics are all independent of the molecular weight of the attached
polymer chain.
3.1 Introduction
Modification of pharmaceutical proteins with hydrophilic polymers such as poly-ethylene-
glycol (PEGylation) is an established method for prolonging the circulatory half-life of
proteins, reducing self-aggregation, increasing water solubility and decreasing antibody
recognition, and it has been used successfully in several marketed proteins [50, 51]. Most
of the benefits of PEGylated proteins reflect the properties of the PEG polymer itself [60].
The PEG polymer is heavily hydrated and consequently it has a large excluded volume
which, among other things, inhibits the approach of other macromolecules, resulting in re-
duced immunogenicity and decreased antibody recognition [117]. Generally, the hydration
of the PEG chain determines the overall hydrodynamic properties of a PEG bioconjugate
[59], and the increased molecular size is one of the most important properties of a PEG-
ylated protein, resulting for example in a prolonged circulation time due to low rates of
clearance from the liver and kidney [117]. Other than increasing the hydrodynamic volume
of the protein upon PEGylation, the conformation, physical properties and electrostatics
of a PEG-conjugated protein may be altered compared with the unmodified protein [59].
Possible changes include conformational changes of both PEG and protein, altered binding
properties resulting from changes in local pI, pKa, hydrophobicity and hydrophilicity of
the protein. However, most studies report an unchanged secondary and tertiary struc-
ture [65, 88, 90], a retained thermodynamic stability [91] and an increased temperature of
aggregation [65] of the protein upon PEGylation, whereas the protein’s biological activ-
ity is not necessarily preserved [49, 62, 65]. Studies regarding the stability, thermal and
structural, as well as the bioactivity of the protein are among the most fundamental when
developing pharmaceutical proteins and the ideal pharmaceutical protein should have a
long shelf-life and a high bioavailability.
Bovine Serum Albumin (BSA) is a transport protein with a molecular weight of 66400
Da [102]. BSA has one free sulfhydryl group, cysteine 34, which does not form a disulfide
bond with another cysteine in the polypeptide backbone [86]. Furthermore, BSA binds
several ligands, and it is possible to monitor the function of BSA in vitro with different
binding assays. This makes BSA a suitable model protein when investigating the effect of
protein PEGylation. Binding mPEG-maleimide (mPEG-MA) to the free cysteine of BSA
ensures both mono-PEGylation and site-specific PEGylation.
The relationship between biophysical characteristics and functional properties of proteins
and their PEGylated analogues are widely reported but to our knowledge only a few
studies have actually investigated these hypotheses experimentally [65, 91, 93, 104]. We
have investigated the effect of PEGylation with 6 linear PEG polymers ranging from 5 kDa
to 60 kDa, providing us with a unique model system for studying the effect of PEG polymer
chain length on the structure, function, thermal and kinetic stability of PEGylated BSA.
Various biophysical characterisation tools, including Circular Dichroism (CD), Differential
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Scanning Calorimetry (DSC) and Dynamic Light Scattering (DLS), were used to study
possible changes in the secondary and tertiary structure as well as the thermodynamic
stability of BSA upon PEGylation. Binding of SDS was used to study functional changes
of BSA upon PEGylation.
3.2 Materials and Methods
PEGylation reaction
Batch PEG grafting was carried out for each protein individually. All solutions were
made up in 10 mM phosphate buffered saline (PBS, Sigma, St. Louis, MO), at pH 7.4.
Bovine serum albumin (98 % pure by PAGE) from bovine plasma (Gibco Invitrogen,
NZ), was used without further purification. The maleimodo-reactants (Mono-methoxy
poly (ethylene glycol) maleimido-propionamide) were of nominal molecular weights 5000,
10000, 20000, 30000, 40000 and 60000 Da, and were a kind gift from Dr Reddy’s UK
(former Dow Pharma). 1.2 mole of solid mPEG-MA reagent was added per mole of protein
to 5 mL of 20 mg/mL native bovine serum albumin and the protein solution was mixed
with the PEG reagent and left stirring in an open 10 mL beaker at room temperature
overnight. Samples were acidified with one drop of 0.1 M HCl to stop the reaction.
The samples, including a non-PEGylated native BSA sample as a control, were separated
individually by ion exchange chromatography (IEC) using a HiPrep 16/10 QFF Anion
Exchange column (Amersham Bioscience, Uppsala, Sweden), preparing the column first
with 5 CV of 10 mM PBS pH 7.4, 1M NaCl and then 5 CV of 10 mM PBS pH 7.4. 5 mL
samples were then injected onto the IEC column and the proteins were eluted with a 15
CV linear gradient to 10 mM PBS, 1 M NaCl at 5 mL/min. The protein elution profile was
monitored by UV absorbance at 280 nm and collected in 2 mL fractions. Fractions were
analysed by SDS-PAGE, and fractions containing >80 % monoPEGylated BSA monomer,
detected by SDS-PAGE, were pooled. These fractions were then polished by injecting 6
mL samples onto a Size Exclusion Chromatography, (SEC) HiPrep 16/60 Sephacryl S-200
column (Amersham Bioscience, Uppsala, Sweden), with PBS running buffer at 1 mL/min.
The protein elution profile was monitored by UV absorbance and fractions containing >90
% monoPEGylated BSA monomer, as subsequently detected by SDS-PAGE, were pooled.
The purification was carried out on an AKTAexplorer 10TM liquid chromatography system
with an A-900 autosampler and detected by a differential refractometer detector (model
RID-10A from Shimadzu, Tokyo, Japan). The chromatography system was operated using
Unicorn software, version 4.0, (Amersham Bioscience, Uppsala, Sweden). The protein
samples were frozen in liquid nitrogen and lyophilised in a Labconco Freezone 2.5 Total
Lab system freeze dryer (Kansas City, MO) overnight at 3.0 Pa -49 ℃. The lyophilised
protein samples were kept at -20 ℃ until use. Prior to the experiments, all native BSA
and PEGylated BSA solutions were dissolved in PBS buffer and then dialysed intensively
against PBS. The dialysate was used as reference. The purity of the BSA and PEGylated
BSA samples was tested by SDS-PAGE (see fig 4.2), and revealed that the individual
PEGylated BSA samples contained all > 90 % PEGylated BSA and approximately 5 %
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native BSA monomer and 4 % native BSA dimer, respectively.
Isothermal Titration Calorimetry (ITC)
The calorimetric measurements were made with a VP-ITC instrument from MicroCal
(Northhampton, MA). Before the loading the solutions into the cell and syringe, respec-
tively, the solutions were degassed by stirring under vacuum. The protein concentration
was kept in the range 18-25 µM and determined using a Nanodrop spectrophotometer
(Thermo Scientific Wilmington, DE). The concentration of SDS was 2.4 mM. The protein
solution was loaded into the cell and titrated 40 times with aliquots of 5 µl surfactant
solution at 25 ℃. The raw ITC data were analyzed using the Origin software package
from Microcal. The heat of dilution, defined by the plateau level when the binding is
fully saturated was subtracted from the data also using the analysis software package
from Microcal. The concentration of SDS used here is slightly above the critical micellar
concentration (CMC) (measured in a separate experiment, see [118]) and a small fraction
of the surfactant will thus be delivered in a micellar form. The accompanying heat of
demicellization was subtracted as described earlier [99].
Circular Dichroism (CD) Spectroscopy
Spectra of BSA in the far-UV region (180-260 nm) were recorded on a Jasco J-810 CD
Spectropolarimeter. The light path of the cuvette was 0.1 mm and a protein concentration
of 0.8 mg/mL was used. The spectra were recorded at room temperature. Each spectrum is
an average of 5 scans. All spectra were background-corrected, smoothed and transformed
into molar ellipticity (Θ cm2 dmol−1). A value of 114 g/mol was used as a mean residue
weight for BSA.
Spectra of BSA in the near-UV region (250-350 nm) were recorded on the same spectropo-
larimeter. The light path of the cuvette was 10 mm and a protein concentration of 0.8
mg/mL was used. The spectra were recorded at room temperature. Each spectrum is
an average of 5 scans. All spectra were background-corrected, smoothed and transformed
into molar ellipticity (Θ cm2 dmol−1).
Differential Scanning Calorimetry (DSC)
DSC experiments were performed with a MicroCal VP-DSC (Northhampton, MA). Prior
to scanning, all solutions were degassed by stirring under vacuum. A pressure of 2 atm
was applied over the cells during scanning, and a scan rate of 1 ℃/min was used. The
concentration of BSA was 0.8 mg/mL and buffer scans were subtracted from BSA scans.
DSC data was analysed using the Origin software from MicroCal Inc., supplied with the
instrument. A baseline was subtracted prior to analysis. The apparent unfolding tempera-
ture (Tm) values were determined as the temperature corresponding to the maximum Cp,
and the errors are determined by repeatable experiments. The enthalpy is calculated from
the area under the peak bound by the baseline and the errors are based on the adjustment
of this baseline.
Dynamic Light Scattering (DLS)
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The DLS experiments were performed with a Wyatt DynaPro Titan (Santa Barbara,
CA) which employs a 829 nm laser and collects scattering intensity data at a fixed angle
of 90 ℃. Cuvette temperature was controlled using a thermoelectric solid-state heating
module (Peltier heat pump). Solutions were examined in a quartz cuvette with 12 µL cell
volume containing glass viewing windows for in situ scattering measurements. Samples
were centrifuged at 10.000 rpm for 10 minutes prior to analysis. The scan rate for was 1
℃/min and 10 minutes was allowed for temperature calibration prior to each experiment.
3.3 Results
Isothermal Titration Calorimetry
ITC was used to measure the binding between BSA and the ligand SDS. The enthalpogram
for the binding of SDS to native BSA shows two clear inflection points separating three
plateaus (figure 3.1).
Figure 3.1: Enthalpograms showing the binding of SDS to native BSA and the 6 PEG-
ylated BSA compounds. The ordinate shows the observed enthalpy change ∆Hobs in kJ
per mol SDS injected, and the abscissa is the concentration of SDS expressed by the surfac-
tant: protein molar ratio. Visually and thermodynamically, there is a significant difference
between the binding profiles of the native BSA compared to the PEGylated BSA species.
The enthalpogram for native BSA show two inflection points and three plateaus are found,
whereas the PEGylated BSA species all have only one inflection point and two plateaus.
This indicates that SDS binds differently to native BSA compared to PEGylated BSA.
The insert shows an enthalpogram for the binding of 8 kDa PEG to native BSA. As seen
on the figure no binding of PEG to BSA is found.
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ITC data for the binding to the two classes of independent sites is modelled as described
in Nielsen et al. [99]. Briefly, it is assumed that the native BSA molecule has two classes of
sites, which can bind the same type of ligand. These sites are thermodynamically similar
and can be characterised by a binding constant (K), an enthalpy of binding (∆H) and
a number of binding sites (N). These 6 values are found by a non-linear, least square
minimisation routine giving a maximum likelihood value (figure 3.1 and table 3.1.)
Low affinity sites
N ∆H K T ∆S
(kJ/mol) (M−1) (J/mol)
BSA 5.8±0.1 -23.9 ±0.4 3.4(±0.5)·104 7.8
BSAa 5.3±0.03 -28.1±1.0 3.7(±0.6)·105 2.0±3
5 kDa-PEG BSA 5.3±0.06 -22.6 ±0.3 3.7(±0.6)·105 9.3
10 kDa PEG-BSA 4.8±0.05 -21.7±0.3 4.4(±0.6)·105 10.5
20 kDa PEG-BSA 5.6±0.06 -22.2±0.3 4.7(±0.8)·105 10.0
30 kDa PEG-BSA 4.7±0.05 -22.6±0.3 3.4(±0.4)·105 7.0
40 kDa PEG-BSA 3.9±0.04 -22.6±0.3 4.4(± 0.6)·105 9.48
60 kDa PEG-BSA 4.9±0.04 -22.2±0.2 4.8(±0.4)·105 10.3
High affinity sites
N ∆H K T ∆S
(kJ/mol) (M−1) (J/mol)
BSA 1.7 ±0.1 -34.3±0.8 3.4(±2.1) ·107 8.8
BSAb 2.9 ±0.1 -35.5±1.1 3.3 ·107 7.4±3
5 kDa PEG-BSA - - - -
10 kDa PEG-BSA - - - -
20 kDa PEG-BSA - - - -
30 kDa PEG-BSA - - - -
40 kDa PEG-BSA - - - -
60 kDa PEG-BSA - - - -
a data from [99]
b data from [99]
Table 3.1: Summary of thermodynamic and stoichiometric parameters of the binding of
SDS to BSA and PEGylated BSA at T= 25 ℃.
The enthalpogram for the binding of SDS to native BSA shows two clear inflexion points
separating three plateaus (figure 3.1). This is in accordance with previously reported
results ([99, 119]) and indicates that a reasonable simplification of the multiple binding
processes is a picture of SDS associating with two classes of independent binding sites (high
affinity/low affinity) for the native BSA. Due to a small amount of available PEGylated
BSA the ITC measurements and DSC measurements were only performed twice, but as
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the results were very alike we have only used one of each measurement.
The enthalpograms for the binding of SDS to PEGylated BSA species show a different
course than that of native BSA, namely one clear inflection point separating two horizontal
regions (figure 3.1). It seems reasonable to assume that the PEGylated BSA molecule
contains only low-affinity binding sites, as the plateaus are found around the enthalpy
values -20 kJ/mol and 0 kJ/mol. These values are of the same magnitude as the low-
affinity sites of native BSA, supporting the conclusion that only low-affinity binding sites
are found on PEGylated BSA. This class of binding site includes several sites that are
thermodynamically similar [99, 119] and has been modelled as a one-site model wherefrom
3 parameters are found, the binding constant (K), an enthalpy of binding (∆H) and a
number of binding sites (N). ITC data for the binding to one class of independent sites
are readily modelled, see table 3.1. From the results of the modelling it is suggested that
the total number of binding sites is reduced upon PEGylation.
Circular Dichroism
The secondary and tertiary structures of PEGylated BSA were investigated by far-UV
and near-UV Circular Dichroism.
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Figure 3.2: Far-UV CD scans of native BSA and 6 PEGylated BSA species. The sec-
ondary structure of BSA is maintained upon PEGylation. There is no significant differ-
ence between the secondary structure of native BSA and the secondary structure of the 6
PEGylated BSA compounds.
Figure 3.2 shows the far-UV CD scans for the native BSA and the 6 PEGylated BSA com-
pounds. The scans show that the secondary structure of the PEGylated BSA compounds
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lines up with the secondary structure of native BSA. Also, there is no significant change
in the secondary structure between the various PEGylated BSA species.
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Figure 3.3: Near-UV CD scans of native BSA and 6 PEGylated BSA species. The ter-
tiary structure of BSA and the 6 PEGylated BSA species is practically unaffected by
PEGylation, and does not change with the attached PEG chain length. The small differ-
ences in the CD scans found around 270-300 nm for 10 kDa PEGylated BSA and 60 kDa
PEGylated BSA compared to native BSA and the other PEGylated BSA compounds are
probably due to very small changes in the mobility and nature (polarisability, H-bonding)
of specific aromatic amino acids, most likely tyrosine.
Figure 3.3 shows the near-UV CD scans of the native BSA and the PEGylated species.
The tertiary structure of BSA did not change upon PEGylation. There are small but
non systematic differences in the overlaid spectra around 280 nm, are considered being
insignificant.
Differential Scanning Calorimetry
The thermal stability of PEGylated BSA was investigated by DSC. The native BSA and
the 6 PEGylated BSA compounds were measured separately, showing that the apparent
unfolding temperature, Tm, was affected by PEGylation but not by the PEG molecular
weight (figure 3.4). The apparent Tm was lower for the PEGylated BSA than for the native
BSA, 82.5 ± 0.7 ℃ for native BSA and approximately 2 ℃ lower for the PEGylated BSA
compounds (table 3.2). A DSC scan of pure 40 kDa PEG was also performed. This
showed that the thermal transition of PEG was above 100 ℃ (data not shown). It is
hence unlikely that the PEG polymer itself does contribute to the DSC thermogram in
the investigated temperature range. Even though the native BSA thermogram does not
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show clear signs of aggregation behaviour (exothermal signal), the native BSA solution
was milk-white upon heating whereas the solutions of the PEGylated BSA compounds
were transparent.
Figure 3.4: DSC scan and DLS measurements of BSA and the 6 PEGylated BSA species
with various covalently attached linear PEGs. The DSC scans reveal that PEGylation
slightly decreases the apparent unfolding temperature, Tm. The DLS measurements are
plotted with the DSC scans, and as expected, the aggregation temperature, Tagg, increases
with PEGylation.
Dynamic Light Scattering
The thermodynamic stabilities of BSA and PEGylated BSA were measured by DLS in 7
separate experiments. The intensity is plotted as a function of temperature in figure 3.4.
The temperature of aggregation, Tagg is estimated by reading off the intersection of the
intensity curves with three intensity threshold values 1 · 106, 2 · 106 and 3 · 106 counts/sec.
As the temperature of aggregation change linearly with the intensity threshold values in
the investigated intensity range, we choose the temperature at the lowest intensity (1 ·106)
as the temperature of aggregation.
The raw DSC scan and the DLS intensity data are plotted in the same figure to illustrate
the difference between the changes in the unfolding temperature and the aggregation tem-
perature. The apparent unfolding temperature, the temperature of aggregation and the
difference between these two characteristic temperatures are given in table 3.2. The tem-
peratures listed in table 3.2 show that PEGylation increases the aggregation temperature
of the protein relative to the unfolding temperature of the protein.
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Tm (℃) ∆H (kJ/mol) Tagg (℃) (Tm-Tagg)
BSA 82.5 ± 0.2 1250 ± 150 71 11.5 ± 0.2
5 kDa PEG BSA 79.7 ± 0.2 1000 ± 100 75 4.7 ± 0.2
10 kDa PEG BSA 79.8 ± 0.2 1060 ± 150 81 -1.2 ± 0.2
20 kDa PEG BSA 79.8 ± 0.2 1030 ± 100 82 -2.2 ± 0.2
30 kDa PEG BSA 80.1 ± 0.2 930 ± 130 81 -0.9 ± 0.2
40 kDa PEG BSA 80.5 ± 0.2 950 ± 150 82 -1.5 ± 0.2
60 kDa PEG BSA 80.4 ± 0.2 980 ± 100 77 3.4 ± 0.2
Table 3.2: Table 2. The apparent unfolding temperature, Tm, and the unfolding enthalpy
(∆H) measured by DSC, the aggregation temperature, Tagg, measured by DLS and the
difference between Tm and Tagg.
3.4 Discussion
Most of the available literature on the effect of PEGylation on the structure, stability and
function of proteins has only investigated one non-modified protein and one PEGylated
protein, and these studies have focused on the effect of PEGylation [51, 93, 104]. This
study expands the concepts of PEGylation by investigating the effect of varying the PEG
chain length on the structure, stability and function of BSA.
The structural information obtained with far-UV CD scan show that the secondary struc-
ture of BSA is maintained upon PEGylation, and that the far-UV CD scan obtained in
this work is in accordance with those reported in the literature previously [120]. In ad-
dition, the near-UV CD scans shows that the tertiary structure of BSA is maintained
upon PEGylation. Both the secondary and tertiary structure of the various PEGylated
BSA species does not change with PEG chain length. The small differences in the CD
scans found around 270-300 nm for 10 kDa PEGylated BSA and 60 kDa PEGylated BSA
compared to native BSA and the other PEGylated BSA compounds could be due to small
changes in the properties (mobility, polarisability, H-bonding) of specific aromatic amino
acids, most likely tyrosine. However, the overall tertiary structure of 10 kDa PEGylated
BSA and 60 kDa PEGylated BSA is still considered to be essentially identical to that of
the native BSA and the other PEGylated BSA compounds.
The thermal stability of BSA and PEGylated BSA was measured by DSC, and the un-
folding temperature and related unfolding enthalpy are presented in Table 3.2. There is a
range of unfolding temperatures of BSA reported in the literature, based on studies where
the ionic strength, the pH or the concentration of anionic surfactants have been changed
[121–124]. Our unfolding temperature values are in the high end of the range of those
reported in the literature. The enthalpies are generally of the same order of magnitude
as those obtained in the literature [122, 124]. The unfolding enthalpies are lower for the
PEGylated BSA compounds than the native BSA, but the unfolding enthalpies are alike
for all the PEGylated BSA compounds. The bimodal appearance of the DSC scans is
especially pronounced for native BSA, and can be correlated to the domain structure of
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BSA [124]. The PEGylated BSA compounds with the smaller PEGs attached (5 kDa to
30 kDa) does not seem to have this distinct bimodal appearance, however the peaks are
broadened. The broadening of DSC peaks of BSA has been reported in the literature
previously [121, 125, 126]. The PEG molecular weight dependence on the appearance of
the DSC scan may be related the fact that the molecular weight of the attached PEG has
different impacts on the stability of the two domains of BSA.
From the results presented in figure 3.4 it is evident that the apparent unfolding tem-
perature, Tm, for native BSA is slightly lower than that of the PEGylated BSA species.
Dhalluin et al. found a slight increase in Tm with PEGylation using interferon-alpha (2a)
[91]. How PEGylation affects the apparent unfolding temperature of a certain protein de-
pends on several factors including the degree of PEGylation, the location of the polymer
chain, the buffer composition and the specific local environment [127]. A slight decrease
in Tm with PEGylation may be found for some proteins, whereas a slight increase may be
found for other proteins. The results obtained in this study also reveal that there is no
difference in the thermal stability, measured by Tm, between a 5 kDa PEGylated BSA and
a 60 kDa PEGylated BSA. Thus, a longer PEG chain length does not contribute more to
the stability of the protein than a short PEG chain. Rather, it appears that the thermal
stability is independent of the molecular weight of the attached PEG polymer.
In analogy to the effect of PEGylation on the apparent unfolding temperature, the tem-
perature of aggregation, Tagg, depends on PEGylation but is relatively insensitive to the
size of the attached PEG polymer. The data in table 3.2 shows that under the investi-
gated conditions, aggregation can be detected about 11 ℃ below Tm for the unmodified
protein. In this case Tagg practically coincides with the first endothermic deflection in
the DSC signal in Fig 3.4. These observations suggest that the thermally unfolded form
of (unmodified) BSA has a very poor colloidal stability and thus aggregates immediately
upon its formation during heating. Aggregation of the PEGylated form of BSA begins at
a temperature much closer to Tm when an appreciable fraction of the protein is denatured
(c.f. Figure 3.4). This behaviour may be rationalized along the lines of the Lumry-Eyring
model for irreversible protein denaturation [94] which stipulates that an irreversible tran-
sition (such as aggregation) is preceded by a reversible denaturation step.
2k
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Figure 3.5: The Lumry Eyring model, N is the native protein, D is the denatured protein
and A is the aggregated protein.
Thus we suggest that PEGylation of BSA slightly increases the equilibrium constant K
(lowers Tm) but has a stronger, reducing effect on k3, so that the aggregation of the
denatured (D) is slowed down. This is illustrated by the difference between Tm and Tagg
in table 3.2, where there is a large difference between Tm and Tagg for the unmodified BSA
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but a only a small difference (positive or negative) between Tm and Tagg for the PEGylated
BSA compounds. The general suppression of protein aggregation by PEG observed here is
in accord with earlier reports [65, 95] and the suggestion that this is mainly due to changes
in k3 (and not K) has also been put forward before [65]. Steric hindrance of favourable
peptide-peptide contacts appears to be a likely course for the effect of PEG on k3, but
the lack of a correlation of PEG size and Tagg suggests that other as of yet unidentified
factors may be involved in the PEG induced increase of the colloidal stability.
The ligand binding properties of BSA were investigated with ITC. Previous studies of the
binding of serum albumins have reported, that the thermodynamics and stoichiometry of
binding fatty acids (FA) to BSA is similar to that of binding Sodium Dodecyl Sulphate
(SDS) [99–101]. Because of the major experimental challenges in working with FA binding
due to their insolubility, tendency to aggregate and adsorb to surfaces, we used the binding
of a single sulfonic (instead of a carboxylic) acid anion to BSA. Sodium dodecyl sulphate,
a sulfonic acid, forms stable micellar aggregates that are easily handled experimentally.
The binding of SDS to BSA and PEGylated compounds of BSA reflects the functional
properties of BSA so the effect of PEGylation on the function of BSA can be monitored.
The type of binding sites and their thermodynamic characteristics such as the binding en-
thalpies, the binding constants and the number of binding sites are listed in table 3.1.The
values obtained by modelling the binding of SDS to PEGylated BSA are similar to the
low affinity binding site found for the native BSA. Compared with the shape of the actual
enthalpogram in figure 3.1 this suggests that the PEGylated BSA molecule contains only
one type of binding site. The number of binding sites, high affinity as well as low affinity,
is slightly lower than reported previously [99, 119] but of the same order of magnitude.
There is surprisingly little variation within the parameters characterising the low affinity
sites of the 6 PEGylated BSA compounds. The function of PEGylated BSA seems to be
the same whether a small PEG polymer chain or a long PEG polymer chain is attached.
Crystallographic and thermodynamic investigations of the these sites on structurally simi-
lar serum albumin have revealed that the binding sites for negatively charged ligands with
large acyl chains can be roughly divided into two classes: high affinity and low affinity,
and that within each class the binding parameters are similar [99, 102, 103]. It has been
suggested that the hydrophobic regions of PEG would interact with the hydrophobic clus-
ters on the protein surface, resulting in a structure of the PEG-protein complex, where
PEG is coiled on the protein surface [104]. This may explain the change in the binding
properties of BSA upon PEGylation. The PEG polymer could compete with SDS for
interaction sites on the protein surface and thus weaken SDS-BSA affinities, but control
ITC experiments in which an 8 kDa PEG polymer was titrated to unmodified BSA failed
to show direct binding (Fig. 3.1).
In the protein screening process that is often performed early in the protein drug develop-
ment process, one of the goals is to find out whether certain protein modifications affect
the structure, stability and function of a potential pharmaceutical protein. Biophysical
characterisation screening tools often include techniques such as DLS, DSC and CD, all
of which complement one another in determining possible changes to the structure, ki-
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netic and thermodynamic stability of the protein. However, this study suggests that even
though the protein appears to be structurally unaffected by PEGylation, its function is
significantly altered. In fact, the high-affinity sites, which are the physiologically relevant
[102, 128], appear to be completely inactivated by the PEGylation. Based on a compre-
hensive analysis of crystallographic data of HSA, it has previously been reported that only
one of the 35 cysteines in HSA is not a part of an S-S bridge, and this residue is not close
to any binding site [102, 119]. As BSA and HSA are structurally similar and comparable,
and the distance from the cleavage in HSA, where most of the high affinity binding sites
for SDS are found, to cysteine 34 is approximately 45 Å, it seems reasonable to assume
that the cysteine 34 onto which the PEG is attached is not close to any of the binding
site. For this reason the differences in the binding properties of BSA and PEGylated BSA
cannot be explained by the PEG being located close to a binding site and in this way
sterically hindering the binding of SDS to the high affinity sites of BSA.
3.5 Conclusion
BSA was monoPEGylated with 6 different linear PEG polymers ranging from 5 kDa to
60 kDa in molecular weight. The results from the CD scans suggested that the secondary
and tertiary structure of BSA is unaltered upon PEGylation. From the DSC measure-
ments it was evident that the thermodynamic stability of the protein is slightly decreased
by the covalently attached PEG, but independent of the PEG molecular weight. The
aggregation temperature, derived from DLS measurements, increases with PEGylation,
but is independent of the size of the attached PEG. The binding of SDS to BSA and
PEGylated BSA reveals that the function of BSA as a transport protein may be changed
significantly when the protein is PEGylated. Of the two high-affinity binding sites and six
low-affinity binding sites found on native BSA, only five of the low-affinity binding sites
are retained on the PEGylated BSA species, and this change was found to be independent
of the PEG chain length. Thus, PEGylation may leave a protein structurally unaffected
but profoundly changed in terms of function.
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4 The binding kinetics of PEGylated
BSA
4.1 Introduction
Modification of pharmaceutical proteins with hydrophilic polymers such as poly-ethylene-
glycol (PEGylation) is an established method for prolonging the circulatory half-life of
proteins, reducing self-aggregation, increasing water solubility and decreasing antibody
recognition, and it has been used successfully in several marketed proteins [50, 51]. Most
of the benefits of PEGylated proteins reflect the properties of the PEG polymer itself [60].
The PEG polymer is heavily hydrated and consequently it has a large excluded volume
which, among other things, inhibits the approach of other macromolecules, resulting in re-
duced immunogenicity and decreased antibody recognition [117]. Generally, the hydration
of the PEG chain determines the overall hydrodynamic properties of a PEG bioconjugate
[59], and the increased molecular size is one of the most important properties of a PEG-
ylated protein, for example resulting in a prolonged circulation time due to low rates of
clearance from the liver and kidney [117]. Other than increasing the hydrodynamic volume
of the protein upon PEGylation, the conformation, physical properties and electrostatics
of a PEG-conjugated protein may be altered compared with the unmodified protein [59].
Possible changes include conformational changes of both PEG and protein, altered binding
properties resulting from changes in local pI, pKa, hydrophobicity and hydrophilicity of
the protein. However, most studies report an unchanged secondary and tertiary structure
[65, 88, 90], a retained thermodynamic stability [91] and an increased temperature of ag-
gregation of the protein upon PEGylation [65], whereas the protein’s biological activity is
not necessarily preserved [49, 62, 65].
SPR has been widely used during the past decades to obtain detailed information on the
binding properties of different biomolecular interactions [129–135]. SPR is mainly used to
obtain detailed information about the binding kinetics and binding affinities of a variety of
biomolecular interactions. The key advantage of SPR is the use of biosensors which allow
real-time analysis of reactions without labelling requirements (radioactive or fluorescent).
Fundamentally the SPR sensor consists of a thin metal film in contact with the fluid
medium to be analysed. Light passes through the fluid and is reflected from the metal film.
At specific wavelengths or angles a part of the incident light couples into a surface plasmon
wave travelling along the interface of the fluid medium and the metal, resulting in a sharp
attenuation in reflectivity. This is known as the surface plasmon effect. The wavelengths
and angles of this occurrence depend strongly on the refractive index (RI) of the fluid
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medium. SPR biosensors measure only relative changes in the molecular mass attached to
the sensor surface from the beginning of the interaction being studied [136]. Despite the
fact that SPR has been extensively used during the past decades investigations regarding
the properties of PEGylated proteins by SPR are still a new discipline. However, a few
studies have shown how the binding affinity determined by the association, dissociation
and hence equilibrium constant changes as a protein is modified by PEGylation [96, 137].
The most common commercially available SPR-based biosensors are Biacore 2000 and
3000 systems, which are equipped with a four flow-cell fluidic system [136]. For this study
a ProteOn™ XPR36 Protein Interaction Array System from Bio Rad was used. The
instrument is characterised by having the capability of measuring 36 protein interactions
in a single injection cycle [138].
Bovine Serum Albumin (BSA) is a transport protein with a molecular weight of 66400
Da [102]. BSA has one free sulfhydryl group, cysteine 34, which does not form a disulfide
bond with another cysteine in the polypeptide backbone [86]. Furthermore, BSA binds
several ligands including fatty acids, and it is possible to monitor the function of BSA
in vitro with different binding assays. This makes BSA a suitable model protein when
investigating the effect of protein PEGylation. Binding mPEG-maleimide (mPEG-MA)
to the free cysteine of BSA ensures both mono-PEGylation and site-specific PEGylation.
We have investigated the effect of monoPEGylation with 6 linear PEG polymers ranging
from 5 kDa to 60 kDa, providing us with a unique model system for studying the effect
of PEG polymer chain length on the binding kinetics of BSA and PEGylated BSA. From
the results presented in chapter 3 we concluded that the binding of SDS to BSA changed
upon PEGylation but was independent of the molecular weight of the PEG chain. To
further investigate the possible altered binding properties of BSA due to PEGylation, we
have used Surface Plasmon Resonance (SPR) to measure the binding between anti-BSA
and BSA or PEGylated BSA1. The purpose of the present study is to investigate how the
binding of BSA and various PEGylated BSA (the analyte) species to immobilised anti-
BSA (the ligand) changes with PEGylation as well as PEG molecular weight. Additionally
BSA and the PEGylated BSA species are immobilised on the chip and anti-BSA is run
over as an analyte. This makes it possible to compare two independent ways of measuring
the binding between anti-BSA and BSA or PEGylated BSA.
Binding kinetics
The SPR detector is a continuous, real time detector, which makes it possible to estimate
the kinetics of a given reaction. Consider the case where an immobilised protein (the
ligand) will forma complex with the soluble counterpart (the analyte). In the case of a 1:1
reaction the complex-conformation rate can then be written as [139, 140]:
d[LA]
dt
= ka[L]t[A]t − kd[LA]t (4.1)
1 All experiments were carried out at University of Canterbury, New Zealand.
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where ka is the association rate constant, kd is the dissociation rate constant. [L]t can be
substituted by [L]0-[LA]t, where [L]0 is the total concentration of ligands on the surface
of the chip and [LA]]t is the concentration of complexes, and then
d[LA]
dt
= ka[A]t([L]0 − [LA]t)− kd[LA]t (4.2)
As the signal observed, R, will be proportional to the formation of the LA complex, and
Rmax will be proportional to the surface concentration of active ligands on the surface,
equation 4.2 can be rewritten to:
dR
dt
= kaCA(Rmax −R)− kdR (4.3)
= kaCARmax − (kaCA + kd)R (4.4)
Here dRdt is the formation rate of surface associated complexes and CA is the constant
concentration of analyte in the solution. Solving this differential equation gives:
Rt =
ka(CA)Rmax[1− exp(−CAka + kd)t]
CAka + kd
(4.5)
The concentration of analyte in the solution is, in this case, much larger than the concen-
tration of immobilised ligand which is why it can be considered as a constant. Rmax is the
maximum signal, equivalent to surface concentration of ligand, [L]0, if all the immobilised
ligands have bound an analyte. (Rmax - Rt) expresses the number of vacant analytes on
the surface of the chip, expressed in response units. The SPR data in the present study
are fitted to the Langmuir model, a simple 1:1 biomolecular interaction, which is the
most common kinetic fit model used for SPR data analysis [138]. The Langmuir model
is based on a scenario, where the reaction occurs between the ligand immobilized to the
chip surface and the analyte that is flowed across it. As the analyte interacts with the
ligand, a complex is formed following pseudo first-order kinetics. When the analyte is
washed away from the chip, the two molecules dissociate. It is assumed that the binding
is equivalent and independent for all binding sites, and that the reaction is not limited by
mass transport.
SPR measurements
A SPR experiment consists primarily of 4 steps, immobilisation, association, dissociation
and regeneration, three of these steps are shown on figure 4.1. In the immobilisation step
the ligand is bound to the surface of the SPR chip, in the association step the analyte
solution is flowing across the surface of the chip and binds to the immobilised ligand. In
the dissociation step buffer is flowing across the surface of the chip, removing most of
the bound analytes. The regeneration step ’cleans’ the chip, removes excess analytes and
primes the chip for the next experiment.
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Figure 4.1: T sketch of the SPR response as a function of time. The association rate
constant, ka, is related to the association process, stippled line, and the dissociation rate
constant, kd, is related to the association process, dotted line. The regeneration step
follows the dissociation.
All analysed samples were concomitant with the binding experiments injected onto an un-
coated reference channel. The data were evaluated with the ProteOn™ software (version
2.1.0.36), applying the simple 1:1 Langmuir binding model. The obtained sensorgrams
were group fitted over the whole concentration range as association and dissociation are
considered being concentration independent. The association rate constants, ka, the disso-
ciation constants, kd, and the maximum response, Rmax, were determined for each sample.
The equilibrium constants were then calculated from the association constant and the dis-
sociation constant (kd/ka=KD).
4.2 Materials and Methods
PEGylation reaction
Batch PEG grafting was carried out for each protein individually as described in section
3.2. Briefly, all solutions were made up in 10 mM phosphate buffered saline (PBS, Sigma,
St. Louis, MO), at pH 7.4. Bovine serum albumin (98 % pure by SDS-PAGE) from bovine
plasma (Gibco Invitrogen, NZ), was used without further purification. The maleimodo-
reactants (Mono-methoxy poly (ethylene glycol) maleimido-propionamide) were of nominal
molecular weights 5000, 10000, 20000, 30000, 40000 and 60000 Da, and were a kind gift
from Dow Pharma, UK. 1.2 mole of solid mPEG-MA reagent was added per mole of protein
to 5 mL of 20 mg/mL native bovine serum albumin and the protein solution was mixed
with the PEG reagent and left stirring in an open 10 mL beaker at room temperature
overnight. Samples were acidified with one drop of 0.1 M HCl to stop the reaction.
The samples, including a non-PEGylated native BSA sample as a control, were separated
individually by ion exchange chromatography (IEC) using a HiPrep 16/10 QFF Anion
Exchange column (Amersham Bioscience, Uppsala, Sweden), preparing the column first
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with 5 column volumes (CV) of 10 mM PBS pH 7.4, 1M NaCl and then 5 CV of 10 mM
PBS pH 7.4. 5 mL samples were then injected onto the IEC column and the proteins
were eluted with a 15 CV linear gradient to 10 mM PBS, 1 M NaCl at 5 mL/min. The
protein elution profile was monitored by UV absorbance at 280 nm and collected in 2
mL fractions. Fractions were analysed by SDS-PAGE, and fractions containing >80 %
monoPEGylated BSA monomer, detected by SDS-PAGE, were pooled. These fractions
were then polished by injecting 6 mL samples onto a Size Exclusion Chromatography,
(SEC) HiPrep 16/60 Sephacryl S-200 column (Amersham Bioscience, Uppsala, Sweden),
with PBS running buffer at 1 mL/min. The protein elution profile was monitored by
UV absorbance and fractions containing >90 % monoPEGylated BSA monomer, as sub-
sequently detected by SDS-PAGE, were pooled. The purification was carried out on an
AKTAexplorer 10™ liquid chromatography system with an A-900 autosampler and de-
tected by a differential refractometer detector (model RID-10A from Shimadzu, Tokyo,
Japan). The chromatography system was operated using Unicorn software, version 4.0,
(Amersham Bioscience, Uppsala, Sweden). The purity of the PEGylated BSA solutions
was investigated by gel electrophoresis. SDS-PAGE analysis was carried out using a 12 %
Bis-Tris gel from Invitrogen. The gels were loaded with an average of 5 µg (10 µL load
volume) per well and run at 120 mA constant current per gel. The running buffer was
MES running buffer. The gel was washed in 150 mL 0.1 M perchloric acid for 15 minutes
until 40 mL 5 % barium chloride solution and 15 mL 0.1 M iodine solution were added to
detect protein bands containing PEG compounds, as described in [141]. After discolour-
ing in water, the gel was coloured with Coomassie blue. From figure 4.2 it is evident that
PEGylated proteins are not behaving like non-PEGylated proteins when analysed by gel
electrophoresis. It would be natural to anticipate that a 66 kDa protein with a 20 kDa
PEG attached would show a band around 86 kDa, but due to the high hydration of the
PEG, the 20 kDa PEGylated 66 kDa protein shows a band at 106 kDa (fig. 4.2).
The PEG-staining gel technique is based on the complex formation between PEG and
barium iodide, and the PEG-stained gel (4.2b) reveal that only lane 2-5 contain PEG-
compounds. It has previously been shown, that PEG binds to SDS micelles [142] and that
PEGylation decreases the mobility of the protein [141, 143]. For this reason the molecular
weight of a PEGylated protein on a SDS gel will not correspond to the actual molecular
weight of the PEGylated protein. Due to the low mobility of the PEGylated protein, the
location of a PEGylated protein on a SDS gel corresponds to the molecular weight of the
protein added twice the molecular weight of the attached PEG polymer.
BSA or PEGylated BSA as analyte
The GLC SPR chip was activated by a mixture of 130 µL 4 M 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide hydrochloride (EDAC) and 130 µL 1 M N-hydroxysulfosuccinimide
(NHS). Polyclonal anti-BSA molecules were immobilised on the chip at a flow rate of
30 µL/min and a contact time of 300 seconds. The remaining carboxyl groups were
deactivated by ethanol amine hydrochloride. Measurements were carried out at 25 ℃,
using a flow rate of 100 µL/min with an association phase of 60 sec after injection, followed
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(a) SDS PAGE of PEGylated BSA. The
numbers on the left side are the molecular
marker in kDa.
(b) A so-called PEG stained gel. The
gel is stained with iodide as described in
[141].The bonds refer to the 20 kDa PEG-
ylated BSA and the 30 kDa PEGylated
BSA, respectively. The vague colored band
corresponding to the native BSA is some
minor, non-specific staining of protein by
the iodide.
Figure 4.2:
Lane 1 and 7, bench mark protein ladder.
Lane 2 and 3, 20 kDa PEGylated BSA.
Lane 4 and 5, 30 kDa PEGylated BSA.
Lane 6 native BSA.
The location of the PEGylated species on the gel reveals that a 20 kDa PEGylated BSA is located
at 66+2 · 20 ~106 kDa and a 30 kDa PEGylated BSA is located at 66+2 · 30 ~126 kDa. Analysis
of the gel on figure 4.2a reveals a ~5 % of native BSA within the PEGylated BSA samples after
purification. The purity of 5 kDa, 10 kDa, 40 kDa and 60 kDa are similar (data not shown).
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by a dissociation phase of 600 sec. The proteins and antibodies were diluted in PBS
buffer, filtered, and the BSA and PEGylated BSA solutions were injected at concentrations
between 0.01 mg/mL and 0.625 µg/mL. The binding process is illustrated in figure 4.3.
Association
PEGylated protein
Dissociation
Antibody
Figure 4.3: The binding of a PEGylated BSA molecule to the immobilised anti-BSA (Y-
shaped).
Anti-BSA as analyte
The GLC SPR chip was activated by a mixture of 130 µL 0.4 mM 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide hydrochloride (EDAC) and 130 µL 0.1 mMN-hydroxysulfosuccinimide
(NHS). BSA and the various PEGylated BSA species were immobilised on the chip in dif-
ferent channels at a flow rate of 30 µL/min and a contact time of 867 seconds. The
remaining carboxyl groups were deactivated by ethanol amine hydrochloride. Measure-
ments were carried out at 25 ℃, using a flow rate of 50 µL/min with an association phase
of 500 sec after injection, followed by a dissociation phase of 600 sec. The proteins and
antibodies were diluted in PBS buffer, filtered, and the antibody solutions were injected at
concentrations between 0.025 mg/mL and 1.56 µg/mL. The binding process is illustrated
in figure 4.4.
Association
Dissociation
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PEGylated protein
Figure 4.4: The binding of anti-BSA (Y-shaped) to the immobilised PEGylated BSA
molecule.
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For this instrument the working ranges are 3·103-3·106 M−1s−1 for ka, 5·10−5-6·10−1 s−1
for kd and 2·10−4- 1.6· 10−11 M for KD [138]. For subtraction of bulk effects caused
by changes in the buffer composition or nonspecific binding, a subtraction of a reference
channel is performed.
4.3 Results
BSA or PEGylated BSA as analyte
The SPR response of the binding of BSA or PEGylated BSA to the immobilised anti-
BSA is found in figure 4.5. From the data shown in this figure it is evident, that the RU
from the binding of the unmodified BSA is much larger than that of the PEGylated BSA
compounds. The RU from the binding of the PEGylated BSA compounds to anti-BSA
appears to be independent of the molecular weight of the attached PEG.
Figure 4.5: The raw data for the association and dissociation of BSA and PEGylated BSA
to immobilised anti-BSA.
The results shown in figure 4.5 were modelled by using the Langmuir 1:1 model and a
family of curves at different, known concentrations for the same species. One curve from
each of those families is shown in figure 4.5. From the modelling the association rate
constants of BSA and the PEGylated BSA compounds to the immobilised anti-BSA are
found, see figure 4.6a. The association rate constants of BSA and PEGylated BSA to
anti-BSA are of the same order of magnitude, but ka for 5 kDa PEGylated BSA is lower
than that of the native protein but ka increases almost linearly with the molecular weight
of the attached PEG. The dissociation rate constants of BSA and the PEGylated BSA
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compounds from anti-BSA are shown in figure 4.6b. Those constants are also found by
using the Langmuir 1:1 model and a family of curves at different, known concentrations
for the same species. The dissociation rate constants are very low, especially kd for 40
kDa PEG-BSA and 60 kDa PEG-BSA, which are outside the detection ranges given on
page 64. However, generally the kd values seem to depend on PEGylation and on the
molecular weight of the attached PEG, and the rates of dissociation are of the same order
of magnitude. The equilibrium constants, KD=kd/ka, as a function of PEG molecular
weight are plotted in figure 4.6c. The equilibrium constant for the binding of BSA or
PEGylated BSA to immobilised anti-BSA illustrate the same tendency as the dissociation
constant; a slight dependence on PEGylation and on the molecular weight of the attached
PEG.
(a) The association rate constants as a function
of PEG molecular weight.
(b) The dissociation rate constant as a function
of PEG molecular weight.
(c) The equilibrium constant as a function
of PEG molecular weight.
Figure 4.6: Association rate constants, dissociation rate constants and the resulting equi-
librium constant of the binding of BSA or PEGylated BSA to the immobilised anti-BSA
as a function of the molecular weight of the PEG polymer attached to the immobilised
BSA molecules. The ka, kd and KD of unmodified BSA to immobilised anti-BSA is located
at PEG molecular weight zero. The error bars are too small to be shown.
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The results are summarised in table 4.1.
Analyte ka (M−1s−1) kd (s−1) KD (M)
BSA 4.6 · 105 ± 3.2 · 103 3.5 · 10−5 ± 7.7· 10−7 7.5 · 10−11
10 kDa PEG-BSA 3.8 · 105 ± 2.4 · 103 1.6 · 10−5 ± 6.7· 10−7 4.1 · 10−11
20 kDa PEG-BSA 4.5 · 105 ± 2.8 · 103 1.1 · 10−5 ± 6.8· 10−7 2.5 · 10−11
40 kDa PEG-BSA 4.9 · 105 ± 3.3 · 103 1.4 · 10−7 ± 6.9· 10−7 2.9 · 10−13
60 kDa PEG-BSA 5.9 · 105 ± 4.3 · 103 3.5 · 10−6 ± 7.4· 10−7 5.8 · 10−12
Table 4.1: The association rate constant, the dissociation rate constant and the equi-
librium constant of the binding of BSA and PEGylated BSA compounds to immobilised
anti-BSA.
Anti-BSA as analyte
The raw SPR data for the binding of anti-BSA to immobilised BSA or PEGylated BSA
compounds are found in figure 4.7.
Figure 4.7: The raw SPR data for the association and dissociation of anti-BSA to tethered
BSA or PEGylated BSA. The insert shows the order of the PEGylated BSA compounds.
The SPR response is much higher for the binding of anti-BSA to tethered BSA compared
to the binding to PEG-BSA. The SPR data are fitted to the 1:1 binding model, and the
fitting results for two selected data set are shown in figure 4.8, and from the results it is
evident that the model parameters fits the SPR data quite well.
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Figure 4.8: The fitted data for the binding of anti-BSA to BSA and 30 kDa PEGylated
BSA. The other experiments are fitted in the same manner and the fit are of similar quality
as those shown.
From the Langmuir fitting model, the association rate constants of anti-BSA to the immo-
bilised BSA and PEGylated BSA compounds are found, and the association rate constants
are plotted as a function of the PEG molecular weight in figure 4.9a. As with the reversed
assay orientation experiment, the dissociation rate constants of anti-BSA to BSA and its
PEGylated compounds appear to be independent of PEGylation and molecular weight of
the PEG polymer, see figure 4.9b. The dissociation rate constants depends slightly on
PEGylation, but all the values are of the same order of magnitude. Again, there appears
to be no dependence on the molecular weight of the attached PEG. The equilibrium con-
stants for the binding of anti-BSA to the immobilised BSA or PEGylated BSA compounds
reflect the tendency of the dissociation constants, and seems to depend slightly on whether
the protein is PEGylated or not, but it does not seem to depend on the molecular weight
of the attached PEG polymer, see figure 4.9c.
The results are summarised in table 4.2.
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(a) The association rate constants as a function
of PEG molecular weight.
(b) The dissociation rate constant as a function
of PEG molecular weight.
(c) The equilibrium constant as a function
of PEG molecular weight.
Figure 4.9: Association rate constants, dissociation rate constants and the resulting equi-
librium constant of the binding of anti-BSA to the immobilised BSA and PEGylated BSA
as a function of the molecular weight of the PEG polymer attached to the immobilised
BSA molecules. The ka, kd and KD of anti-BSA to immobilised unmodified BSA is located
at PEG molecular weight zero. The error bars are too small to be shown.
Ligand ka (M−1 s−1) kd (s−1) KD (M)
BSA 5.4 · 105 ± 3.8 · 103 7.0 · 10−5 ± 2.3 · 10−6 1.3 · 10−10
10 kDa PEG-BSA 4.8 · 105 ± 4.2 · 103 1.2 · 10−4 ± 2.9 · 10−6 2.5 · 10−10
20 kDa PEG-BSA 5.8 · 105 ± 4.4 · 103 1.1 · 10−4 ± 2.7 · 10−6 1.9 · 10−10
40 kDa PEG-BSA 4.4 · 105 ± 4.4 · 103 1.2 · 10−4 ± 3.3 · 10−6 2.7 · 10−10
60 kDa PEG-BSA 4.8 · 105 ± 5.0 · 103 1.0 · 10−4 ± 3.6 · 10−6 2.3 · 10−10
Table 4.2: The association rate constant, the dissociation rate constant and the equilib-
rium constant of the binding of anti-BSA to the immobilised BSA and PEGylated BSA
compounds.
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4.4 Discussion
The binding kinetics of BSA and PEGylated BSA to anti-BSA was investigated using SPR
with two identical but reversed assay orientations as illustrated in figure 4.3 and figure
4.4. The study was intended to provide knowledge on possible changes in the binding
between BSA and anti-BSA, including information on how the association rate constant,
the dissociation rate constant and the equilibrium constant might change with PEGylation
and with the molecular mass of the attached PEG polymer. The association constant
is describing how fast the analyte-ligand complex is formed, whereas the dissociation
constant is describing how fast the formed complex is broken. Both constants can be
affected by the mass transfer (or transport) effects. However if the flow rate across the
SPR chip is sufficiently high, this effect can be minimised. Several experiments with
varying flow rates were conducted and no differences were found in either the association
or the dissociation constants (data not shown).
The SPR response to the binding of BSA or PEGylated BSA to anti-BSA is depending
significantly on PEGylation, and it applies to both assay orientations that the binding
between anti-BSA and unmodified BSA results in the largest SPR response compared to
the binding between anti-BSA and the PEGylated BSA compounds. The SPR response
seems to be independent on the molecular weight of the grafted PEG moiety. This is
surprising as we expected using a PEGylated BSA with a high molecular weight PEG
would lead to a higher response due to the higher total molecular weight of the PEG-protein
complex. However the lower SPR response from both experiments could be due to a lower
number of interactions between PEGylated BSA and anti-BSA compared to unmodified
BSA and anti-BSA. The anti-BSA used is polyclonal, and conclusions regarding binding
of anti-BSA to specific epitopes on BSA and possible steric hindrance from the attached
PEG cannot be drawn. This problem could be solved by using a monoclonal antibody
but we did not succeed in finding one commercially available. However for the BSA or
PEGylated BSA ligand experiment an explanation of the lower RU for the binding of anti-
BSA to the PEGylated BSA could be found in a lower number of immobilised PEG-protein
molecules. The latter hypothesis is further developed in appendix B, where a model of
the conformation of a PEGylated BSA molecule on the SPR chip is put forward.
From the fitting results obtained in this study it appears as though the association rate
constants are independent of PEGylation and also independent of the molecular weight
of the attached PEG polymer. The complex formation between anti-BSA and BSA or
PEGylated BSA happens at the same rate regardless of which protein is ligand and which
serves as analyte. The association rate constants are up to a factor 100 higher than similar
studies of the binding of PEGylated proteins reported in the literature [66, 96]. Yang et al.
[66] found association rate constants from 1.0 · 103-4.6 · 104 M−1 s−1 and Kubetzko et al.
[96] found ka values from 6.1 · 104-9.8 · 105 M−1 s−1. This could indicate that the binding
between anti-BSA and BSA is particularly fast. It is noticeable that the association rate
constants are not affected by PEGylation. We expected using a PEGylated BSA with a
high molecular weight PEG would lead to a slower binding (lower ka) due to more steric
hindrance. But even when attaching a PEG polymer of similar molecular weight as the
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protein, there appears to be no difference in the association between BSA or PEGylated
BSA and anti-BSA.
While there does not seem to be any change in the association with PEGylation or with
assay orientation and hence the initial binding itself, the dissociation process appears to
give a somewhat different picture. From the raw SPR data in figure 4.5 and figure 4.7 it is
evident that the dissociation curve is nearly straight, indicating a very slow dissociation.
Even though the data fit on figure 4.8 show that the Langmuir model fits nicely, the actual
values for kd for both experiments are hard to interpret. The interpretation of the value
of the dissociation constant and the way it changes with PEGylation and PEG molecular
weight should be done carefully and is not unambiguous. In general our kd results are
approximately lower than those obtained in the two comparable studies of the dissociation
of PEGylated proteins from immobilised antibodies [66, 96]. Here Yang et al. [66] found
dissociation rate constants from 2.6·10−4 to 6.8·10−4 s−1 and Kubetzko et al. [96] found
kd values from 2.6·10−5 to 5.0·10−5 s−1. The dissociation rate constants describing the
dissociation of PEGylated BSA from the immobilised anti-BSA are outside the measurable
range of the instrument, which in itself indicate that the interpretations of the modelling
results can only be guiding. Still, overall the dissociation rate constants obtained in our
experiments are of similar values and the dissociation rate constants do not appear to be
affected significantly by the orientation of the assay, by PEGylation or by the molecular
weight of the attached PEG polymer.
The equilibrium dissociation constant, KD, calculated from kd/ka, is the inverse of the
binding constant, and can for this reason be used as a measure for the binding strength;
a strong binding equals a low equilibrium constant, whereas a weak binding equals a
higher equilibrium constant. The equilibrium dissociation results reported in this study
are subject to uncertainty, as KD is calculated from kd. However from the KD results
summarised in table 4.1 and table 4.2 it is seen that the obtained equilibrium dissociation
constants are of the same order of magnitude for all interactions. Hence PEGylation,
molecular weight of the grafted PEG moiety and orientation of the assay do not seem to
influence the binding kinetics of the current study significantly.
To our knowledge there are only a few comparable experiments in the literature, where
the binding between antibodies and PEGylated proteins have been measured with SPR
[66, 67, 96]. In two of these studies ([66, 96]) the authors refrain from commenting on
the large reduction in SPR response with PEGylation, which we have also observed. We
have investigated whether this observation could have to do with the difference between
the refractive index of the BSA and the PEGylated BSA solutions and have treated more
closely in appendix C. The authors mostly reflect on the variations in the association
and dissociation rate constants, and they all observe that the association rate constant is
reduced upon PEGylation, but the dissociation rate constant is practically independent
of PEGylation. Briefly, Yang et al. [66] report SPR studies on single-chain antibodies and
3 PEGylated compounds hereof with 5 kDa, 20 kDa and 40 kDa PEG polymers attached.
Yang et al. report a trend toward slower association rate constants with increasing mass
of the attached PEG polymer, whereas the dissociation rate constants of the PEGylated
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species did not differ significantly from the unmodified protein to the PEGylated com-
pounds. They argue that the association is altered due to the physical hindrance by the
bulky and mobile PEG moiety, and that this hindrance does not affect the dissociation
rate constants. Kubetzko et al. [96] report SPR studies on site-specifically 20 kDa PEG-
ylated variants of anti-p185(HER-2) antibody fragments, and they have experimentally
determined, that the observed association rate constants of the PEGylated monomer are
5.4-fold slower than that of the unmodified monomer, led to approximately a 5-fold reduc-
tion in apparent affinity. Kubetzko et al. conclude that neither a reduction in the function
antibody concentration nor a slower diffusion seems to be responsible for the decrease in
the observed association rate constants. Kubetzko et al. argue that it appears to be a
combination of intramolecular and intermolecular blocking mechanisms, which cause the
alteration in the kinetic and equilibrium binding of the PEGylated proteins. Clark et al.
[67] have investigated a 5 kDa PEGylated derivatives of human growth hormone (hGH),
and report that increasing the level of PEG modification linearly reduced the affinity of
hGH for its receptor. Clark et al. measured a relative decrease in binding affinity and as-
sociation rate constants and a relative increase in dissociation rate constants by comparing
the unmodified hGH to the PEGylated compound.
There are examples in the literature of measurements of the binding of BSA to anti-BSA
including work done by Kausaite et al. [140] and Chiem and Harrison [144]. Kausaite et al.
did SPR measurements and Chiem and Harrison did affinity capillary electrophoresis mea-
surements with monoclonal anti-BSA. Both equilibrium constants are larger than the ones
obtained in this study, see table 4.3.
Sample ka (M−1 s−1) kd (s−1) KD (M)
BSA analyte
BSA 4.6 · 105 ± 3.2 · 103 3.5 · 10−5 ± 7.7· 10−7 7.5 · 10−11
BSA [140] 9.63 · 103 7.85 · 10−3 8.2 · 10−7
Anti-BSA analyte
BSA 5.4 · 105 ± 3.8 · 103 7.0 · 10−5 ± 2.3 · 10−6 1.3 · 10−10
BSA [144] 2.68 · 10−8
Table 4.3: Association rate constants and dissociation rate constants for the binding of
BSA to anti-BSA.
These differences may be explained by the fact that Kausaite et al. and Chiem and Harrison
have used other anti-BSA antibodies than we have. Also our equilibrium constants are
based on the dissociation rate constants obtained by Langmuir modelling, which were very
slow and with high deviations. The inverse of the equilibrium constant, the binding con-
stant, can be found by the use of ITC. Studies have shown that binding constants obtained
by ITC are comparable in size to those obtained by SPR [145]. However, measuring the
binding between anti-BSA and BSA/PEGylated BSA with ITC was beyond the scope of
72 The binding kinetics of PEGylated BSA
this particular study.
4.5 Conclusion
The binding of BSA and PEGylated BSA to anti-BSA was measured by SPR using two
similar, but reversed orientation assays. The SPR response was fitted using 1:1 biomolecu-
lar interaction model, yielding the association rate constant, the dissociation rate constant
and the equilibrium dissociation constant of the binding reaction. The SPR response was
markedly affected by PEGylation, and the response decreased significantly when reflecting
the binding between anti-BSA and PEGylated BSA as compared to the anti-BSA/BSA
binding. From the present study it is concluded, that the association rate constants are
unaffected by PEGylation, molecular weight of the attached PEG polymer as well as assay
orientation. These ka results are not in accordance with those previously reported in the
literature and might be explained by the use of a polyclonal antibody. From SPR response
it was evident, that the dissociation rate constants were very low, and the subsequent mod-
elling revealed that Kd in some of the experiment were too low for the instrument to model.
But overall kd appeared to be slightly depending on PEGylation, but independent of the
molecular weight of the attached PEG polymer and of the orientation of the assay. The
equilibrium dissociation constant reflected the variations in the dissociation rate constant,
and was also slightly dependent on PEGylation, but unaffected by the molecular weight
of the PEG polymer as well as the assay orientation.
5 Biophysical Characterisation of
GlycoPEGylated human rFVIIa
Int. J. Pharm. 406 (2011) 62-68
Bitten Plesnera,b, Peter Westha, Anders D. Nielsenb,†
aDepartment of Science, Roskilde University, P.O. Box 260, Universitetsvej 1, DK-4000
Roskilde, Denmark
bNovo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
†Corresponding author. Tel.: +45 30 79 65 75; fax: +45 44 43 40 73
Email address: ADNi@novonordisk.com (A. D. Nielsen).
Abstract
The effects of GlycoPEGylation on the structural, kinetic and thermal stability of recombi-
nant human rFVIIa were investigated using rFVIIa and linear 10 kDa and branched 40 kDa
GlycoPEGylated recombinant human FVIIa derivatives. The secondary and tertiary struc-
ture of rFVIIa measured by Circular Dichroism (CD) was maintained upon PEGylation.
In contrast, the thermal and kinetic stability of rFVIIa was affected by GlycoPEGylation,
as the apparent unfolding temperature Tm measured by Differential Scanning Calorimetry
(DSC) and the temperature of aggregation, Tagg, measured by Light Scattering (LS) both
increased with GlycoPEGylation. Both Tm and Tagg were independent of the molecular
weight and the shape of the PEG chain. From the present biophysical characterisation
it is concluded that after GlycoPEGylation, rFVIIa appears to be unaffected structurally
(secondary and tertiary structure), slightly stabilised thermally (unfolding temperature)
and stabilised kinetically (temperature of aggregation).
Keywords: GlycoPEGylation, rFVIIa, Circular Dichroism, Differential Scanning Calorime-
try, Light Scattering, stability.
5.1 Introduction
Coagulation factor VIIa (FVIIa) is a trypsin-like serine protease, which in the presence
of calcium initiates the blood coagulation when associated with its cofactor tissue factor
(TF) which is exposed upon vascular injury [146, 147]. TF-bound FVIIa activates factor
IX and factor X resulting in a burst of thrombin, fibrin deposition and the formation of a
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haemostatic plug on the surface of activated platelets [146]. Deficiencies in the coagulation
system due to partial or complete deficiency of FVIII or FIX, haemophilia A or haemophilia
B respectively can lead to severe morbidity or mortality if the bleeding is left untreated.
A safe and efficient way to prevent bleeds and joint destruction in haemophilia is pro-
phylactically by dosing factor (F) FVIII or FIX 2-4 times weekly [148], and recent stud-
ies have shown that prophylactic treatment with rFVIIa (NovoSevenr) of haemophilia
patients with inhibitors reduces the frequency of bleedings significantly as compared to
conventional on-demand haemostatic therapy [149]. However rFVIIa has a short circula-
tion time (2-4 hours in humans), and it is assumed that rFVIIa should be administered
daily if used for long-term prevention [149, 150]. Hence, development of rFVIIa deriva-
tives with longer circulation time could result in both fewer administrations and better
patience compliance. Modification of pharmaceutical proteins with hydrophilic polymers
such as poly-ethylene-glycol (PEGylation) is an established method for prolonging circu-
latory half-life of proteins, reducing self-aggregation, increase water solubility and increase
stability [82, 117]. PEGylation has been used successfully in several marketed proteins
including Pegasysr (40 kDa PEG Interferon alpha-2a,Roche), Oncasparr (5 kDa PEG-L-
aspariginase, Enzon), Cimziar (40 kDa PEG Anti-TNFα, UCB Pharma) and Neulastar
(20 kDa PEG G-CSF, AMGEN) [50–52]. Due to the risk of losing activity of FVIIa
because of the numerous interactions with the cell surface, TF, FIX and FX there is a
limitation in the unspecific chemical modification of this protein. For this reason a novel
strategy for site-directed PEGylation using glycosyltransferases to attach PEG to glycan
residues, the enzyme based GlycoPEGylation™ technology, is used to covalently attach
either a linear 10 kDa or a branched 40 kDa PEG polymer to rFVIIa. The site of PEG
attachment to rFVIIa is demonstrated to be one of the two N-linked glycans of rFVIIa
(Asn145 or Asn322) located on the light chain and heavy chain, respectively [64].
The most important property of a PEGylated protein is the increased molecular size re-
sulting form the large hydrodynamic volume of the PEG [61]. The underlying mechanisms
for the effect of PEG is not fully understood, but it is evident that the hydrodynamic ra-
dius is significantly increased by PEG leading to reduced renal clearance, especially of
smaller proteins [50, 63]. Most of the benefits of PEGylated proteins reflect the properties
of the PEG polymer itself [60]. The PEG polymer is heavily hydrated and consequently
it has a large excluded volume which among other things inhibits the approach of another
molecule, this could in theory result in reduced immunogenicity and decreased antibody
recognition [82, 151]. The favourable properties as postponed or prevented aggregation
and thermal stabilisation are caused by the heavily hydrated PEG polymer, and the prop-
erties of the PEG polymer are transferred to the PEGylated compounds [59]. Favourable
pharmacokinetic and pharmacodynamic profiles are also a consequence of the improved
hydrodynamic properties [82]. Other than increasing the hydrodynamic volume of the
protein upon PEGylation, the conformation, physical properties and electrostatics of a
PEG-conjugated protein may be altered compared with the unmodified protein [59], and
the protein’s biological activity is not necessarily preserved [49, 62, 65]. However most
studies report an unchanged secondary and tertiary structure [65, 88, 90, 152, 153], an
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increased thermal stability [91] and an increased temperature of aggregation [65, 152] of
the protein upon PEGylation. Studies regarding the stability, both thermal and struc-
tural, as well as the bioactivity of the protein are among the most fundamental when
developing pharmaceutical proteins and the ideal pharmaceutical protein should have a
long shelf-life and a high bioavailability. Also, the physical stability of a pharmaceutical
protein has a significant impact on the ability to design a suitable liquid protein drug, as
insoluble aggregates can increase immunogenic responses and are not biologically active.
We study the effect of GlycoPEGylation on the thermal, kinetic and structural stability
of rFVIIa with one linear 10 kDa and one branched 40 kDa PEG polymer. This provides
us with a relevant pharmaceutical model system for investigating the biophysical effects
of PEGylation. Biophysical characterisation tools, including Circular Dichroism (CD),
Differential Scanning Calorimetry (DSC) and Light Scattering (LS), were used to study
possible changes in the secondary and tertiary structure as well as the thermal and ki-
netic stability of rFVIIa upon GlycoPEGylation. To our knowledge no study has yet been
published on a highly relevant pharmaceutical protein which combines investigations of
the effect of GlycoPEGylation on the structural, thermal and kinetic stability using both
linear and branched PEG polymers. This study contributes to the further understanding
of the basic biophysical properties of PEGylated pharmaceutical proteins.
5.2 Materials and Methods
Materials
rFVIIa, 10 kDa GlycoPEGylated rFVIIa and 40 kDa GlycoPEGylated rFVIIa was pro-
duced by Novo Nordisk A/S, Denmark, as described in [64]. L-Histidine was purchased
from Aijonomoto AminoScience (Raleigh, N.C.), calciumchloride-dihydrate from Merck
(Germany), Barium Chloride 20 w/w from Ampliqon (Denmark), 0.1 N iodine solution
from Sigma-Aldrich (Germany), 70 % perchloric acid from Merck (Germany), LDS sam-
ple buffer and MES SDS running buffer and Simple Blue Safe Stain all from Invitrogen
(Carlsbad, CA). All protein solutions were dialysed in Slide-A-LyzerTM 30.000 MWCO
dialyse cassettes against 10 mM histidine, 10 mM CaCl2, pH 5.75
SDS-PAGE
SDS-PAGE analysis was carried out using a 12 % Bis-Tris gel from Invitrogen. The gels
were loaded with an average of 5 µg per well and run at 120 mA constant current per
gel. The running buffer was MES running buffer. The gel was washed in 150 mL 0.1
M perchloric acid for 15 minutes until 40 mL 5 % barium chloride solution and 15 mL
0.1 M iodine solution were added to detect protein bands containing PEG compounds, as
described in [141]. After discolouring in water, the gel was coloured with Coomassie blue.
MALDI-TOF MS
Mass spectrometric analysis was performed on a Bruker Daltonics Microflex MALDI-TOF
instrument equipped with a nitrogen laser (337 nm). The instrument was operated in linear
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mode with delayed extraction, and the accelerating voltage in the ion source was 25kV.
Sample preparation was done as follows: 1 µl sample-solution was mixed with 10 µl matrix-
solution (alphacyano-cinnamic acid dissolved in a 5:4:1 mixture of acetonitrile:water:3%
TFA) and 1 µl of this mixture was deposited on the sample plate and allowed to dry before
insertion into the mass spectrometer. Calibration was performed using external standards
(a range of standard proteins) and the resulting accuracy of the mass determinations is
within 0.1%.
Circular Dichrosim (CD) Spectroscopy
Spectra of rFVIIa in the far-UV region (180-260 nm) were recorded on a Jasco J-810 CD
Spectropolarimeter. The light path of the cuvette was 0.05 mm and a protein concentration
of 2.4 mg/mL was used. The spectra were recorded at room temperature. Each spectrum is
an average of 5 scans. All spectra were background-corrected, smoothed and transformed
into molar ellipticity (Θ cm2 dmol−1). A value of 114 g/mol was used as a mean residue
weight for rFVIIa. Spectra of rFVIIa in the near-UV region (250-350 nm) were recorded
on the same Spectropolarimeter. The light path of the cuvette was 10 mm and a protein
concentration of 2.4 mg/mL was used. The spectra were recorded at room temperature.
Spectra at selected temperatures in the range 10 ℃ - 80 ℃ spectra were obtained in a
2 mm cuvette. Each spectrum is an average of 5 scans. All spectra were background-
corrected, smoothed and transformed into molar ellipticity (Θ cm2 dmol−1).
Differential Scanning Calorimetry (DSC)
DSC experiments were performed with a MicroCal VP-DSC (Northhampton, MA). Prior
to scanning, all solutions were degassed by stirring under vacuum. A pressure of 2 atm
was applied over the cells during scanning, and a scan rate of 1 ℃/min was used. The
concentration of rFVIIa was 2-2.4 mg/mL, and buffer scans were subtracted from protein
scans. DSC data was analysed using the Origin software from MicroCal Inc., supplied
with the instrument. A baseline was subtracted prior to analysis. The apparent dena-
turation temperatures (Tm) values were determined as the temperature corresponding to
the maximum Cp.
Light Scattering (LS)
The LS experiments were performed with a Wyatt DynaPro Titan (Santa Barbara, CA)
which employs a 829 nm laser and collects scattering intensity data at a fixed angle of 90
℃. Cuvette temperature is controlled using a thermoelectric solid-state heating module
(Peltier heat pump). Solutions are examined in a quartz cuvette with 12 µL cell volume
containing glass viewing windows for in situ scattering measurements. The concentration
of rFVIIa was 1-2 mg/mL. 200 µL samples volumes are centrifuged at 10.000 RPM for 10
minutes prior to analysis. A scan rate of 1 ℃/min was used.
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5.3 Results
After dialysis the purity of the protein solutions were determined by SDS-PAGE and
by MALDI-TOF MS. SDS-PAGE has often been used to characterise the distribution of
PEGylated proteins [154]. It is assumed that the higher molecular weight gel band ladders
represented the mono- or di-GlycoPEGylated rFVIIa compounds (fig. 5.1).
(a) A PEG stained gel. The gel is
stained with iodide as described in
[141].
(b) SDS PAGE of rFVIIa and Glyco-
PEGylated rFVIIa.
Figure 5.1:
Lane 1 and 5, bench mark protein ladder.
Lane 2: rFVIIa.
Lane 3: 10 kDa PEG-rFVIIa.
Lane 4: 40 kDa PEG-rFVIIa.
The gel is stained with iodine (fig. 5.1a), discoloured in water and subsequently stained
with Coomassie blue (fig. 5.1b).
The PEG-staining gel technique is based on the complex formation between PEG and
barium iodide, and the PEG-stained gel (figure 5.1a) reveal that only lane 3 and lane 4
contain PEG-compounds. It has previously been shown, that PEG binds to SDS micelles
[142] and that PEGylation decreases the mobility of the protein [141, 143]. For this reason
the molecular weight of a PEGylated protein on a SDS gel will not correspond to the actual
molecular weight of the PEGylated protein. Due to the low mobility of the PEGylated
protein, the location of a PEGylated protein on a SDS gel corresponds to the molecular
weight of the protein added approximately 2.5 times the molecular weight of the attached
PEG polymer. Comparing the results in the PEG-stained gel with the very same gel,
78 Biophysical Characterisation of GlycoPEGylated human rFVIIa
only now Coomassie blue stained, it is evident, that the three bands in lane 3 (10 kDa
PEG-rFVIIa) and the two bands in lane 4 (40 kDa PEG-rFVIIa) are GlycoPEGylated
compounds of rFVIIa. From the results on the SDS-PAGE gel (fig 5.1) it is shown that
the rFVIIa sample was pure and contained only rFVIIa with a molecular mass of 50
kDa. The third lane reveals that 10 kDa PEG-rFVIIa is not only mono-GlycoPEGylated.
There are 3 different GlycoPEGylated species in this protein solution. These compounds
have apparent molecular weights of 75 kDa, 110 kDa and 125 kDa, respectively. This
corresponds to mono-GlycoPEGylated 10 kDa PEG-rFVIIa (50 kDa + 2.5 x 10 kDa) ∼
75 kDa, di-GlycoPEGylated 10 kDa PEG-rFVIIa (50 kDa + 2.5 x 2 x 10 kDa) ∼ 110 kDa
and tri-GlycoPEGylated rFVIIa (50 kDa + 2.5 x 3 x 10 kDa) ∼ 125 kDa. The fourth lane
contains mainly mono-GlycoPEGylated 40 kDa PEG-rFVIIa with a molecular weight of
(50 kDa + 2.5 x 40 kDa) ∼ 160 kDa but also a small amount of di-GlycoPEGylated 40
kDa PEGylated rFVIIa at (50 kDa + 2.5 x 2 x 40 kDa) ∼ 250 kDa.
The results of the MALDI-TOF MS spectra of rFVIIa, 10 kDa PEG-rFVIIa and 40 kDa
PEG-rFVIIa are shown in figure 5.2.
Figure 5.2: MALDI-TOF spectra of rFVIIa, 10 kDa PEG-rFVIIa and 40 kDa PEG-rFVIIa,
see text for further details.
The MS spectra show that the rFVIIa solution only contains a 50 kDa protein, and
the peak pattern corresponds to different charges (16606 Da peak corresponds to triple
charged rFVIIa, 24787 corresponds to double charged rFVIIa and 49433 corresponds to
single charged). The 10 kDa PEG-rFVIIa solution contains a mono-GlycoPEGylated, 60
kDa, and smaller amounts of a di-GlycoPEGylated compound, at 70 kDa, of 10 kDa PEG-
rFVIIa. The peak at 36400 corresponds to double charged di-GlycoPEGylated rFVIIa,
and the 30529 and 20389 are double and triple charged mono-GlycoPEGylated rFVIIa,
respectively. The 40 kDa PEG-rFVIIa solution contains mono-GlycoPEGylated 40 kDa
PEG-rFVIIa, which is reflected at the 92 kDa peak. Peaks at 46 and 31 kDa are as-
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signed to double and triple charged mono-GlycoPEGylated 40 kDa PEG-rFVIIa. The tri-
GlycoPEGylated 10 kDa rFVIIa compound and the di-GlycoPEGylated 40 kDa rFVIIa
compound are not detectable with MS.
Structural Stability
The secondary structure of rFVIIa and GlycoPEGylated rFVIIa is investigated by far-UV
CD in order to study the effect of GlycoPEGylation. The far-UV CD scan reflecting the
secondary structure of rFVIIa, 10 kDa PEG-rFVIIa and 40 kDa PEG-rFVIIa are prac-
tically inseparable, however there is a small deviation in the far-UV signal at very low
wavelength between the 10 kDa PEG-rFVIIa and the two other rFVIIa compounds. The
near-UV CD scans show no change in the tertiary structure of rFVIIa upon GlycoPEG-
ylation. The near-UV CD scan show two characteristic peaks around 286 nm and 292 nm
most likely corresponding to signals from the tryptophan residues.
Figure 5.3: Far-UV CD scan and near-UV CD scan of rFVIIa, 10 kDa PEG-rFVIIa and 40
kDa PEG-rFVIIa. The far-UV CD scans show only little variation between the spectrum
of 10 kDa PEG-rFVIIa and the two spectrums of rFVIIa and 40 kDa PEG-rFVIIa, and
the near-UV CD scans show that GlycoPEGylation has no notable effect on the tertiary
structure (near-UV CD) of rFVIIa.
Thermal, kinetic and structural stability
The thermal stability is investigated by three different complementing techniques: DSC,
LS and CD. From the CD scans it is evident that the GlycoPEGylated rFVIIa compounds
maintain some residual tertiary structure at high temperatures (> 70 ℃) (fig 5.4). The
appearance of the near-UV CD heating scan is different from the unmodified protein to
the two GlycoPEGylated protein compounds. It is evident that the tertiary structure of
the GlycoPEGylated rFVIIa molecules is less affected by the increase in temperature than
the unmodified protein.
We chose to follow one characteristic wavelength, 286 nm, throughout the CD heating
scan (fig. 5.5). This wavelength was chosen as the CD signal at this specific wavelength
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Figure 5.4: Near-UV CD at different temperatures (see legends) of rFVIIa, 10 kDa PEG-
rFVIIa and 40 kDa PEG-rFVIIa. The spectra show that the unfolding process differs from
the non-modified protein to the GlycoPEGylated proteins. The GlycoPEGylated proteins
maintain some residual tertiary structure at 70 ℃ and above, whereas CD signal from the
unmodified protein is showing no tertiary structural characteristics at these temperatures.
The native rFVIIa solution was milk-white upon heating whereas the solutions of the
GlycoPEGylated rFVIIa compounds were transparent.
changes significantly upon heating, as illustrated in figure 5.4, and corresponds to the first
of the two characteristic peaks.
The overall CD signal at 286 nm is different for the unmodified protein compared to the
GlycoPEGylated protein compounds. The low temperature range CD signal for all the
three compounds is around 2000 deg cm−2 mol−1 and decreases slowly until 50 ℃ where
the CD signal decreases significantly for all the three compounds to around -1000 deg cm−2
mol−1. For rFVIIa there is a drop in the CD signal around Tm, whereupon the signal
increases and stabilises around 0 deg cm−2 mol−1. The GlycoPEGylated rFVIIa com-
pounds, on the other hand, demonstrate a more continuous course and stabilises around
-1500 deg cm−2 mol−1. The CD signals were differentiated with respect to the tempera-
ture in order to obtain the transition midpoint (Tm) value, which is defined as the point
where the tangent has the largest slope, see table 5.1.
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Figure 5.5: Near-UV CD signals of rFVIIa, 10 kDa PEG-rFVIIa and 40 kDa PEG-rFVIIa
versus temperature at 286 nm. Triangles, circles and squares are chosen in favour of
solid lines to clearly illustrate the differences around 60 ℃, and the error bars are hidden
under the symbols. From the results represented in this figure it is clear that the tem-
perature dependent CD signal at 286 nm is different from the unmodified protein to the
GlycoPEGylated proteins. The two GlycoPEGylated proteins are alike.
The DSC thermograms and the LS intensity data are plotted in the same figure (figure
5.6) to illustrate the difference between the thermal and kinetic changes. Three differ-
ent characteristic temperatures are found from figure 5.6. The onset temperature, Tonset,
corresponding to the temperature where the unfolding of the unmodified rFVIIa or Glyco-
PEGylated rFVIIa initiates. The apparent unfolding temperature, Tm, where half of
the unmodified rFVIIa or GlycoPEGylated rFVIIa molecules are folded, the other half
unfolded theoretically, and the temperature of aggregation, Tagg, the aggregation onset
temperature. There is a clear difference between the appearance of the DSC scan of the
unmodified rFVIIa and the GlycoPEGylated rFVIIa compounds as the former is showing
signs of aggregation identified by a sharp drop in Cp and large, immeasurably aggregates
in the LS experiment. The aggregation of the two GlycoPEGylated compounds appears
to happen at a slower rate, detectable by LS.
The DSC thermograms reveal that GlycoPEGylation increases the apparent unfolding
temperature, Tm. The temperature of aggregation, Tagg is found by differentiating the
intensity of the LS signal with respect to the temperature. Linear regression was performed
on this last part of the curve, where the intensity increases due to formation of aggregates.
The calculated intercept with the x-axis, where the scattering intensity is zero, is named
Tagg, temperature of aggregation in the following. The LS measurements demonstrate
that the aggregation temperature, Tagg, increases with GlycoPEGylation (table 5.1).
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Figure 5.6: DSC thermograms and LS intensity measurements of rFVIIa, 10 kDa PEG-
rFVIIa and 40 kDa PEG-rFVIIa as a function of temperature. The dotted line correspond
to the LS intensity (the error bars are hidden under the symbols), the solid line correspond
to the DSC thermogram. The insert illustrate where the onset temperature, Tonset, the
temperature of aggregation, Tagg, and the apparent unfolding temperature, Tm, are found.
The rFVIIa aggregates formed close to Tagg were too large for the LS detector to measure,
and continuous intensity measurements as a function of temperature were impossible after
53 ℃ for rFVIIa.
Tm (℃) Tonset (℃) Tm (℃) ∆H (kJ/mol) Tagg (℃) (Tonset-Tagg)
(CD) (DSC) (DSC) (DSC) (LS)
rFVIIa 60.3±0.2 50.9±0.2 57.7±0.2 NA 50.8±0.4 0.1
10 kDa PEG-rFVIIa 59.9±0.2 53.3±0.1 59.0±0.2 140 57.1±0.2 -3.8
40 kDa PEG-rFVIIa 60.7±0.2 52.9±0.1 59.0±0.2 134 57.9±0.9 -5
Table 5.1: The unfolding temperature measured by CD, the onset temperature of the
peaks in the DSC heating scan, the apparent unfolding temperature, Tm, measured by
DSC, the aggregation temperature, Tagg, measured by LS and the difference between
Tonset and Tagg. The extraction of the enthalpy of unfolding of rFVIIa is not possible due
to the irreversibility of the denaturation process.
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The structural information obtained with far-UV and near UV-CD scans shows that both
the secondary and the tertiary structure of rFVIIa are maintained upon GlycoPEGylation
and the structures do not change with PEG chain length nor with the PEG conformation
(linear or branched). Minor differences in the CD scans are observed around 210-200 nm for
the 10 kDa GlycoPEGylated rFVIIa compound compared to the 40 kDa GlycoPEGylated
rFVIIa compound and the unmodified rFVIIa, the origin of this small difference is not
known but it could reflect changes in β-turns [127].
Structural, kinetic and thermal stability
The DSC, LS and CD heat scans were all performed at the same scan rate, which makes it
possible to compare the kinetics. The three different measurement types are complemen-
tary and they illustrate each different aspects of the unfolding or aggregation processes.
The unfolding and aggregation pathway can be described by a model put forward by
Lumry and Eyring in 1954 [94]. According to the Lumry Eyring model, irreversible pro-
tein denaturation involves at least two steps. The first step is the reversible unfolding
of the native protein (N), characterised by the rate constants, k1 and k2. This step is
followed by an irreversible change of the unfolded protein (D), into an inactivated, irre-
versible aggregate (A), characterised by the rate constant k3. The unfolded state, D, is
characterised by having some tertiary structure.
2k
k1 k3 k1
k2
N D A K=
Figure 5.7: The Lumry Eyring model, N is the native protein, D is the unfolded protein
and A is the aggregated protein.
From our experimental results it is suggested that the covalent attachment of a PEG
polymer to rFVIIa influences at least two of the three rate constants mentioned above.
The aggregation of the protein depends on the unfolding of the protein to occur first.
The aggregation is measured by LS; the unfolding is measured by CD, whereas DSC mea-
sures unfolding, an endothermic event, as well as aggregation, which here is an exothermic
event. There is an equilibrium between the native (N) and the unfolded (D) state, which
shifts towards unfolding as the temperature increases. This process is followed by the irre-
versible step from unfolding (D) to aggregation (A), which is also promoted with increasing
temperature.
From the results shown in figure 5.6 it is evident that the apparent unfolding temperature,
Tm, of the GlycoPEGylated rFVIIa compounds is slightly higher than that of rFVIIa. This
is in accordance with previous studies, which have reported that PEGylation can increase
the apparent unfolding temperature, Tm, compared to the unmodified protein [63, 91].
For rFVIIa it seems as though a longer, and branched, PEG chain does not contribute
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more to the thermal stability than a shorter, linear PEG chain. Taking a closer look at
the DSC thermograms and the LS intensities for the GlycoPEGylated rFVIIa compounds
(fig. 5.6) it is evident that GlycoPEGylation delays the thermally induced aggregation of
rFVIIa, and that the thermally induced aggregation event begins while endothermic pro-
cesses dominates. The formation of aggregates will contribute exothermally to the total
heat signal. As the heat measured by DSC is the total contribution from both unfold-
ing and aggregation, an extensive formation of aggregates beginning shortly after Tonset
may shift the location of the peak in the thermogram towards a lower temperature. Thus
GlycoPEGylation may not directly stabilise rFVIIa thermally, but could affect the value
of Tm indirectly by postponing the formation of the thermally induced aggregates. The
hypothesis that GlycoPEGylation prevents or postpones the aggregation of rFVIIa is sup-
ported by the results of the CD heating scans. The changes in the CD signal at 286 nm
in the heating scan (fig. 5.5) indicate that the non-modified rFVIIa undergo a conforma-
tional change in the tertiary structure around the apparent unfolding temperature and
no tertiary structure can be detected at higher temperature. As the physical appearance
of the rFVIIa solution upon heating was milk-white, the non-detectable tertiary struc-
ture above 70 ℃ could be a sign of aggregation and precipitation. The GlycoPEGylated
rFVIIa compounds, on the other hand, do maintain some non-native residual tertiary
structure upon unfolding, even at 90 ℃, as the CD signal stabilises around 1500 deg cm−2
mol−1 (fig. 5.5). These observations support the general conception that PEGylation may
not necessarily prevent the protein from unfolding [91, 152], but it hinders protein-protein
interactions, which can lead to aggregation and precipitating.
Nielsen and Rischel have investigated the thermal stability of rFVIIa and 40 kDa PEG-
rFVIIa with DSC and High Resolution Ultra Sonic Spectroscopy (HR-US) [152]. On the
basis of the DSC measurements they conclude, that the denaturation of rFVIIa is irre-
versible. In contrast they find that the unfolding of 40 kDa PEG-rFVIIa is characterised
by being partly reversible, as approximately 60 % reversibility is observed after heating to
60 ℃. Based on HR-US experiments they report that the post-denaturation aggregation
process is delayed upon GlycoPEGylation. In addition it is suggested, that the Glyco-
PEGylated protein demonstrate a less pronounced aggregation. All these conclusions are
supported by the results obtained in this study.
Based on the results obtained in this study it seems reasonable to assume that the equi-
librium constant k1/k2, reflecting the equilibrium between the native and the unfolded
protein, is independent of GlycoPEGylation, since unfolding process for rFVIIa seems to
be similar, whether the protein is GlycoPEGylated or not. The rate constant k3, on the
other hand, describing the step from unfolding to aggregation, decreases when the pro-
tein is GlycoPEGylated. The thermally induced rFVIIa aggregates formed close to Tagg
were too large for the LS detector to measure, and continuous intensity measurements as
a function of temperature were impossible after 53 ℃ for rFVIIa. As the light scatter-
ing increases with the sizes of the formed aggregates [155], a high intensity count most
likely corresponds to large aggregates. The increase in the LS intensity is much slower for
the GlycoPEGylated rFVIIa compounds, thus the formation of aggregates is reduced and
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happens at a lower rate. The fact that PEGylating a protein postpones the aggregation
has also been reported previously [65, 95, 152]. By comparing the difference between the
onset of unfolding, Tonset, with the onset of aggregation, Tagg, (figure 5.6 and table 5.1),
it is evident that (Tagg - Tonset) is of the same order of magnitude for both for 10 kDa
PEG-rFVIIa and 40 kDa PEG-rFVIIa. Given that both GlycoPEGylated compounds
postpone the aggregation behaviour of rFVIIa, but not the thermally induced unfolding,
indicates that PEGylating a protein may affect the aggregation properties of a protein
but not through thermal stabilisation of the protein. This is in agreement with previously
reported studies on insulin [65].
It is noticeable that the PEG molecular weight and shape has no effect on the thermal,
the structural or the kinetic stability of rFVIIa. All of the results obtained in this study
indicate that attaching a PEG moiety of similar size as rFVIIa appears to have the same
effect as attaching a smaller 10 kDa PEG to rFVIIa. From a pharmaceutical formulation
point of view these results indicate that the decision of what shape and size of PEG to use
for GlycoPEGylation of rFVIIa depends on other factors than those currently investigated.
Instead, the size and shape PEG should be chosen as that which gives the best biological
effect.
Favourable properties, such as postponed or prevented aggregation and thermal stabili-
sation are caused by the heavily hydrated PEG polymer, and the properties of the PEG
polymer are transferred to the GlycoPEGylated compounds. In particular, the postponed
and decreased aggregation is crucial in protein drugs as this increases the stability of the
protein.
5.5 Conclusion
Recombinant human Factor VII was mono-GlycoPEGylated with two different PEG poly-
mers, a 10 kDa linear PEG and a 40 kDa branched PEG. The CD measurements suggest
that the secondary and tertiary structure of rFVIIa is maintained upon GlycoPEGylation.
The DSC and LS measurements suggests that GlycoPEGylation delays the thermally
induced aggregation, and slightly increases the unfolding temperature of the protein (in-
crease from 57.7 ± 0.2 ℃ to 59.0 ± 0.2 ℃), both of which are independent of the molecular
weight and size of the attached PEG polymer. From the biophysical characterisation of
rFVIIa and GlycoPEGylated rFVIIa in the present study it is concluded, that rFVIIa after
GlycoPEGylation appears to be unaffected structurally (secondary and tertiary structure),
slightly stabilised thermally (unfolding temperature), and stabilised kinetically (tempera-
ture of aggregation).
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Abstract
The effects of calcium chloride on the structural, kinetic and thermal stability of recom-
binant human Factor VIIa (rFVIIa) were investigated using rFVIIa and two GlycoPEG-
ylated recombinant human FVIIa derivatives, a linear 10 kDa PEG and a branched 40
kDa PEG, respectively. Three different CaCl2 concentrations were used; 10 mM, 35 mM
and 100 mM. The secondary and tertiary structure of rFVIIa at 25 ℃, measured by Cir-
cular Dichroism (CD), was maintained upon GlycoPEGylation as well as CaCl2 content.
In contrast the thermal stability of the three rFVIIa compounds, measured by Differential
Scanning Calorimetry (DSC) and Circular Dichroism (CD), and aggregation behaviour,
measured by Light Scattering (LS), was affected by the increasing calcium concentration.
Increasing the CaCl2 concentration from 10 mM to 35 mM resulted in a decrease in the
apparent unfolding temperature, Tm, of rFVIIa, whereas the concentration of CaCl2 has
to be raised to 100 mM in order to see the same effect on the GlycoPEGylated rFVIIa
compounds. The temperature of aggregation of rFVIIa, Tagg, increased as the CaCl2
concentration increased from 35 mM to 100 mM, while Tagg for the GlycoPEGylated
rFVIIa compounds was practically independent of the CaCl2 concentration. From the
obtained results it is concluded that GlycoPEGylation postpones the calcium induced
thermal destabilisation of rFVIIa, and a much higher calcium concentration also post-
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pones the thermally induced aggregation of rFVIIa. The thermally induced aggregation
of the GlycoPEGylated rFVIIa compounds is unaffected by an increasing calcium chloride
concentration.
Keywords: rFVIIa, GlycoPEGylation, protein aggregation, protein unfolding, salt effects,
Ca2+.
6.1 Introduction
For blood coagulation factor VIIa (FVIIa) the presence of calcium ions is vital, as these
ions assist in initiating the blood coagulation cascade including the association of tissue
factor (TF), and following the activation of factor IX and factor X resulting in a burst
of thrombin, fibrin deposition and the formation of a haemostatic plug on the platelet
surface [146]. Deficiencies in the coagulation system due to partial or complete deficiency
of FVIII or FIX, haemophilia A or haemophilia B respectively, can lead to severe morbidity
or mortality if the bleeding is left untreated.
A safe and efficient way to prevent bleeds and joint destruction in haemophilia is with
the use of prophylaxis giving FVIII or FIX 2-4 times weekly [148]. Recent studies have
shown that prophylactic treatment with recombinant FVIIa (rFVIIa, NovoSevenr) in
haemophilia patients with inhibitors against FVIII or FVIX reduces the frequency of
bleedings significantly as compared to conventional on-demand haemostatic therapy [149].
However, based on the half-life and circulation time of rFVIIa (2-4 h), it is assumed that
rFVIIa should be administered daily if used for long-term prevention [149, 150]. Hence,
development of rFVIIa derivatives with longer circulation time could result in both fewer
administrations and better patient compliance. Modification of pharmaceutical proteins
with hydrophilic polymers such as poly-ethylene-glycol (PEGylation) is an established
method for prolonging circulatory half-life, reducing self-aggregation, increase water solu-
bility and increase stability [82, 117]. Due to the risk of losing activity of FVIIa because
of the numerous interactions with the cell surface, TF, FIX and FX there is a limitation
in the unspecific chemical modification of this protein. For this reason a novel strategy for
site-directed PEGylation using glycosyltransferases to attach PEG to glycan residues, the
enzyme based GlycoPEGylation™ technology is used to covalently attach either a linear
10 kDa or a branched 40 kDa PEG polymer to rFVIIa, a technique originally described by
DeFrees et al. [79]. The site of PEG attachment to rFVIIa is demonstrated to be one of the
two N-linked glycans of rFVIIa (Asn145 or Asn322) located on the light chain and heavy
chain, respectively [64]. It is assumed that the specific location of the GlycoPEGylation
site and presence of small amounts of di-GlycoPEGylated species are irrelevant in relation
to the overall interpretation of the obtained results.
From a pharmaceutical formulation point of view altering the salt concentration in the
protein buffer is of interest in relation to its effect on the protein stability. Addition of
electrolytes to proteins in solution can have complex effects on the physical stability of the
protein. Electrolytes can modify the conformational stability, the equilibrium solubility
(e.g. salting-in and salting-out) and the formation of aggregates [2]. Salts can interact
with the unpaired charged side chains of proteins and stabilise or destabilise the native
6.1 Introduction 89
state of the protein. The former is a result of the binding of mainly multivalent ions to
the unpaired charged surface available side chains, which can lead to cross-linking between
the charges and thus stabilisation. The latter is found e.g. if the ions bind more strongly
to the unfolded state of the protein than to the native state [2]. A number of physical
properties of aqueous salt solutions follow the rank order of the Hofmeister series, which
arrange solutes according to their ability to act as kosmotrope (salting-out) or chaotrope
(salting-in) agents [156, 157]
In this study the effect of CaCl2 on the thermal, kinetic and structural stability of rFVIIa
and GlycoPEGylated rFVIIa compounds is investigated. Ca2+ binding is an important
stabiliser for a number of proteins, and structural aspects of the specific Ca2+ binding to
rFVIIa are of great importance for understanding its physiological function [158]. There
are a total of 9 specific binding sites for Ca2+ in three distinct regions on rFVIIa, and
they all have different affinities [159, 160]. The binding of these 9 Ca2+ ions are vital for
the initiation of the blood coagulation cascade, as the binding of Ca2+ is a prerequisite
for the high-affinity binding of rFVIIa to TF [160–162]. All the Ca2+ binding sites are
saturated when the calcium buffer concentration exceeds 10 mM [159]. In the present
study we have used three CaCl2 concentrations ranging from 10 mM to 100 mM to make
sure all the specific binding sites of rFVIIa are saturated, and hence focus the study on
the effect of low affinity binding of Ca2+. The physical stability of liquid protein drugs is
an important property to investigate as insoluble aggregates may increase immunogenic
responses and are not biologically active. CaCl2 is a potential salting in agent, which
interacts more strongly with the unfolded form than with the native form, consequently
shifting the equilibrium towards the unfolding reaction [157]. This behaviour is pronounced
at concentrations around 100 mM [157, 163]. Investigating the stability of rFVIIa and
GlycoPEGylated rFVIIa in higher concentrations of CaCl2 than 10 mM is of relevance
in relation to the pharmaceutical development, purification and formulation processes,
during which the protein concentration often exceeds 1 mg/mL (1 mg/mL NovoSevenr
contains 10 mM CaCl2). When concentrating rFVIIa an addition of CaCl2 is needed in
order to keep rFVIIa in solution. In contrast, the absence of visual precipitate suggests
that GlycoPEGylated rFVIIa stays in solution in 10 mM CaCl2 even at high concentration
(> 10 mg/mL).
The effect on the physical stability rFVIIa of increasing the CaCl2 concentration is investi-
gated by using rFVIIa, and two GlycoPEGylated rFVIIa compounds, a 10 kDa linear kDa
and 40 kDa branched PEG. This provides us with a relevant pharmaceutical model system
for studying the effect of an increasing Ca2+ concentration on both a native protein and
its two GlycoPEGylated compounds. Biophysical characterisation tools, including Circu-
lar Dichroism (CD), Differential Scanning Calorimetry (DSC) and Light Scattering (LS),
were used to study possible changes in the secondary and tertiary structure as well as the
thermal and kinetic stability of rFVIIa, 10 kDa PEG-rFVIIa and 40 kDa rFVIIa upon an
increase in CaCl2 concentration.
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6.2 Materials and Methods
Materials
rFVIIa, 10 kDa GlycoPEGylated rFVIIa and 40 kDa GlycoPEGylated rFVIIa was pro-
duced by Novo Nordisk A/S, Denmark, as described in [64]. L-Histidine was purchased
from Aijonomoto AminoScience (Raleigh, N.C.), calciumchlorid-dihydrate from Merck
(Germany), Barium Chloride 20 w/w from Ampliqon (Denmark), 0.1 N iodine solution
from Sigma-Aldrich (Germany), 70 % perchloric acid from Merck (Germany), LDS sam-
ple buffer and MES SDS running buffer and Simple Blue Safe Stain all from Invitrogen
(Carlsbad, CA). All protein solutions were dialysed in Slide-A-LyzerTM 30.000 MWCO
dialyse cassettes against the desired buffer. Three different buffers were used, only vary-
ing in CaCl2 content. Buffer 1 contained 10 mM Histidine (HIS), 10 mM CaCl2. Buffer
2 contained 10 mM HIS and 35 mM CaCl2. Buffer 3 contained 10 mM HIS and 100 mM
CaCl2. All buffers were adjusted to pH 5.75
SDS-PAGE
SDS-PAGE analysis was carried out using a 12 % Bis-Tris gel from Invitrogen. The gels
were loaded with an average of 5 µg protein per well and run at 120 mA constant current
per gel. The running buffer was MES running buffer. The gel was washed in 150 mL 0.1
M perchloric acid for 15 minutes until 40 mL 5 % barium chloride solution and 15 mL
0.1 M iodine solution were added to detect protein bands containing PEG compounds, as
described in [141]. After discolouring in water, the gel was coloured with Coomassie blue.
MALDI-TOF MS
Mass spectrometric analysis was performed on a Bruker Daltonics Microflex MALDI-TOF
(Billerica, MA) equipped with a nitrogen laser (337 nm). The instrument was operated
in linear mode with delayed extraction, and the accelerating voltage in the ion source was
25kV. 1 µl sample-solution was mixed with 10 µl matrix-solution (alphacyano-cinnamic
acid dissolved in a 5:4:1 mixture of acetonitrile:water:3% TFA) and 1 µl of this mixture
was deposited on the sample plate and allowed to dry before insertion into the mass
spectrometer. Calibration was performed using external standards (a range of standard
proteins) and the resulting accuracy of the mass determinations is within 0.1%.
Circular Dichrosim (CD) Spectroscopy
Spectra of rFVIIa in the far-UV region (180-260 nm) were recorded on a Jasco J-810 CD
Spectropolarimeter (JASCO International Co. Ltd., Hachioji City, Japan). The light path
of the cuvette was 0.05 mm and a protein concentration of 2.4 mg/mL was used. The
spectra were recorded at room temperature. Each spectrum is an average of 5 scans. A
value of 114 g/mol was used as a mean residue weight for rFVIIa. Spectra of rFVIIa in
the near-UV region (250-350 nm) were recorded on the same Spectropolarimeter. The
light path of the cuvette was 10 mm and a protein concentration of 2.4 mg/mL was used.
The spectra were recorded at room temperature. Spectra at selected temperatures in the
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range 10 ℃-80 ℃ spectra were obtained in a 2 mm cuvette. Each spectrum is an average
of 5 scans. All spectra were background-corrected, smoothed and transformed into molar
ellipticity (Θ cm2 dmol−1) as described in [127].
Differential Scanning Calorimetry (DSC)
DSC experiments were performed with a MicroCal VP-DSC (Northhampton, MA). Prior
to scanning, all solutions were degassed by stirring under vacuum. A pressure of 2 atm
was applied over the cells during scanning, and a scan rate of 1 ℃/min was used. The
concentration of rFVIIa was 2-2.4 mg/mL, and buffer scans were subtracted from protein
scans. DSC data was analysed using the Origin software from MicroCal Inc., supplied
with the instrument. A baseline was subtracted prior to analysis. The apparent dena-
turation temperatures (Tm) values were determined as the temperature corresponding to
the maximum Cp, the errors are determined by repeatable experiments. The enthalpy is
calculated from the area under the peak bound by the baseline, and the errors are based
on the adjustment of this baseline.
Light Scattering (LS)
The LS experiments were performed with a Wyatt DynaPro Titan (Santa Barbara, CA)
which employs a 829 nm laser and collects scattering intensity data at a fixed angle of 90
℃. Cuvette temperature is controlled using a thermoelectric solid-state heating module
(Peltier heat pump). Solutions are examined in a quartz cuvette with 12 µL cell volume
containing glass viewing windows for in situ scattering measurements. The concentration
of rFVIIa was 1-2 mg/mL. 200 µL samples volumes are centrifuged at 10.000 RPM for 10
minutes prior to analysis. A scan rate of 1 ℃/min was used.
6.3 Results
Purity
After dialysis the purity of the protein solutions were determined by SDS-PAGE and
by MALDI-TOF MS as described and published in Plesner et al. [164]. Briefly, it was
shown that the rFVIIa sample was pure and contained only rFVIIa with a molecular
mass of 50 kDa. The 10 kDa PEG-rFVIIa solution contains a mono-GlycoPEGylated,
60 kDa, and smaller amounts of a di-GlycoPEGylated compound, at 70 kDa, of 10 kDa
PEG-rFVIIa. The 40 kDa PEG-rFVIIa solution contains mono-GlycoPEGylated 40 kDa
PEG-rFVIIa with a molecular mass of 92 kDa. It is assumed that the specific location of
the GlycoPEGylation site and presence of small amounts of di-GlycoPEGylated species
are irrelevant in relation to the overall interpretation of the results obtained in this study.
Structural Characteristics
The secondary structure of rFVIIa and GlycoPEGylated rFVIIa is investigated by far-UV
CD and the results have been reported previously [164]. From that study it was evident
that the far-UV CD scans of rFVIIa and 40 kDa PEG-rFVIIa are inseparable, and there
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is only a small variation in the far-UV signal at very low wavelength between the native
rFVIIa and the 40 kDa PEG-rFVIIa compared to the 10 kDa GlycoPEGylated rFVIIa
compound. The near-UV CD scans show no change in the tertiary structure of rFVIIa
upon GlycoPEGylation. Due to the high absorbance of Cl− ions below 200 nm [127], it
was not possible to measure far-UV CD scans on samples containing 35 mM and 100 mM
CaCl2.
Figure 6.1: Far-UV CD scan and near-UV CD scan of rFVIIa, 10 kDa PEG-rFVIIa and 40
kDa PEG-rFVIIa in 10 mM HIS, 10 mM CaCl2, pH 5.75. The far-UV CD scans show only
little variation between the spectrum of 10 kDa PEG-rFVIIa and the two spectrums of
rFVIIa and 40 kDa PEG-rFVIIa, and the near-UV CD scans show that GlycoPEGylation
has no notable effect on the tertiary structure (near-UV CD) of rFVIIa. Results adapted
from [164].
Thermal, kinetic and structural stability
The effect of increasing the CaCl2 buffer content on the thermal, kinetic and structural
stability of rFVIIa and GlycoPEGylated rFVIIa is investigated by three different comple-
mentary techniques: DSC, LS and CD. From the CD scans it is evident that there is no
difference between the thermally induced structural changes upon an increase in CaCl2 in
rFVIIa and GlycoPEGylated rFVIIa, respectively (figure 6.2).
We chose to follow one characteristic wavelength, 286 nm, throughout the CD heating
scan. This wavelength was chosen as the CD signal at this specific wavelength changes
markedly upon heating, see figure 6.3. The CD signal at 286 nm reflects primarily the
aromatic amino acids tryptophan (290-305 nm) and tyrosine (275-282 nm) [127].
It is shown in figure 6.3 that from 60 ℃ and above the change in the 286 nm CD signal is
independent of the CaCl2 content, but clearly different from the unmodified rFVIIa to the
GlycoPEGylated rFVIIa compounds. For rFVIIa there is a clear drop in the CD signal
around Tm, whereupon the signal increases and stabilises around 0 deg cm−2 mol−1. On
the other hand, the GlycoPEGylated rFVIIa compounds demonstrate a more continuous
course. Differentiating the CD signal with respect to the temperature gives an estimate of
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Figure 6.2: Near-UV CD at different temperatures (see legends) of rFVIIa, 10 kDa
PEG-rFVIIa and 40 kDa PEG-rFVIIa. The left panels show results obtained in 10 mM
HIS, 35 mM CaCl2, pH 5.75 and the right panels show results obtained in 10 mM HIS,
100 mM CaCl2, pH 5.75. The spectra in both panels are similar, indicating that there
are no or very small differences in the thermally induced unfolding due to increasing
CaCl2 content. Both panels also show spectra which indicate that the thermally induced
unfolding process differs from the non-modified protein to the GlycoPEGylated proteins.
The GlycoPEGylated proteins maintain some residual tertiary structure at 60 ℃ and
above, whereas CD signal from the native protein shows no structural characteristics at
these temperatures. The native rFVIIa solution was milk-white upon heating whereas
the GlycoPEGylated rFVIIa compounds were transparent. Similar results are found for
rFVIIa and its GlycoPEGylated compounds in 10 mM HIS, 10 mM CaCl2, pH 5.75 [164].
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Figure 6.3: Near-UV CD signals of rFVIIa, 10 kDa PEG-rFVIIa and 40 kDa PEG-rFVIIa
versus temperature at 286 nm in 10 mM HIS, 35 mM CaCl2, pH 5.75 and 10 mM HIS,
100 mM CaCl2, pH 5.75. The temperature dependent near-UV CD signals appears to be
independent of the CaCl2 concentration, but different from the unmodified protein to the
GlycoPEGylated proteins. The thermally induced unfolding of the two GlycoPEGylated
proteins are alike. Differentiating the CD signal with respect to the temperature gives an
estimate of the unfolding temperature, see table 6.1. Similar results are obtained in 10
mM HIS, 10 mM CaCl2, pH 5.75 [164].
the unfolding temperature based on the thermally induced structural changes, see table
6.1.
The DSC thermograms and the LS intensity data are plotted in the same figure (fig-
ure 6.4). The effect of CaCl2 on the thermal stability of rFVIIa, 10 kDa PEG-rFVIIa
and 40 kDa PEG-rFVIIa is investigated by DSC. From the resulting thermograms it is
evident, that the thermal stability of rFVIIa depends on both CaCl2 content and Glyco-
PEGylation (figure 6.4). The apparent unfolding temperature of rFVIIa decreases at 35
mM and 100 mM CaCl2 compared to 10 mM CaCl2, whereas 10 kDa PEG-rFVIIa and
40 kDa PEG-rFVIIa are not thermally destabilised until the CaCl2 concentration reaches
100 mM. There is a substantial difference between the appearances of the thermograms
after Tm has been reached. From the DSC thermograms and the LS intensities for the
GlycoPEGylated rFVIIa compounds (figure 6.4) it appears that GlycoPEGylation delay
the thermally induced aggregation of rFVIIa at 10 mM CaCl2 and 35 mM CaCl2. At 100
mM CaCl2 the unmodified rFVIIa and the GlycoPEGylated rFVIIa compounds display
similar aggregation behaviour.
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Figure 6.4: DSC thermograms and LS intensity measurements of rFVIIa, 10 kDa PEG-
rFVIIa and 40 kDa PEG-rFVIIa as a function of temperature in buffers with 3 different
CaCl2 concentrations. The dotted line correspond to the LS intensity, the solid line corre-
spond to the DSC thermogram. The insert illustrate where the onset temperature, Tonset,
the temperature of aggregation, Tagg, and the apparent unfolding temperature, Tm, are
found. The rFVIIa aggregates formed close to Tagg were too large for the LS detector
to measure, and continuous intensity measurements as a function of temperature were
impossible after 53 ℃ for rFVIIa. The obtained results at 10 mM HIS, 10 mM CaCl2, pH
5.75 are from [164]
6.4 Discussion
The effect of CaCl2 on the thermal, structural and kinetic stability of rFVIIa was mea-
sured by three complementary techniques; DSC, CD and LS. The three different mea-
surement types illustrate each different aspect of the unfolding or aggregation processes.
The unfolding and aggregation pathway can be illustrated by a model put forward by
Lumry and Eyring in 1954. According to the Lumry Eyring model, irreversible protein
denaturation involves at least two steps. The first step is the reversible unfolding of the
native protein (N), characterised by the rate constants, k1 and k2. This step is followed by
an irreversible change of the unfolded protein (D), into an inactivated, irreversible aggre-
gate (A), a step characterised by the rate constant k3. The unfolded state is characterised
by having some non-native residual tertiary structure.
It is our experimental approximation, that the aggregation is measured by LS; the unfold-
ing is measured by CD, whereas DSC measures unfolding, an endothermic event, as well
as aggregation, an exothermic event. We hypothesize, that during the heating scan there
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Tm (℃) Tonset (℃) Tm (℃) ∆H (kJ/mol) Tagg (℃) (Tonset-Tagg)
(CD) (DSC) (DSC) (DSC) (LS)
10 mM CaCl2
a
rFVIIa 60.3±0.2 50.9±0.2 57.7±0.2 NA 50.8±0.4 0.1
10 kDa PEG-rFVIIa 59.9±0.2 53.3±0.1 59.0±0.2 140 57.1±0.2 -3.8
40 kDa PEG-rFVIIa 60.7±0.2 52.9±0.1 59.0±0.2 134 57.9±0.9 -5
35 mM CaCl2
rFVIIa 59.9±0.2 49.0±0.1 55.2 ±0.2 NA 49.8±0.7 -0.8
10 kDa PEG-rFVIIa 59.3±0.2 51.0± 0.1 58.0 ±0.2 140 56.8±0.3 -5.8
40 kDa PEG-rFVIIa 59.3±0.2 52.3±0.1 58.6±0.2 153 57.7±0.2 -5.4
100 mM CaCl2
rFVIIa 61.5±0.2 48.3±0.1 55.1±0.2 NA 59.3±0.4 -11
10 kDa PEG-rFVIIa 59.9±0.2 47.6±0.2 55.3±0.2 147 59.2±0.4 -11.6
40 kDa PEG-rFVIIa 59.7±0.2 47.1±0.1 55.0±0.2 156 56.7±0.2 -9.6
a From Plesner et al. [164]
Table 6.1: The apparent unfolding temperature, Tm, measured by CD, the onset tem-
perature Tonset, the Tm and corresponding enthalpy measured by DSC, the aggregation
temperature, Tagg, measured by LS and the difference between Tonset and Tagg. The ex-
traction of the enthalpy of unfolding of rFVIIa is not possible due to the irreversibility of
the denaturation process.
is an equilibrium between the native (N) and the unfolded (D) state, which shifts towards
unfolding as the temperature increases. This process is followed by the irreversible step
from unfolding (D) to aggregation (A), which is also temperature driven. Our experimen-
tal results show that an increasing CaCl2 influences at least two of the three rate constants
mentioned above.
2k
k1 k3 k1
k2
N D A K=
Figure 6.5: The Lumry Eyring model, N is the native protein, D is the denatured protein
and A is the aggregated protein.
The thermally induced unfolding of rFVIIa and GlycoPEGylated rFVIIa at three differ-
ent CaCl2 concentrations is measured by CD (figure 6.2), and is further illustrated by the
changes in the CD signal at 286 nm (figure 6.3). The CD heating scans show that the
non-modified rFVIIa undergo a conformational change in the tertiary structure around
the apparent unfolding temperature and no tertiary structure can be detected at higher
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temperature. This trend is observed at all calcium concentrations. As the physical ap-
pearance of the rFVIIa solution upon heating was milk-white, the non-detectable tertiary
structure above 70 ℃ could be a sign of temperature induced aggregation. The Glyco-
PEGylated rFVIIa compounds, on the other hand, seems to maintain some non-native
residual tertiary structure upon unfolding as the CD signal stabilises around 5000 Θ cm−2
mol−1 (figure 6.3).
From the DSC and LS results obtained in 10 mM and 35 mM CaCl2 shown in figure 6.4,
it is evident that both the apparent unfolding temperature, Tm, and the temperature of
aggregation, Tagg, of the GlycoPEGylated rFVIIa compounds are higher that than of the
unmodified protein. There is no notable difference between the 10 kDa GlycoPEGylated
rFVIIa and the 40 kDa GlycoPEGylated rFVIIa. The increase in both Tm and Tagg
with PEGylation is in accordance with previous studies [63, 91, 152]. The combined DSC
and LS results in figure 6.4 illustrate that the thermally induced aggregation event for
rFVIIa begins while endothermic processes dominates. The formation of aggregates will
contribute exothermally to the total heat signal. As the heat measured by DSC is the total
contribution from both unfolding and aggregation, an extensive formation of aggregates
beginning shortly after Tonset may shift the location of the peak in the thermogram towards
a lower temperature. Increasing the CaCl2 concentration from 10 mM to 35 mM result in
a minor decrease in both Tm (measured by DSC) and Tagg for rFVIIa, most pronounced
is the decrease in Tm. Thus, increasing the CaCl2 concentration appears to result in a
decrease in the thermal stability of rFVIIa.
At 100 mM CaCl2 the apparent unfolding temperature measured by DSC is similar for
rFVIIa, 10 kDa GlycoPEGylated rFVIIa and 40 kDa GlycoPEGylated rFVIIa. The ther-
mal stability of the GlycoPEGylated rFVIIa compounds increases compared to thermal
stability of rFVIIa, when the CaCl2 concentration is increased from 10 mM to 35 mM.
The GlycoPEGylated compounds are not thermally destabilised until the concentration
of CaCl2 reaches 100 mM. In addition the thermally induced aggregation of all the inves-
tigated compounds appears to occur at a higher temperature at 100 mM CaCl2 compared
to the lower calcium concentrations.
It is noticeable how both the native rFVIIa and the GlycoPEGylated rFVIIa compounds
display different aggregation behaviours at 100 mM CaCl2. At 100 mM CaCl2 the ther-
mally induced aggregation does not only set in at a higher temperature for all the in-
vestigate proteins, native and GlycoPEGylated, the difference between Tonset and Tagg is
10-11 degrees as opposed to 1-5 degrees at lower CaCl2 concentrations. Based on the LS
and DSC measurements it is suggested that rFVIIa (unmodified and GlycoPEGylated) in
general is stabilised by electrostatic interactions which are weakened by the addition of
CaCl2, and that CaCl2 might interact preferentially with the protein in the unfolded state,
’D’. Both effects stabilise the aqueous ’D’ state, as the equilibrium constant K increases
and the rate constant k3 decreases with increasing calcium concentration, leading to a
lower apparent Tm and a higher Tagg.
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Based on the results obtained in this study it seems reasonable to assume that the equilib-
rium constant K, reflecting the equilibrium between the native and the unfolded protein, is
independent of the increase in CaCl2 content from 10 mM to 35 mM as well as independent
of GlycoPEGylation, since unfolding process for rFVIIa appears to be similar, whether
the protein is GlycoPEGylated or not (fig. 6.3). The rate constant k3, on the other hand,
describing the step from unfolding to aggregation, decreases dramatically when the protein
is GlycoPEGylated. And k3 of rFVIIa is markedly decreased as the CaCl2 concentration
is increased from 35 mM to 100 mM, where Tagg increases from ∼ 50 ℃ at 10 mM and 35
mM CaCl2 to ∼ 59 ℃ at 100 mM CaCl2. From the LS results in figure 6.4, it is evident,
that the formation of aggregates is affected by GlycoPEGylation as well as CaCl2 content.
At 10 mM and 35 mM CaCl2 the thermally induced rFVIIa aggregates formed close to
Tagg were too large for the LS detector to measure, and continuous intensity measurements
as a function of temperature were impossible. As the light scattering increases with the
sizes of the formed aggregates [155], a high intensity count corresponds to large aggre-
gates. The increase in the LS intensity is much slower for the GlycoPEGylated rFVIIa
compounds in general, thus the formation of thermally induced aggregates is reduced and
happens at a lower rate. At 100 mM CaCl2 the formation of thermally induced rFVIIa
aggregates seems to follow a similar pattern as the GlycoPEGylated rFVIIa compounds.
The aggregates are formed slower and to a lower extent compared to the aggregates formed
at lower CaCl2 concentration.
6.5 Conclusion
Recombinant human Factor VIIa was GlycoPEGylated with two different PEG polymers, a
10 kDa linear PEG and a 40 kDa branched PEG, and the stability of these compounds was
investigated at three different CaCl2 concentrations. The addition of salt, CaCl2, seems to
have the same effect on the stability of rFVIIa, regardless of GlycoPEGylation. However,
the thermal destabilising effect and postponed aggregation appear to be depending on the
concentration of CaCl2 once the protein is GlycoPEGylated. The thermal and kinetic
effects of increasing the CaCl2 concentration is found at 35 mM for rFVIIa, whereas the
concentration of CaCl2 has to be raised to 100 mM in order to see the same effect on
the GlycoPEGylated rFVIIa compounds. Thus GlycoPEGylation postpones the calcium
induced thermal destabilisation of rFVIIa, and a sufficiently high calcium concentration
also postpones the aggregation of rFVIIa.
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Abstract
The effects of GlycoPEGylation on the molar hydrodynamic volume of recombinant hu-
man rFVIIa were investigated using rFVIIa and two GlycoPEGylated recombinant human
FVIIa derivatives, a linear 10 kDa PEG and a branched 40 kDa PEG, respectively. Molar
hydrodynamic volumes were determined by capillary viscometry and mass spectrometry.
The intrinsic viscosities of rFVIIa, its two GlycoPEGylated compounds, and of linear 8
kDa, 10 kDa, 20 kDa and branched 40 kDa PEG polymers were determined. The mea-
sured intrinsic viscosity of rFVIIa is 6.0 mL/g, while the intrinsic viscosities of 10 kDa
PEG-rFVIIa and 40 kDa PEG-rFVIIa are 29.5 mL/g and 79.0 mL/g, respectively. The
intrinsic viscosities of the linear PEG polymers are 20, 22.6 and 41.4 mL/g for 8, 10, and
20 kDa, respectively, and 61.1 mL/g for the branched 40 kDa PEG. From the results of the
intrinsic viscosity and MALDI-TOF measurements it is evident, that the molar hydrody-
namic volume of the conjugated protein is not just an addition of the molar hydrodynamic
volume of the PEG and the protein. The molar hydrodynamic volume of the GlycoPEG-
ylated protein is larger than the volume of its composites. These results suggest that both
the linear and the branched PEG are not wrapped around the surface of rFVIIa but are
chains that are significantly stretched out when attached to the protein.
Keywords: GlycoPEGylation, rFVIIa, intrinsic viscosity, molar hydrodynamic volume,
capillary viscometry
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7.1 Introduction
Coagulation factor VIIa (FVIIa) is a trypsin-like serine protease, which in the presence
of calcium initiates the blood coagulation when associated with its cofactor tissue factor
(TF) which is exposed upon vascular injury [146, 147]. TF-bound FVIIa activates factor
IX and factor X resulting in a burst of thrombin, fibrin deposition and the formation of
a haemostatic plug on the surface of activated platelets [146]. Deficiencies in the coag-
ulation system due to partial or complete deficiency of FVIII or FIX, haemophilia A or
haemophilia B respectively can lead to severe morbidity or mortality if the bleeding is left
untreated. A safe and efficient way to prevent bleeds and joint destruction in haemophilia
is with the use of prophylaxis giving FVIII or FIX 2-4 times weekly [148]. Recent studies
have shown that prophylactic treatment with recombinant FVIIa (rFVIIa, (NovoSevenr))
of haemophilia patients with inhibitors reduces the frequency of bleedings significantly as
compared to conventional on-demand haemostatic therapy [149]. However, based on the
half-life and circulation time of rFVIIa (2-4 h), it is assumed that rFVIIa should be ad-
ministered daily if used for long-term prevention [149, 150]. Hence, development of rFVIIa
derivatives with longer circulation time could result in both fewer administrations and bet-
ter patient compliance. Modification of pharmaceutical proteins with hydrophilic polymers
such as poly-ethylene-glycol (PEGylation) is an established method for prolonging circu-
latory half-life, reducing self-aggregation, increase water solubility and increase stability
[82, 117]. Due to the risk of losing activity of FVIIa because of the numerous interactions
with the cell surface, TF, FIX and FX there is a limitation in the unspecific chemical
modification of this protein. For this reason a novel strategy for site-directed PEGylation
using glycosyltransferases to attach PEG to glycan residues, the enzyme based Glyco-
PEGylation technology is used to covalently attach either a linear 10 kDa or a branched
40 kDa PEG polymer to rFVIIa. The site of PEG attachment to rFVIIa is demonstrated
to be one of the two N-linked glycans of rFVIIa (Asn145 or Asn322) located on the light
chain and heavy chain, respectively [64]. It is assumed that the specific location of the
GlycoPEGylation site and presence of small amounts of di-GlycoPEGylated species are ir-
relevant in relation to the overall interpretation of the results obtained in this study. Most
of the benefits of PEGylated proteins reflect the properties of the PEG polymer itself [60]
and the hydration of the PEG chain determines the overall hydrodynamic properties of
PEG bioconjugates [59, 61]. The underlying mechanisms for the effect of PEG is not fully
understood, but it is evident that the hydrodynamic radius is significantly increased by
PEG leading to reduced clearance, especially of smaller proteins [63].
When developing a pharmaceutical protein solution intended for injection, the viscosity
of the solution plays a key role. The final viscosity of an aqueous protein solution can
be estimated from knowledge of the intrinsic viscosity or the molar hydrodynamic volume
of the protein in question together with the concentration of protein in solution. Inves-
tigations regarding possible changes in the molar hydrodynamic volume of rFVIIa upon
GlycoPEGylation are of high relevance in the drug development process. The present work
examines the change in molar hydrodynamic volume of rFVIIa upon GlycoPEGylation by
measuring the intrinsic viscosity and the molar mass of rFVIIa, PEG and GlycoPEGylated
rFVIIa.
7.2 Materials and Methods 101
7.2 Materials and Methods
Materials
rFVIIa, 10 kDa GlycoPEGylated rFVIIa and 40 kDa GlycoPEGylated rFVIIa were pro-
duced by Novo Nordisk A/S, Denmark, as described in [64]. L-Histidine was purchased
from Aijonomoto AminoScience (Raleigh, N.C.), and calcium chloride-dihdyrat was pur-
chased from Merck (Germany). Barium chloride 20 w/w solution from Ampliqon (Den-
mark), 0.1 N iodine solution from Sigma-Aldrich (Germany), 70 % perchloric acid from
Merck (Germany), LDS sample buffer and MES SDS running buffer and Simple Blue
Safe Stain are all from Invitrogen (Carlsbad, CA). All protein solutions were dialysed in
Slide-A-LyzerTM 30.000 MWCO dialyse cassettes against the 10 mM HIS, 100 mM CaCl2
adjusted to pH 5.75. The PEG-rFVIIa solutions were subsequently concentrated in Ami-
con cells with 30.000 MWCO, while rFVIIa was concentrated and buffer exchanged with
a Tangential Flow Filtration system using a 0.1 m2 30.000 MWCO membrane. Linear
Polyethylene glycol 8 kDa was purchased from Amresco (Solon, OH), polyethyleneglycol
10 kDa and 20 kDa were purchased from Merck (Germany), branched polyethyleneglycol
40 kDa (GL2-400CA) was purchased from NOF Corporation (Japan).
SDS-PAGE
SDS-PAGE analysis was carried out using a 12 % Bis-Tris gel from Invitrogen. The gels
were loaded with an average of 5 µg per well and run at 120 mA constant current per
gel. The running buffer was MES running buffer. The gel was washed in 150 mL 0.1
M perchloric acid for 15 minutes until 40 mL 5 % barium chloride solution and 15 mL
0.1 M iodine solution were added to detect protein bands containing PEG compounds, as
described in [141]. After removal of excess colouring in water, the gel was coloured with
Coomassie blue.
MALDI-TOF MS
Mass spectrometric analysis was performed on a Bruker Daltonics Microflex MALDI-TOF
(Billerica, MA) instrument equipped with a nitrogen laser (337 nm). The instrument was
operated in linear mode with delayed extraction, and the accelerating voltage in the ion
source was 25 kV. Sample preparation was done as follows: 1 µL sample-solution was
mixed with 10 µL matrix-solution (alphacyano-cinnamic acid dissolved in a 5:4:1 mixture
of acetonitrile:water:3% TFA) and 1 µl of this mixture was deposited on the sample plate
and allowed to dry before insertion into the mass spectrometer. Calibration was performed
using external standards (a range of standard proteins) and the resulting accuracy of the
mass determinations is within 0.1%.
Capillary viscometry
The viscosity measurements were performed with a Micro-Ubbelohde Schott 53b 10/l
capillary viscometer. The flow times varied from 90 sec to 280 sec, and the reproducibility
was ± 0.2 sec for the pure PEG solutions and ± 1 sec for the rFVIIa and GlycoPEGylated
102 The hydrodynamic volume changes of Factor VIIa due to GlycoPEGylation
rFVIIa solutions. The dimensions of this viscometer are such that the kinetic correction
can be neglected [165]. Viscosity measurements were carried out at 25.0 ± 0.1 ℃ in
a constant temperature water bath. The viscosity values, η, of the various solutions
were determined from the flow times of the solvent (ts) and of the solutions (t) for low
concentrations of the high PEG MW solutions, and higher concentration for short PEG
MW solutions. The time was measured with a quartz stopwatch. 5 different concentrations
of each solute were measured, and each flow time measurement was repeated three times.
The concentrations of the GlycoPEGylated rFVIIa species are all based on the total weight
concentration of the complex (protein and PEG).
7.3 Results
After dialysis the purities of the proteins were determined by SDS-PAGE and by MALDI-
TOF MS.
SDS-PAGE
The apparent molar mass of GlycoPEGylated proteins was assessed by SDS-PAGE [154].
It is assumed that the higher molecular weight gel bands represent one (or more) molar
incremental addition of PEG to the protein.
The PEG-staining gel technique is based on the complex formation between PEG and
barium iodide, and the PEG-stained gel (figure 7.1a) reveals that only lanes 3 and 4
contain PEG-compounds. It has previously been shown, that PEG binds to SDS micelles
[142] and that PEGylation decreases the mobility of the protein [141, 143]. For this reason
the apparent molecular weight of a PEGylated protein on a SDS gel will not correspond
to the actual molecular weight of the PEGylated protein. Due to the low mobility of
the PEGylated protein, the location of a PEGylated protein on a SDS gel corresponds to
the molecular weight of the protein plus 2.5 times the molecular weight of the attached
PEG polymer. Comparing the results in the PEG-stained gel with the very same gel,
only now Coomassie blue stained, it is evident, that the three bands in lane 3 (10 kDa
PEG-rFVIIa) and the two bands in lane 4 (40 kDa PEG-rFVIIa) are GlycoPEGylated
compounds of rFVIIa. From the results on the SDS-PAGE gel (figure 7.1b) it is seen
that the rFVIIa sample was pure (> 95 %) and contained only rFVIIa with a molecular
mass of 50 kDa. The third lane reveals that 10 kDa PEG-rFVIIa is not only mono-
GlycoPEGylated. There are 3 different GlycoPEGylated species in this protein solution.
These compounds have an apparent molecular weights of 75 kDa, 110 kDa and 125 kDa,
respectively. This corresponds to mono-GlycoPEGylated 10 kDa PEG-rFVIIa (50 kDa +
2.5 x 10 kDa) ∼ 75 kDa, di-GlycoPEGylated 10 kDa PEG-rFVIIa (50 kDa + 2.5 x 2 x
10 kDa) ∼ 110 kDa and tri-GlycoPEGylated rFVIIa (50 kDa + 2.5 x 3 x 10 kDa) ∼ 125
kDa. The fourth lane contains mainly mono-GlycoPEGylated 40 kDa PEG-rFVIIa with
a molecular weight of (50 kDa + 2.5 x 40 kDa) ∼ 160 kDa but also a very small amount
of di-GlycoPEGylated 40 kDa GlycoPEGylated rFVIIa at (50 kDa + 2.5 x 2 x 40 kDa)
∼ 250 kDa.
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(a) PEG stained gel. The gel is stained
with iodide as described in [141].
(b) SDS PAGE of PEGylated rFVIIa.
Figure 7.1:
Lane 1 and 5, bench mark protein ladder.
Lane 2: rFVIIa.
Lane 3: 10 kDa PEG-rFVIIa.
Lane 4: 40 kDa PEG-rFVIIa.
The gel is stained with iodine (fig. 7.1a), discoloured in water and subsequently stained
with Coomassie blue (fig. 7.1b).
MALDI-TOF
The results of the MALDI-TOF MS spectra of rFVIIa, 10K-rFVIIa and 40K-rFVIIa are
shown in figure 7.2.
The MALDI-TOF MS spectrum of rFVIIa shows one dominating peak, at 49.4 kDa,
equivalent to the expected molecular mass of rFVIIa [166]. Its peak pattern corresponds
to different charges, e.g. 16606 Da peak corresponds to triple charged rFVIIa, 24787
corresponds to double charged rFVIIa and 49433 corresponds to single charged. The 10
kDa PEG-rFVIIa solution contains a monoPEGylated, 61 kDa, and smaller amounts of
a di-GlycoPEGylated compound, at 73 kDa. The peak at 36400 corresponds to dou-
ble charged di-GlycoPEGylated rFVIIa, and the 30529 and 20389 are double and triple
charged mono-GlycoPEGylated rFVIIa, respectively. The 40 kDa PEG-rFVIIa solution
contains mono-GlycoPEGylated 40 kDa PEG-rFVIIa, which is seen as the 92 kDa peak.
Peaks at 46 and 31 kDa are assigned to double and triple charged mono-GlycoPEGylated
40 kDa PEG-rFVIIa.
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Figure 7.2: MALDI-TOF spectra of rFVIIa, 10 kDa PEG-rFVIIa and 40 kDa PEG-rFVIIa,
see text for further details.
The MS spectrum of 10 kDa PEG-rFVIIa shows two peaks, one at 61 kDa, corresponding
to a mono-GlycoPEGylated 10 kDa PEG-rFVIIa, and a smaller peak at 73 kDa cor-
responding to a di-GlycoPEGylated 10 kDa PEG-rFVIIa. The MS spectrum of 40 kDa
PEG-rFVIIa illustrates, that only mono-GlycoPEGylated 40 kDa rFVIIa can be detected.
The amount of di-GlycoPEGylated 40 kDa PEG-rFVIIa is too small to be detected by
MS.
MALDI-TOF spectra for pure PEG samples are summarised in table 7.1 (data not shown).
Intrinsic Viscosity
The intrinsic viscosity of samples of pure PEG, rFVIIa and GlycoPEGylated rFVIIa com-
pounds was measured with an Ubbelohde Capillary viscometer. Values of the intrinsic
viscosity, [η], were found by plotting the measured reduced viscosities according to the
Huggins method [167]:
ηsp
c
= [η] + k1[η]2c (7.1)
and also by plotting the inherent viscosities according to the Kraemer method [168]:
ln ηr
c
= [η] + k1[η]2c (7.2)
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where ηsp =
η−ηs
η , ηr =
η
ηs
, η is the viscosity of the solution, and ηs is the viscosity of
the solvent, respectively. The Huggins and Kraemer constant are k1 and k2, respectively.
Kraemer and Huggins plot were made from the measured solution viscosities at differ-
ent concentrations, and the common intercept is the intrinsic viscosity [η]. The results
obtained for rFVIIa and 40 kDa GlycoPEGylated rFVIIa solutions are seen in figure 7.3.
Figure 7.3: The measured viscosity is plotted as a function of concentration of rFVIIa.
The insert shows the viscosities of 40 kDa PEGylated rFVIIa. Kraemer and Huggins
plot were made from the measured solution viscosities at different concentrations, and the
common intercept is [η]. Note the different y-axis ranges.
The intrinsic viscosities were determined for rFVIIa, 10 and 40 kDa GlycoPEGylated
rFVIIa and the pure PEG samples of similar molecular weight; see table 7.1 and figure
7.4. The intrinsic viscosities, [η], were found by the common intercepts from the Kraemer
and Huggins plot and are an average of two intercepts. The deviations in the determination
of the molar hydrodynamic volume are based on the deviations in the determination of
the intrinsic viscosities. The molecular mass multiplied with the intrinsic viscosity gives
the molar hydrodynamic volume.
From the results in table 7.1 it is evident, that the molar hydrodynamic volume (VH) of
the conjugated protein is not just an addition of the molar hydrodynamic volume of the
PEG polymer and the protein. In figure 7.4 the molar hydrodynamic volume of rFVIIa,
the two GlycoPEGylated rFVIIa compounds and pure PEG are plotted as a function of
PEG molecular weight, zero molecular weight corresponds to the non-modified rFVIIa.
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MW (kDa) [η](mL/g) VH (L/mol)
8 kDa linear PEG 8 19.8 ± 0.15 160
10 kDa linear PEG 10 22.8 ± 0.8 228
20 kDa linear PEG 20 41.5 ± 0.5 827
40 kDa branched PEG 40 61.1 ± 1.9 2442
rFVIIa 50 6.0 ± 0.3 301
10 kDa PEG-rFVIIa 60 29.5 ± 0.9 1770
40 kDa PEG-rFVIIa 90 79.0 ± 2.2 7111
Table 7.1: The molecular weight, the intrinsic viscosity and the corresponding molar hy-
drodynamic volume of pure PEG (linear and branched), rFVIIa and GlycoPEGylated
rFVIIa. The molecular mass multiplied with the intrinsic viscosity gives the molar hydro-
dynamic volume.
Figure 7.4: The molar hydrodynamic volume of rFVIIa, the two GlycoPEGylated rFVIIa
compounds and pure PEG polymers are plotted as a function of the PEG molar mass.
The native protein is placed at PEG molar mass zero. The diamonds are the total molar
hydrodynamic volume of rFVIIa and pure PEG. The error bars are generally so small that
they are hidden behind the symbols.
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The molar hydrodynamic volumes, VH, plotted in figure 7.4 illustrate that VH of the
GlycoPEGylated rFVIIa is larger than the total VH of its composites. The molar hydro-
dynamic volume of the protein-PEG complex is approximately 2.5 times larger than the
sum of its two components.
7.4 Discussion
From the intrinsic viscosity and the molar mass measured by MALDI-TOF, the molar
hydrodynamic volume was calculated. The molar hydrodynamic volume of rFVIIa in-
creases markedly with GlycoPEGylation, and the molar hydrodynamic volume of 40 kDa
PEG-rFVIIa is larger than that of 10 kDa PEG-rFVIIa. When dissolving a PEG poly-
mer or a protein in an aqueous solution, the molecule occupies a certain hydrodynamic
volume determined by the molecular weight and the intrinsic viscosity of the molecule.
By covalently attaching a PEG moiety to the protein the molar hydrodynamic volume
of the protein itself will increase unavoidably. Our intrinsic viscosity and MALDI-TOF
data indicate that the molar hydrodynamic volume is not just an addition of the molar
hydrodynamic volume of PEG and protein, respectively. This observation is in accordance
with studies done on PEGylated haemoglobin [169]. From table 7.1 it is evident that the
VH of both 10 kDa PEG-rFVIIa and 40 kDa PEG-rFVIIa is more than 2.5 times larger
than the total VH of rFVIIa and linear 10 kDa PEG or branched 40 kDa, respectively.
One of the basic characteristics of the PEG polymer is its ability to bind two to three
water molecules per ethylene glycol unit [170]. These properties are transferred to the
protein-PEG complex upon PEGylation, leading to a molecule with an effective molar
hydrodynamic volume that increases up to 2-3 times in this study. We suggest that this
significant increase in molar hydrodynamic volume indicates that the grafted PEG polymer
is not wrapped around the protein; on the contrary it appears as though it is stretched
out from the protein to which it is attached. This hypothesis is illustrated in figure 7.5.
If the very hydrophilic PEG was wrapped around the protein, then it would have only
little effect on the total molar hydrodynamic volume of the PEGylated protein. On the
other hand, if the PEG polymer was located as a ’polymer cloud’ next to the protein and
thus stretched out from the protein, then the polymer would contribute significantly to
the intrinsic viscosity.
The increase in molar hydrodynamic volume of rFVIIa upon GlycoPEGylation seems to
be independent of the shape of the PEG polymer as the molar hydrodynamic volumes
of both GlycoPEGylated species appear to be approximately 2.5 times larger than its
composites.
To illustrate the change in viscosity of rFVIIa with GlycoPEGylation, the viscosity of
rFVIIa, GlycoPEGylated rFVIIa (10 kDa and 40 kDa) and pure PEG at 10 mg/mL are
plotted as a function of PEG molar mass (fig. 7.6). The viscosity at 10 mg/mL based on
the experimental measurements (Huggins and Kraemer constants) described in the section
7.2, Materials and Methods.
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Figure 7.5: The molar hydrodynamic volume of rFVIIa, pure PEG and GlycoPEGylated
rFVIIa. The molar hydrodynamic volumes of the conjugated protein indicate that the
PEG polymer is not wrapped around the protein, on the contrary it appears to be stretched
out from the protein surface.
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Figure 7.6: The viscosities of pure PEG, unmodified rFVIIa and GlycoPEGylated rFVIIa
at 10 mg/mL are plotted as a function of PEG molar mass. The concentrations for the two
PEG-protein solutions are based on protein concentrations in the complex. The rFVIIa
at zero molar mass is the unmodified rFVIIa. All viscosities at 10 mg/mL are calculated
from the Ubbelohde viscometer measurements.
From the results represented in figure 7.6, it is clear that the viscosity of a 10 mg/mL
protein solution increases significantly with GlycoPEGylation. The critical over-lap con-
centration, c∗ (1/[η]), for 10 kDa GlycoPEGylated rFVIIa is approximately 33 mg/mL and
12 mg/mL for 40 kDa PEG-rFVIIa. Above this concentration the viscosity of the solution
increases markedly with concentration as the solution reaches the semi-dilute regime.
If the overall purpose of PEGylating a pharmaceutical protein is increasing the circulation
time while administration is through injection, a difficult balancing act arises. A large
attached PEG will favourably increase the circulation time more than a smaller PEG,
while the overall viscosity of the solution will increase unfavourably. The improved molar
hydrodynamic properties of the protein conjugate will often result in an increased stability
and thus favourable pharmacokinetic and immunological properties as compared to the
unmodified protein [91]. However, the size and shape of the used PEG should be chosen
as on the basis of which gives the best biological effect.
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7.5 Conclusion
From the current study of the molar hydrodynamic volume of rFVIIa, pure PEG and
GlycoPEGylated rFVIIa in solution it is evident, that the molar hydrodynamic volume of
the conjugated protein is not just an addition of the molar hydrodynamic volume of the
PEG and the protein. The molar hydrodynamic volume of the GlycoPEGylated protein
is larger than the volume of its composites. These results suggest that both the linear
and the branched PEG are not wrapped around the surface of rFVIIa but chains are
significantly stretched out when attached to the protein.
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8 Concluding remarks
As the title of this thesis implies the project has treated two different, but separately grow-
ing fields within protein pharmaceutics; highly concentrated protein solutions (Chapter 2)
and PEGylated proteins in solution (Chapters 3, 4, 5, 6 and 7). The common feature is
that all protein systems have been investigated using classical biophysical characterisation
tools. To conclude the studies reported in this Thesis, future perspectives in relation to
both highly concentrated protein solutions and PEGylated proteins solutions are given
here.
The studies on highly concentrated lysozyme solutions were conducted to mimic the phar-
maceutically relevant highly concentrated antibody solutions, and were initially intended
as pilot experiments. However the surprising results that the unfolding temperature de-
creased with increasing protein concentration excited our curiosity and we continued work-
ing, hoping to find a reason for these unexpected findings. This was both exciting and
challenging, and we did a number of experiments varying both the lysozyme and the salt
concentration, trying to unravel the interplay between two opposite forces, the effect of
excluded volume phenomena and the electrostatic interactions. During these experiments
we discovered that the DSC scan of lysozyme under certain circumstances appeared to be
biphasic, suggesting two domains of lysozyme unfolds. This unfolding behaviour was re-
versible, and the biphasic DSC scan reappeared even after heating, cooling and reheating
the lysozyme sample.
It could be very interesting to do a more comprehensive study of the thermal stability of
lysozyme in the pH range 2.5-4 as the surface charge difference between the native and
unfolded state of the protein is pronounced here. By keeping the salt concentration at the
lowest possible level, these experiments could be very complementary to those reported in
chapter 2. By obtaining unfolding temperatures of lysozyme in the pH range mentioned
above, we could attain a better picture of the thermal stability under these specifically
interesting conditions. Meanwhile the use of zeta potentials measurements could be a
great supplement to the surface charge values calculated by PropKa. Measuring the zeta
potential of lysozyme at the different pH values and different salt concentrations could
give a fine estimate of the real surface charges on lysozyme and assist in interpreting the
results obtained by DSC. Studying the effect of salts in the Hofmeister series or di- and
trivalent ions on the thermal stability would also be very relevant in order to see the effect
on the surface charge of lysozyme.
Additionally experimental studies could include more heat scans with High Resolution
Ultrasonic Spectroscopy (HRUS), as described in appendix A in order to get more infor-
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mation on the formed soluble aggregates or heat scans with FTIR to determine possible
changes in the secondary structure of the protein. As most of the other classical biophysical
characterisation tools including CD and DLS need a substantially more dilute sample than
the concentration of 40 mg/mL, which is the lowest used in these experiments, the number
of useful experimental techniques is currently limited.
The effect of altering the salt concentration in the buffer was also investigated in the case
with GlycoPEGylated rFVIIa (see chapter 6). As with lysozyme the thermal stability of
rFVIIa and its GlycoPEGylated compounds was depending on the concentration of salt
in the buffer. However, in this case the surface charge density was not the issue being in
focus. Using CaCl2 seemed like the most obvious salt to use when investigating different
formulations of rFVIIa and GlycoPEGylated rFVIIa due to calcium’s crucial role in the
initiation of the blood coagulation cascade and because rFVIIa has specific binding sites
for the Ca2+ ion. Still, it could be very interesting to investigate the effect of other salts
like MgCl2 and NaCl on the thermal stability of rFVIIa and its two GlycoPEGylated
compounds. Comparing results obtained in a MgCl2 or NaCl buffer with those obtained
in CaCl2 may clarify whether other di-valent ions can destabilise rFVIIa and GlycoPEG-
ylated rFVIIa at high concentration, or if this is solely due to the interactions between
CaCl2 and rFVIIa.
The main focus in this thesis has been biophysical characterisation of PEGylated proteins
using a range of disciplines ranging from calorimetry and spectroscopy to rheology and
surface plasmon resonance. Throughout these investigations one main feature is consistent:
There appears to no dependence on the molecular weight of the attached PEG polymer
in the characteristics investigated. Intuitively one would expect that attaching a PEG
polymer of similar size as the protein would have a different effect than attaching a PEG
polymer, which size-vise is only a tenth of the molecular weight of the protein. But neither
the structure, the apparent unfolding temperature nor the temperature of aggregation
appear to be affected by the variations in PEG molecular weight. The only situation
where a the molecular weight of the attached PEG seemed to have an effect was in the
appearance of the DSC scan of PEGylated BSA. Here the biphasic appearance of the
DSC scan changed slightly depending on the molecular weight of the PEG, the largest
effect assigned the smallest PEG attached. This effect was interpreted along the lines of
a smaller PEG stabilising the thermal unfolding of the two domains in BSA in a different
way than a larger PEG. This effect is not found in the values of the apparent unfolding
temperature, but purely by inspecting the DSC thermograms.
While some of these studies have focused on effects of protein PEGylation by changing
the molecular weight of the attached linear PEG polymers, primarily, the exact same
experiments could have been done on PEGylated proteins with branched or brush-shaped
PEGs. If such experiments were conducted a number of issues could have been elucidated
including investigations regarding the effect of PEG shape on the hydrodynamic volume
and the binding properties. Would the binding profile of SDS to e.g. 10 kDa PEGylated
BSA look the same if the 10 kDa PEG polymer was brush-shaped or branched? And
would the hydrodynamic volume of a 10 kDa PEGylated protein be smaller if the PEG
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was brush-shaped as opposed to linear, as one would guess by instinct? Further knowledge
on the changes in the hydrodynamic volume upon PEGylation would be of great use in
relation to optimising purification processes and developing liquid protein formulations of
higher concentrations intended for injection.
Many studies throughout the past years have elucidated a lot of the issues related to
PEGylation and PEGylated pharmaceutical proteins, the dynamics and conformation of
the PEG chain and its preferred proximity to various regions on the protein surface is, as
yet, unknown.
The biological function of a PEGylated protein depends on the dynamics and the confor-
mation of the PEG chain (or chains for multiple PEGylation) but to our knowledge there
have been no studies that have been specifically aimed at understanding the mechanisms
by which a PEGylated protein may, on the one hand, resist proteolytic degradation yet, on
the other, retain biological function. Both these phenomena involve interactions, and the
protein is apparently able to recognize and interact with its binding partner or receptor
while at the same time a heavily hydrated shell of PEG cause hindrance of interaction
with the immune system through shielding of the protein surface. Being flexible, the PEG
chain might be displaced as the protein binds to a receptor or a ligand but presumably the
PEG is insensitive to the underlying protein construct i.e. whether it is a single protein or
a protein complex. However only little is known of where the PEG chain is located once
the PEG-protein complex is formed. The PEG chain might form a shell around the com-
plex or it might be located as a ’polymer cloud’ next to the protein as the hydrodynamic
volume results indicate (chapter 7). The conformation of the PEG-protein complex is also
yet unknown. While the modelling of the SPR data (appendix B) tried to estimate the
conformation of the PEG chain as a random coil, an extended chain conformation or a
"fried egg" conformation with the PEG flattened out round the surface construct ("yolk" =
protein complex; "white" = PEG moiety), more experiments and subsequent calculations
need to be conducted.
In addition it could be very interesting to measure the shape and conformation of PEG-
ylated proteins Small Angle X-ray Scattering (SAXS) or Small Angle Neutron Scattering
(SANS). Especially SANS could be interesting as one could choose to deuterate the pro-
tein and then PEGylated it, or deuterate the PEG group and then covalently attach this
PEG group to the protein, and thus obtain signals from either group. The following data
processing would then reveal which signal originated from with part of the PEG-protein
complex.
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A High Resolution Ultrasonic
Spectroscopy
According to Povey [171] ultrasonic spectroscopy is one of the most useful techniques
when it comes to measuring physical properties of highly concentrated protein solutions.
Povey also state that measurements of the velocity of sound is the only direct way to
determine the adiabatic compressibility, which, to a biophysicist, can be used in deter-
mining solute-solute and solute-solvent interactions [171]. We have used High Resolution
Ultrasonic Spectroscopy (HRUS) as a supplement to DSC in characterising highly concen-
trated lysozyme solutions. HRUS measures how sound waves propagate through a sample
by detecting the velocity and attenuation of the sound wave through the media and its
reference. The changes in velocity and attenuation can also be measured as a function of
temperature. The variations in the speed of sound relates to the compressibility, density
and hydration of the sample whereas the attenuation relates to the possible formation of
aggregates [171].
Here HRUS has been used to measure the effect of concentration and changing pH on
highly concentrated lysozyme solutions. Basically freeze-dried lysozyme was dissolved in
Milli Q water and filtered through a 22 µ filter. Subsequently pH was adjusted and the
samples were diluted (if needed). Unlike the experimental procedure described in sec-
tion 2.2 these samples were not diluted and then concentrated through an Amicon tube,
repeating the procedure 6 times to remove excess ions. In addition the solutions were
diluted with Milli Q water, and not with a NaCl-buffer with the same salt concentration
as the concentrated protein solution. In other words, these samples are not as well char-
acterised as the lysozyme samples used in chapter 2, but these experiments serve purely
as supporting data, reflecting the same tendency as seen in chapter 2.
The results of the velocity measurements are differentiated with respect to temperature in
order to obtain the point where the change in velocity with temperature is largest. This
point is denoted Tm. The attenuation results are plotted as a function of temperature
without further data processing.
The results are summarised in table A.1 and further illustrated in figure A.1, A.2 and A.3.
As seen on figure A.1 there are noticeable differences between the measurements of the
highly concentrated lysozyme solutions. The experiments can roughly be categorised in
three groups (i) pH 1.5, (ii) pH 2.0, pH 3.0, pH 3.5 and (iii) pH 4.0, pH 4.5 and pH 5.0. It
appears as though the protein solutions in group (i) and (iii) are the most stable solutions,
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pH Tm (℃) pH Conc. (mg/mL) Tm (℃)
1.5 48.0 ± 0.5 1.5 200 48.0 ± 0.5
2.0 67.4 ± 0.5 1.5 160 59.7 ± 0.5
3.0 68.7 ± 0.5 1.5 120 67.4 ± 0.5
3.5 68.5 ± 0.5 1.5 80 68.3 ± 0.5
4.0 65.7 ± 0.5
4.5 66.2 ± 0.5 4.0 200 65.7 ± 0.5
4.0 160 66.7 ± 0.5
4.0 120 67.9 ± 0.5
4.0 80 68.8 ± 0.5
4.0 40 66.6 ± 0.5
Table A.1:
Left panel: The apparent unfolding temperature, Tm, measured by HRUS at 200 mg/mL
and 7 pH values (fig. A.1a).
Right panel: The apparent unfolding temperature, Tm, measured at two pH values and
4-5 different concentrations (fig. A.2a and fig. A.3a).
(a) The change in velocity with temperature as
a function of temperature for highly concentrated
lysozyme solutions.
(b) The attenuation change as a function of tem-
perature for high concentration lysozyme solutions.
Figure A.1: dv/dT (A.1a) and attenuation (A.1b) for high concentration lysozyme solu-
tions.
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whereas group (ii) seems more unstable illustrated by the uneven change in attenuation
and velocity with temperature.
(a) The change in velocity with temperature as a
function of temperature for lysozyme at pH 1.5.
(b) The attenuation change as a function of tem-
perature for lysozyme at pH 1.5.
Figure A.2: HRUS results for the measurements of highly concentrated lysozyme solutions
at pH 1.5
From the results presented in figure A.2 it is evident that the lysozyme solutions at pH
1.5 depend strongly on the concentration of lysozyme.
(a) The change in velocity with temperature as a
function of temperature for lysozyme at pH 4.0
(b) The attenuation change as a function of tem-
perature for lysozyme at pH 4.0.
Figure A.3: HRUS results for the measurements of highly concentrated lysozyme solutions
at pH 4.0
The HRUS results obtained with the lysozyme solutions at pH 4.0 are a very nice example
of how the attenuation and the velocity changes with lysozyme concentration. Both ex-
perimental parameters strongly indicate that the protein unfolding temperature decrease
with increasing protein concentration.
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B Using SPR to estimate the
conformation of PEGylated BSA
A novel approach to using SPR
A spinoff of the SPR experiments represented in chapter 4 was modelling the raw SPR
data without focusing on the binding properties of the ligand and the analyte. This work
is a very tentative exploratory investigation into the possibility that PEG conformation
could explain the SPR responses seen in chapter 4. It is our perception that this work is
not yet fully developed, but serves as a basis for further exploration and development in
the future. Normally SPR is used to determine the binding kinetics between an antibody
and an antigen, see section 4.1. But here we have interpreted the SPR data in a new way
and used the SPR response in estimating the conformation of an immobilised PEGylated
BSA molecule. The data do not reflect binding kinetics but solely the SPR response to
the immobilisation of a protein onto the SPR chip. The SPR response data are generated
by activating the SPR chip with a 10 times diluted activation solution. The activation
is deliberately low to diminish the number of intermolecular interactions between the
immobilised proteins on the chip surface. After activation the native BSA and various
PEGylated BSA species were immobilised onto a SPR chip, see figure B.1.
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Figure B.1: The SPR response to activation and immobilisation as a function of time. The
response equalling the adsorption of BSA or PEGylated BSA is used for the modelling
process. The response is illustrated as RU on the figure, and the measured RU is plotted as
a function of PEG molecular weight on figure B.2. The red dots illustrate the immobilised
protein molecules.
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The corresponding SPR response, RU, was used as one of the modelling parameters.
The RU is plotted as a function of the molecular weight of the attached PEG polymer
(PEGylated BSA) in figure B.2.
Figure B.2: The SPR response to the immobilisation of BSA and various PEGylated BSA
species. The RU values are decreasing with increasing molecular weight of the PEGylated
BSA.
The SPR response data show a decrease in response with increasing PEG size, see figure
B.2. This observation is surprising as the SPR response normally increases with increasing
molecular weight of the immobilised protein [136]. Jung et al. [172] have shown how the
SPR response also depends on the thickness of the adsorbed surface adlayer and the
difference in refractive index between the adsorbed layer and the bulk solution. We put
forward a model which is based on those calculations, the viscosity radius calculations in
Fee and Van Alstine [87], and our own measurements of the refractive index of PEGylated
BSA, see appendix C.
Basically 3 different models are put forward, all of which describe different possible loca-
tions of the polymer around the immobilised BSA. The fundamental basis for the modelling
is the PEG molecular weight dependent viscosity radius, which is described in Fee and
Van Alstine [87], and in section C, and the thickness of the adsorbed layer.
Our basis model is found in figure B.3a, which represents PEGylated BSA in free solution.
The thickness of the adlayer will serve as the main parameter determining whether the
polymer is wrapped around the protein, figure B.3b, sits as a sphere, figure B.3c, or
as an elongated sphere on top of the immobilised protein, figure B.3d. All models are
summarized in figure B.3.
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(a) Model 1, the sphere. PEGylated BSA
in free solution. The BSA is represented
by the black sphere, the PEG polymer is
represented by the transparent sphere sur-
rounding the BSA.
(b) Model 2, the hemisphere. PEGylated
BSA on the SPR chip, the overall struc-
ture is a hemisphere, where the transparent
sphere is the PEG polymer wrapped around
the BSA, represented by a black sphere.
(c) Model 3, sphere on top of sphere. PEG-
ylated BSA on the SPR chip. BSA, the
black sphere, is attached to the SPR chip,
the PEG polymer, represented by the trans-
parent sphere, is floating on top of the pro-
tein.
(d) Model 4, elongated sphere. PEGylated
BSA on the SPR chip. BSA, the black
sphere, is attached to the SPR chip. The
PEG polymer, represented by the transpar-
ent, elongated sphere is floating on top of
protein.
Figure B.3: The thickness of the adlayer (from the chip to the top of the molecule) is
modelled as a function of the viscosity radius of BSA and the attached PEG polymer.
Model 1 illustrates the PEGylated BSA molecule in free solution. Models 2, 3 and 4 are
realistic illustrations of how the PEGylated BSA can be located on the SPR chip.
The SPR response, RU, is directly proportional to the change in refractive index between
the bulk solution and the protein adsorbed onto the chip at a certain distance from the
chip surface [172].
RU ∝ (n protein − n buffer) (B.1)
The refractive index of the protein is calculated from equation C.1, using the Refractive
Index Increments reported in appendix C. The model also depends on the concentration
of protein on the SPR chip, and this concentration depends on the surface coverage. In our
modelling the surface coverage has either been independent or dependent on the molecular
weight of the immobilised PEGylated protein. In the case where the surface coverage is
dependent on the molecular weight of the protein, it is estimated that the surface coverage
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decreases with 1 % per 1 kDa PEG attached to the BSA. Thus the surface coverage
decreases with 60 % when immobilising a 60 kDa PEGylated BSA compared to a native
BSA. If the surface coverage is independent of the molecular weight of the immobilised
PEGylated protein, the same value for the surface coverage is used for all species. This
value is calculated based on the SPR response to immobilising native BSA onto the SPR
chip, which is described further on page 142.
Viscosity Radius
Fee and Van Alstine used Size Exclusion Chromatography (SEC) to determine the vis-
cosity radii of equivalent spheres for proteins covalently grafted with PEG. The viscosity
radius of a PEGylated protein depends on the molecular weight of the protein and the
PEG as well as the viscosity radii of both species [87]. The radius of PEGylated BSA serves
as the basis for modelling the SPR response. The radius is used to calculate the occupied
volume of a spherical PEGylated BSA molecule. The occupied volume is independent of
the model used, and depends only on the size of the PEG.
Modelling
Model 1
It is assumed that the PEGylated BSA in aqueous solution occupies a sphere with a radius
corresponding to the viscosity radius. The first model, model 1, describes the PEGylated
BSA free in solution, and as seen on figure B.4, BSA, black sphere, is not attached to the
chip surface. PEG is illustrated as the transparent sphere surrounding the protein. This
model serves mainly as the basis for the other three models.
r
d1
Figure B.4: Model 1. PEGylated BSA in free solution. The distance d1 equals two
viscosity radii of PEGylated BSA. The volume of the free PEGylated BSA in solution is
calculated from VPEGylated BSA = 43pir
3, where r is the viscosity radius.
The distance d1 refers to the distance from the surface of the chip to the top of the adlayer,
in this case 2 times the viscosity radius of a PEGylated BSA molecule. d1 is an estimate
of the bilayer thickness, see table B.1.
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PEG MW (kDa) d1 (nm)
5 8.2
10 9.7
20 11.8
30 13.7
40 15.5
60 18.8
Table B.1: The bilayer thickness, d1, calculated from the viscosity radius of PEGylated
BSA [87].
Model 2
Model 2 illustrates the case, where the PEG polymer is wrapped around the BSA molecule,
see figure B.5.
c
a
a
d2
Figure B.5: Model 2. PEGylated BSA on the SPR chip, hemisphere. The distance d2
equals c, which is found from the volume of this hemisphere: VPEGylated BSA = 23pia
2c.
The distance d2 refers to the distance from the surface of the chip to the top of the adlayer.
d2 equals the distance c on figure B.5. The volume of a PEGylated BSA molecule and the
distance c is found as:
c = d2 =
3 · VPEGylated BSA
2 · pi · a2
(B.2)
Here a is defined as:
a = Rh BSA + x · Rh PEG (B.3)
Here Rh BSA refers to the viscosity radius of BSA, and Rh PEG refers to the viscosity
radius of pure PEG [87].
And the unknown factor x is found by fitting this hemispherical model to the measured
SPR response data, the values for x is found when the difference between the measured
and calculated SPR response was a minimum. From the data fitting two different values
for a has been found; One describing the case where the surface coverage is independent of
the molecular weight of the PEGylated BSA. The other one describing the case where the
surface coverage is depending on the molecular weight of the PEGylated BSA, see table
B.2.
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PEG MW (kDa) a (nm) d2(nm) a (nm) d2(nm)
(independent of (dependent on
surface coverage) surface coverage)
5 3.5 12.7 3.4 13.3
10 4.0 14.3 4.0 14.1
20 5.0 16.7 5.3 14.7
30 5.2 24.5 5.9 18.6
40 5.7 29.0 6.9 19.1
60 6.2 42.9 9.3 18.9
Table B.2: From the data fitting two different values for a, and then d2 has been found.
One describing the case where the surface coverage is independent of which PEGylated
BSA species is immobilised. The other one describing the case where the surface coverage
is decreasing with increasing PEGylated BSA MW.
Model 3
Model 3 illustrates the situation where the PEG polymer floats like a sphere on top of
the grafted BSA, see figure B.3. The thickness of the bilayer corresponds to two viscosity
radii of native BSA and two viscosity radii of PEG, as determined when it is attached to
the BSA (Rh PEGylated BSA-Rh BSA).
r
d3
Figure B.6: PEGylated BSA on the SPR chip, two spheres. The distance d3 equals 2
Rh BSA+ 2 r. The volume of the PEG molecule attached to the BSA is calculated from
(VPEGylated BSA − VBSA) = 43pir
3.
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PEG MW (kDa) d3(nm) d3(nm)
(independent of (dependent on
surface coverage) surface coverage)
5 10.1 13.5
10 10.9 15.2
20 12.2 17.7
30 13.3 19.8
40 14.2 21.7
60 15.9 25.1
Table B.3: From the data fitting two different values for a, and then d3 has been found.
One describing the case where the surface coverage is independent of which PEGylated
BSA species is immobilised. The other one describing the case where the surface coverage
is decreasing with increasing PEGylated BSA MW.
Model 4
Model 4 describes the situation where the PEG polymer floats as an elongated sphere on
top of the BSA molecule, which is immobilised onto the SPR chip, see figure B.7.
c
a
d4
Figure B.7: PEGylated BSA on the SPR chip, elongated sphere on top of sphere. The
distance d4 equals 2 Rh BSA+ 2 c. The volume of the PEG attached to the BSA is
calculated from (VPEGylated BSA − VBSA) = 43pia
2c.
The bilayer thickness, d4, is calculated from the viscosity radii of BSA and the volume of
the attached PEG polymer.
d4 = 2 · RH BSA + 2 ·
3 · (VPEGylated BSA − VBSA)
4 · pi · a2
(B.4)
In figure B.7 the distance a describes the ’semi-minor axis’ and it is defined as
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a = x ·Rh PEG (B.5)
Rh PEG is the viscosity radius of pure PEG [87].
Modelling the data gives two different values for a, depending on the value of the surface
coverage, and whether the surface coverage is depending on the molecular weight of the
grafted PEGylated BSA or not, see table B.4.
PEG MW (kDa) a (nm) d4(nm) a (nm) d4(nm)
(independent of (dependent on
surface coverage) surface coverage)
5 3.7 12.7 3.5 13.3
10 4.5 14.3 4.6 14.1
20 5.8 16.7 6.5 14.7
30 5.7 24.1 6.9 18.6
40 6.2 28.9 8.3 19.1
60 6.6 42.9 11.3 18.9
Table B.4: From the data fitting two different values for a, and then d4 has been found.
One describing the case where the surface coverage is independent of whatever PEGylated
BSA species is immobilised. The other one describing the case where the surface coverage
is decreasing with increasing PEGylated BSA molecular weight.
Results
The results in figure B.8 show that the hemispherical model, model 2, and the elongated
spherical model, model 4, with the distances d2, table B.2 and d4, table B.4 are the best
fit to the model. However looking at the values for the bilayer thickness they seem to be
fairly large compared to the values for the free PEGylated BSA molecule, see table B.1.
The value of bilayer thickness when describing an immobilised 60 kDa PEGylated BSA
molecule is almost 2.5 times larger in model 2 and model 4 compared to model 1. Model
1 has mainly been used when developing the other models as it can be useful to take the
behaviours at the extremes of the system boundaries under consideration, even if they
appear to be absurd, as these help to bound the solution space under consideration. The
results in figure B.9 show the modelling results, where the surface coverage depends on
the molecular weight of the grafted molecule.
The decrease in surface coverage with larger molecular weight of the grafted PEGylated
BSA can be taken into account in the modelling process profitably. All the 3 realistic
models describe the measured data quite well. The values for the parameter a in model
2 found in table B.2 indicate that the height of the hemisphere is 2-4 times larger than
the width, which will make the grafted PEGylated BSA somewhat cylinder shaped. The
values of a in model 4 found in table B.4 show that the PEG is best described as an
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Figure B.8: The RU response versus the PEG molecular weight. This graph shows
the modelling results based on values of the surface coverage being independent of the
molecular weight of the PEGylated BSA.
ellipsoid on top of the spherical BSA molecule, sitting like an oblate spheroid on top of
the BSA molecule.
In conclusion, the models which describe the case where the surface coverage is depending
on the molecular weight of the PEGylated BSA are overall the best models. Based on
these results the immobilised PEGylated BSA is best described as a hemisphere, where
BSA is encased by PEG, or a sphere, BSA, with an oblate spheroid, PEG, sitting on top.
Concluding remarks
Traditionally SPR has been used as a screening tool for the investigation of the binding
kinetics between antibodies and their corresponding antigens, and it is as such an excellent
instrument. Especially with the growing marked within PEGylated pharmaceutical pro-
teins the use of SPR will inevitably increase, and hopefully the content of this appendix
will shed the light on the various potentials of the Surface Plasmon Resonance technique.
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Figure B.9: The RU response versus the PEG molecular weight. This graph shows the
modelling results based on values of the surface coverage is depending on the molecular
weight of the PEGylated BSA.
Background calculations
The SPR response, RU, is directly proportional to the change in refractive index between
the bulk solution and the protein adsorbed onto the chip at a certain distance from the
chip surface.
RU ∝ (n protein − n buffer)
The refractive index is defined as
n protein = n buffer +C protein ·
dn
dc
The refractive index increment of all the PEGylated BSA solutions was measured, and
used in the modelling process.
The concentration of protein at the surface of the chip was
Cprotein = C ·MWBSA +MWPEG
surface coverage
d
The constant, C, contains unit conversion factors and Avagagro’s Number, d is the thick-
ness of the adsorbed adlayer and the surface coverage is amount of protein molecules per
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nm2. The surface coverage is calculated from the SPR response of the immobilised native
BSA;
RU = m(n protein − n buffer)
Here m in an instrument specific constant, nbuffer is the refractive index of the buffer
and nprotein is the refractive index of the protein dissolved in the buffer. By knowing
the molecular weight of the protein in question, Avagadro’s Number, the thickness of the
adlayer and the protein concentration an estimate of the surface coverage can be made.
The thickness of the adlayer is, at first, based on d being 6.2 nm, which correspond to
twice the viscosity radii of BSA[87].
The radius of PEGylated BSA serves as the basis for modelling the SPR response, as:
Rh PEG-BSA =
A
6
+
2
3A
R2PEG +
1
3
Rh PEG
where
A =
[
108 R 3h BSA + 8R
3
h PEG + 12(81R
6
h BSA + 12R
3
h BSAR
3
h PEG)
1/2
]1/3
Viscosity radius of BSA is
Rh BSA = (0.82 ± 0.02)66.7
1/3 (B.6)
where 66.7 is the molecular weight of BSA in kDa. And the viscosity radius of PEG is
depending on the molecular weight of the polymer.
Rh PEG = 0.1912 ·MW0.559PEG (B.7)
All the radii have the unit Å.
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C Refractive index of PEGylated BSA
Refractive Index
In connection with the SPR measurements we modelled the SPR response as described
in appendix B. Besides being sensitive towards the accumulated mass on the chip surface
[173], the induced surface plasmons are sensitive to changes in the refractive index of the
medium to an extent which makes the SPR response directly proportional to the difference
in refractive index between the bulk solution and the liquid solution to be analysed [172].
Thus the refractive index of the protein solution must also be taken into account when
interpreting SPR data.
Experiments with binding of PEGylated BSA with various linear PEG molecular weights
to anti-BSA have resulted in lower SPR response compared to the similar experiments
with non PEGylated BSA C.1.
Figure C.1: The maximum response versus the PEG molecular weight, based on the
Langmuir modelling. Error bars are too small to be seen.
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The response might be low because the PEG is sterically hindering the binding of BSA to
the immobilised anti-BSA. But the response is not affected by the molecular weight of the
grafted PEG, which is surprising as the SPR response is proportional to the mass of the
adsorbed protein [136, 172, 173]. It would be a curious coincident if an equilibrium exists
between the lower response resulting from the steric hindrance and the higher response
from the higher mass bound to the surface chip, which just cancels out for all the molecular
weight PEGs in question.
A comparable study conducted by Kubetzko et al. [96] shows that the RUmax is much
lower for the 20 kDa PEGylated species compared to the RUmax from the measurements
of the native protein. The response is 1/3 even with a 3 times higher concentration of
native protein. This supports our results, as we also see a reduction in the SPR response
depending on PEGylation.
Another study, conducted by Yang et al. [66], shows the same tendency, almost a 10
fold decrease in the SPR response with PEGylation. The response from non-PEGylated
antibody is 54 RU with a concentration of 135 nM, whereas the response of the 40 kDa
PEG is 62 RU with a concentration of 3141 nM.
The reason for the unexpected low response might be found by looking at the index of
refraction (RI) of the proteins in solution. Basic knowledge about the changes in the RI of
the PEGylated protein compared to the non-PEGylated protein and free PEG in solution
is needed in order to interpret our SPR data properly.
The RI relates to the media’s dielectric constant and is depending on the state of the
media, the temperature as well as the wavelength at which the RI is measured. Pure
water has a RI of 1.333 at 20 ◦C and 589 nm [174]. Most dry, crystalline proteins have
a RI near 1.6 [175], whereas PEG has a RI is 1.4563 [176]. It is a widely held view that
the RI response of a mixture of different molecules or a hybrid molecule is the sum of the
RI responses of the two components. Kunitani et al. [154] state that the RI of a specific
component is a characteristic of the electron density of that component. Since PEG is
attached to the protein by a single covalent bond it is the assumption, that the electron
density of each component should essentially remain unchanged and approximation of
their individual RI additivity should be accurate [177].
Measurements
The index of refraction (RI) of BSA, 5, 8 and 20 kDa PEG1 and 5, 10, 20, 30, 40 and 60 kDa
PEGylated BSA2, all dissolved in PBS buffer, are measured. A Differential Refractometer
Detector RID-10 A from Shimadzu is used to measure the difference in RI between the
buffer solution and the different solutions of BSA, PEG and PEGylated BSA, respectively.
All sample solutions are measured at different protein and PEG concentrations to get an
experimental value for the refractive index increment.
1 Fluka Chemie GmbH (Switzerland)
2 PEGylated proteins from the PEGylation reaction described on page 60
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The refractive index of each individual BSA or PEGylated BSA sample was measured at
5 different concentrations from a dilution series starting at the highest possible protein
concentration from the pooled samples. The concentrations range from 1.35 mg/mL to
100 µg/mL. The pure PEG samples were made of either dissolved mPEG-SPA or pure
PEG to cover the entire range of molecular weight PEGs used for PEGylation. Each
sample was 100 µL and the measurements were done 3 times in immediate continuation
of each other. The obtained values were averaged and the experiments were repeated the
following day. Thus the refractive index of a certain concentration of protein or PEG was
measured at least 6 times.
Theoretical model for the refractive index of PEGylated BSA
Fee and Van Alstine [87] have shown that the viscosity radius of PEGylated proteins
depends on the molecular weight of the native protein and the total weight of the grafted
PEG but not on the PEG molecular weight. The viscosity radius can be used to determine
the volume of a PEGylated protein. The volume of a PEGylated protein can be divided
into two parts, the contribution from the protein and the contribution from the attached
PEG. The volume contribution from the PEG is smaller when attached to the protein, than
when it is free in solution. This observation might be reflected in the measured refractive
index of PEGylated BSA. Kunitani et al. [154] and Jung et al. [172] both suggest using
the Lorenz-Lorenz Equation to estimate the refractive index of an unknown fluid solution,
when all the constituting components are known. The refractive index of a PEG-protein
solution would then be defined as:
n = n buffer +
(
dn
dc
)
PEG
· CPEG +
(
dn
dc
)
protein
· Cprotein (C.1)
Where n buffer is the refractive index of the buffer, (dndc )PEG and (
dn
dc )protein are the specific
refractive index increments for PEG and protein, respectively, and CPEG and Cprotein are
the weight concentrations of the PEG and protein per unit volume. The refractive index
of mono-PEGylated BSA corresponds to a 1:1 molar ratio mixture of the two compounds.
It can be calculated theoretically from equation C.1 and the viscosity radius from Fee and
Van Alstine [87] and the refractive index of the dry protein and dry PEG. The theoretical
model is a mixture of the properties of PEG, BSA and PEGylated BSA dissolved in buffer
and as dry powder. The plot of the correlation between the index of refraction and the size
of the PEG shows a difference in the index of refraction from the PEG-BSA mixture to
the PEGylated BSA, especially at relatively low PEG size, see figure C.4. The PEGylated
BSA has got a higher refractive index than PEG-BSA mixtures.
Refractive Index Results
The refractive index is a linear function of the concentration over a wide range of concen-
trations. The slope of the plot of the refractive index versus concentration is known as
the refractive index increment (RII). The differential refractometer was used to determine
the RII of BSA, PEG and PEGylated BSA in PBS buffer, see figure C.2.
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Figure C.2: The refractive index increment of BSA, PEG and PEGylated BSA in PBS.
The RII is increasing with increasing molecular weight of the PEGylated BSA. The RII of
pure PEG is independent of the molecular weight of PEG. There is a significant difference
between the RII of the 1:1 molar mix of PEG and BSA and the PEGylated BSA. The
RII of native BSA and pure PEG are comparable to the literature values. There is no
difference in the RII between using dissolved activated PEG or pure PEG of the same
molecular weight. The RII at 0 PEG molecular weight corresponds to native BSA.
From figure C.2 it is evident, that the refractive index increment is increasing with in-
creasing molecular weight of the PEGylated BSA. The RII of pure PEG is independent
of the molecular weight of the polymer, which is also found in the literature [176]. The
RII of the 1:1 molar mix of PEG and BSA is clearly lower than the corresponding for the
PEGylated BSA. There is no difference in the RII between using dissolved activated PEG
or pure PEG of the same molecular weight. The maleimido-propionamide group attached
to the activated PEG has thus no influence on the refractive index.
Discussion
It is essential to know the refractive index of a protein solution to be able to interpret data
from various biophysical experiments including Static Light Scattering (SLS), Dynamic
Light Scattering (DLS), Surface Plasmon Resonance (SPR) and other chromatographic
and spectroscopic methods. Experimental results of measurements of the RI as well as the
RII of PEGylated proteins found in the literature have been very sparse. Kubetzko et al.
[96] have set the refractive index increment to 0.166 mg/L for PEGylated mini-antibodies
or to 0.185 mg/L for nonPEGylated mini-antibodies. We have found that PEGylating
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a protein result in a larger refractive index increment compared to the nonPEGylated
species.
Our measurements of the RII of BSA are comparable to the literature values [175], [178],
[179], see table C.1. There is no apparent correlation between the refractive index and
the size of the protein. The slight difference between the refractive indices is most likely
depending on the content of the protein bulk solution (whether the bulk solution con-
tained phenols, alcohol, chaotropic or kosmotropic agents), small temperature differences
or difference in the reagent purity.
BSA PEG
1,89 ·10−4 ± 0.01 ·10−4L/g (in PBS) 1.33·10−4 ± 0.053· −4 L/g (in PBS)
1.571-1.590·10−4 L/g (in (NH4)2SO4)[175] 1.34 ·10 −4 L/g (in water)[180]
1.90 · 10−4 ± 0.02 ·10−4L/g (in Milli-Q water)[179]
1.83 ·10−4 L/g (in Milli-Q water) [179]
Table C.1: The experimental values, on top, and the literature values for the refractive
index increment of native BSA and different MW PEGs.
Studies have shown that the index of refraction of dry proteins range from 1.35-1.6 [172,
175, 181].
The absolute index of refraction of a solutions is calculated from the refractive index
increment of the solute added the refractive index of the solvent, equation C.1. For a
protein solution of a given concentration, the experimental measurements of the refractive
index can be compared to theoretical calculations of the same solution when the RI of the
buffer and the RII of the solute is known, see figure C.3.
From figure C.3 it is clear, that the measured refractive indices of the PEGylated BSA
solutions are larger than the refractive index of the 1:1 molar ratio of BSA and PEG by
themselves.
Kendrick et al. [182] argue that the refractive index increment is a function of its chemical
groups and independent of higher order structures. We see a slightly different tendency
in our measurements. As seen in figure C.2 the RII of a solution of BSA and PEG is
depending on whether they are covalently linked or not. So the RII is not only a function
of the chemical groups, but also dependent of higher order structures.
Background calculations
The difference between these two models is mainly the amount of occupied volume. The
occupied volume of the PEGylated BSA molecule is more than the mixture of BSA and
PEG.
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Figure C.3: The refractive index of various 0.33 mg/mL solutions is plotted versus the
molecular weight. The filled squares and triangles are calculated values, whereas the open
squares are experimentally measured values.
The refractive index of a mixture of PEG and BSA can be calculated from a variation of
equation C.1.
n BSA PEG mixture = nBSA ·
VBSA
VBSA + VPEG
+ nPEG ·
VPEG
VBSA + VPEG
(C.2)
The volume of BSA is
VBSA =
4 · pi(RH BSA)3
3
=
4 · pi(0.82 ·MW1/3BSA)
3
3
(C.3)
The volume of PEG is
VPEG =
4 · pi(RHPEG)3
3
=
4 · pi(0.1912 ·MW 0.559PEG )
3
3
(C.4)
For the PEGylated BSA the refractive index can also be calculated from equation C.1:
n PEGylated BSA = nBSA ·
VBSA
VBSA +VPEG attached
+ nPEG ·
VPEG attached
VBSA +VPEG attached
(C.5)
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The volume of the attached PEG is found by calculating the viscosity radius of PEGylated
BSA, using the equations given in Fee and Van Alstine [87]:
RH PEG−BSA =
1
6
[
108 (RH PEG)
3 + 12(81(RH BSA)
6 + 12(RH BSA)
3(RH PEG)
3)1/2
]1/3
+
2
3
[
(RH PEG)2(
108 (RH PEG)3 + 12(81(RH BSA)6 + 12(RH BSA)3(RH PEG)3)1/2
)1/3
]
(C.6)
RH PEG attached = RH PEG−BSA − RH BSA (C.7)
VPEG attached =
4 · pi · (RH PEG attached)3
3
(C.8)
The index of refraction of the BSA and PEG mixture (n_mix) and the PEGylated BSA
(n_PEGylated BSA) as a function of PEG molecular weight in Da is plotted in figure
C.4.
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Figure C.4: The theoretical change in refractive index (RI) versus PEG MW for a 1
mg/mL PEGylated BSA and a 1:1 molar, 1 mg/mL mixture of PEG and BSA. Red line
shows the RI of a 1:1 molar mixture of PEG and BSA, whereas the blue dotted line shows
the RI of PEGylated BSA. The refractive index of a solution 1:1 molar solution of PEG
and BSA depends clearly on whether they are covalently attached to each other
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